Single 3436993005f205eca6caf3 PDF

Eurofins Scientific SE (ERF)
Financial and Strategic SWOT Analysis Review
Report Code: GDPH34964FSA

Published: July 2020
Eurofins Scientific SE (ERF) - Financial and Strategic SWOT Analysis Review
Company Snapshot
23 Val Fleuri Phone +356 26 185320 Revenue 4,562.80 (million EUR)
Luxembourg City Fax +356 26 185331 Net Profit 195.30 (million EUR)
1526 Website www.eurofins.com Employees 47,000
Pharmaceuticals &
Luxembourg Exchange ERF [Euronext Paris] Industry
Healthcare
Company Overview
Eurofins Scientific SE (Eurofins) is a life sciences company, which provides analytical testing services to clients in various industries.
The company offers food and feed testing, biopharma services, pharma discovery services, pharma early development, pharma
central laboratory, biopharma product testing, agroscience services, product testing, forensic services and environmental testing. Its
analytical methods help in evaluating the safety, identity, composition, origin, authenticity and purity of biological products and
substances. It harnesses its expertise in logistics and information technology to deliver a range of services.
Key Executives SWOT Analysis
Name Title Eurofins Scientific SE, SWOT Analysis
Gilles G. Martin Chairman Strengths Weaknesses
Valerie Hanote Director
Dominant Position Decline in Working Capital
Stuart Anderson Director
Operational Performance
Yves-Loic Martin Director
Fereshteh Pouchantchi Director
Source: Annual Report, Company Website, Primary and Secondary Opportunities Threats
Research, GlobalData
Share Data Growth Drivers Competition
Eurofins Scientific SE Strategic Acquisitions Intellectual Property Risk
Share Price (EUR) as on 16-Jul- 557.60
2020
Source: Annual Report, Company Website, Primary and Secondary Research,
EPS (EUR) 16.69 GlobalData
Market Cap (million EUR) 10,541
Enterprise Value (million EUR) 13,436
Shares Outstanding (million) 18
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
Financial Performance Recent Developments
Jul 14,2020 Eurofins publishes robust method to analyse
SARS-CoV-2 in wastewater samples, providing
early warning of potential COVID-19 outbreak at
a given site
Jul 02,2020 Eurofins Launches CE-IVD Marked Rapid POC
Testing Devices to Identify Past Exposure to
COVID ...
Jun 29,2020 Eurofins DiscoverX further expands its bioassay
certification program with Catalent Biologics
Jun 03,2020 Eurofins Technologies Launches Total Antibody
(IgG, IgA and IgM) Detection ELISA Assays to Aid
the Rapid Identification of Persons Who Have
Source: Annual Report, Company Website, Primary and Secondary
Been Exposed To SARS-CoV-2 (COVID-19)
Research, GlobalData Source: Annual Report, Company Website, Primary and Secondary Research,
GlobalData
© GlobalData 2020. This product is licensed and is not to be photocopied. Page 2

Table of Contents
Table of Contents............................................................................................................................................................................... 3
List of Tables.................................................................................................................................................................................. 7
List of Figures ................................................................................................................................................................................ 7
Section 1 - About the Company ......................................................................................................................................................... 9
Eurofins Scientific SE - Key Facts........................................................................................................................................................ 9
Eurofins Scientific SE - Key Employees ............................................................................................................................................. 10
Eurofins Scientific SE - Key Employee Biographies .......................................................................................................................... 12
Eurofins Scientific SE - Major Products and Services ....................................................................................................................... 13
Eurofins Scientific SE - History ......................................................................................................................................................... 14
Eurofins Scientific SE - Company Statement .................................................................................................................................... 20
Eurofins Scientific SE - Locations And Subsidiaries .......................................................................................................................... 21
Head Office.................................................................................................................................................................................. 21
Other Locations & Subsidiaries ................................................................................................................................................... 21
Section 2 – Company Analysis.......................................................................................................................................................... 28
Company Overview .......................................................................................................................................................................... 28
Eurofins Scientific SE - Business Description .................................................................................................................................... 29
Product Category: Agroscience Services .......................................................................................................................................... 30
Agroscience Services - Overview ..................................................................................................................................................... 30
Product Category: Biopharma Services............................................................................................................................................ 30
Biopharma Services - Overview ....................................................................................................................................................... 30
Product Category: Clinical Diagnostics............................................................................................................................................. 30
Clinical Diagnostics - Overview ........................................................................................................................................................ 30
Product Category: Consumer Product Testing ................................................................................................................................. 30
Consumer Product Testing - Overview ............................................................................................................................................ 30
Product Category: Environmental Testing ....................................................................................................................................... 30
Environmental Testing - Overview ................................................................................................................................................... 30
Product Category: Food and Feed Testing ....................................................................................................................................... 30
Food and Feed Testing - Overview................................................................................................................................................... 30
Product Category: Genomics Services ............................................................................................................................................. 31
Genomics Services - Overview ......................................................................................................................................................... 31
Product Category: REACH Services .................................................................................................................................................. 31
REACH Services - Overview .............................................................................................................................................................. 31
Geographical Segment: Europe ....................................................................................................................................................... 31
Europe - Performance ...................................................................................................................................................................... 31
Eurofins Scientific SE, Europe, Revenue Performance EUR (m) ....................................................................................................... 32
Geographical Segment: North America ........................................................................................................................................... 33
North America - Performance .......................................................................................................................................................... 33
Eurofins Scientific SE, North America, Revenue Performance EUR (m) ........................................................................................... 34
Geographical Segment: Rest of the World ...................................................................................................................................... 35
Rest of the World - Performance ..................................................................................................................................................... 35
Eurofins Scientific SE, Rest of the World, Revenue Performance EUR (m) ...................................................................................... 36
Eurofins Scientific SE - SWOT Analysis ............................................................................................................................................. 37
SWOT Analysis - Overview ............................................................................................................................................................... 37
Eurofins Scientific SE - Strengths ..................................................................................................................................................... 37
Eurofins Scientific SE - Weaknesses ................................................................................................................................................. 38
Eurofins Scientific SE - Opportunities .............................................................................................................................................. 39
Eurofins Scientific SE - Threats ......................................................................................................................................................... 40
Eurofins Scientific SE - Key Competitors .......................................................................................................................................... 41
Section 3 – Company Financial Ratios ............................................................................................................................................. 42
Financial Ratios - Capital Market Ratios........................................................................................................................................... 42
Financial Ratios - Annual Ratios ....................................................................................................................................................... 43
Performance Chart ........................................................................................................................................................................... 46

Financial Performance ..................................................................................................................................................................... 46

Financial Ratios - Interim Ratios ...................................................................................................................................................... 47
Financial Ratios - Ratio Charts.......................................................................................................................................................... 48
Section 4 – Company’s Mergers & Acquisitions, Capital Raising and Alliances ............................................................................... 49
Eurofins Scientific SE, Transactions by Year, 2014 to YTD 2020 ...................................................................................................... 49
Eurofins Scientific SE, Transactions by Type, 2014 to YTD 2020 ...................................................................................................... 50
Eurofins Scientific SE, Transactions by Region, 2014 to YTD 2020 .................................................................................................. 51
Eurofins Scientific SE, Pharmaceuticals & Healthcare, Transaction By Therapy Area, 2014 to YTD 2020 ....................................... 52
Eurofins Scientific SE, Medical Devices Transaction, 2014 to YTD 2020 .......................................................................................... 53
Eurofins Scientific SE, Mergers and Acquisitions Transactions, 2014 to YTD 2020 ......................................................................... 54
Eurofins Scientific SE, Mergers and Acquisitions Transaction Summary, 2014 to YTD 2020 ........................................................... 55
Eurofins Scientific SE, Strategic Alliances Transactions, 2014 to YTD 2020 ..................................................................................... 57
Eurofins Scientific SE, Strategic Alliances, by Transaction Phase, 2014 to YTD 2020 ...................................................................... 58
Eurofins Scientific SE, Strategic Alliances Transactions Summary, 2014 to YTD 2020 ..................................................................... 59
Eurofins Scientific SE, Private Equity/Venture Capital Transactions, 2014 to YTD 2020 ................................................................. 60
Eurofins Scientific SE, Venture Capital Transactions, by Stage of Financing 2014 to YTD 2020 ...................................................... 61
Eurofins Scientific SE, Private Equity/Venture Capital Transactions Summary, 2014 to YTD 2020 ................................................. 63
Eurofins Scientific SE, Equity and Debt Offerings, 2014 to YTD 2020 .............................................................................................. 64
Eurofins Scientific SE, Equity and Debt Offerings Transactions Summary, 2014 to YTD 2020......................................................... 65
Eurofins Scientific SE, Recent Transactions Summary ..................................................................................................................... 66
Acquisition ....................................................................................................................................................................................... 69
Eurofins Scientific Acquires Transplant Genomics ........................................................................................................................... 69
Eurofins Scientific to Acquire TestAmerica Environmental Services from JSTI Group ..................................................................... 70
Eurofins Acquires Covance from LabCorp ........................................................................................................................................ 71
Eurofins Scientific Acquires VTT Expert Services and Labtium from VTT Technical Research Centre of Finland ............................ 73
Eurofins Scientific to Acquire PHAST ............................................................................................................................................... 74
Eurofins Scientific Acquires Lab Frontier ......................................................................................................................................... 75
Eurofins Scientific Acquires NMDL-LCPL .......................................................................................................................................... 76
Eurofins Scientific Acquires Selcia.................................................................................................................................................... 77
Eurofins Scientific Acquires Pasteur................................................................................................................................................. 78
Eurofins Acquires EAG Laboratories from Odyssey Investment Partners........................................................................................ 79
Eurofins Pharma Services Acquires Majority Stake in Advinus Therapeutics .................................................................................. 80
Eurofins Scientific to Acquire DiscoverX .......................................................................................................................................... 82
Eurofins Scientific Acquires Amatsigroup from Ekkio Capital .......................................................................................................... 83
Eurofins GSC Lux Acquires ANA Laboratories .................................................................................................................................. 85
Eurofins Scientific to Acquire Genoma Group ................................................................................................................................. 86
Eurofins Scientific Acquires Alphora Research ................................................................................................................................ 87
Eurofins Scientific to Acquire GATC Biotech .................................................................................................................................... 88
Eurofins Scientific to Acquire MVZ fur Laboratoriumsmedizin ........................................................................................................ 89
Eurofins Scientific to Acquire Villapharma Research ....................................................................................................................... 90
Eurofins Scientific Acquires VRL Laboratories.................................................................................................................................. 91
Eurofins Scientific Acquires Advantar Laboratories ......................................................................................................................... 92
Eurofins Scientific Acquires ams Laboratories ................................................................................................................................. 93
Eurofins Scientific Acquires Sinensis Life Sciences ........................................................................................................................... 94
Eurofins Scientific Acquires Biomnis for USD250 Million................................................................................................................. 95
Eurofins Scientific Acquires 75% Stake in Emory Genetics Lab for USD40 Million .......................................................................... 96
Eurofins Scientific Acquires Diatherix Labs for USD50 Million ......................................................................................................... 98
Eurofins Acquires Experchem .......................................................................................................................................................... 99
Eurofins Scientific Acquires QC Laboratories (QCL) ....................................................................................................................... 100
Eurofins Scientific Acquires Boston Heart Diagnostics .................................................................................................................. 101
Eurofins Scientific to Acquire SF Analytical Labs ............................................................................................................................ 102
Eurofins Genomics Acquires VBC-Biotech ..................................................................................................................................... 103
Innolab do Brasil Completes Acquisition Of Integrated Petroleum Expertise From HRT Participacoes ........................................ 104
Eurofins Scientific Completes Acquisition of Viracor-IBT Labs For USD255 Million ...................................................................... 105
Eurofins Scientific Acquires IDmyk................................................................................................................................................. 107

Asset Transactions ......................................................................................................................................................................... 108

Eurofins Advinus Acquires Assets of Gomti Life Sciences .............................................................................................................. 108
Eurofins Scientific to Acquire Testing Business from Exova........................................................................................................... 109
Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of Merck ................................................ 110
Contract Service Agreement .......................................................................................................................................................... 111
Bionure Enters API Manufacturing Agreement with Advinus for BN-201 ..................................................................................... 111
Debt Offerings ................................................................................................................................................................................ 112
Eurofins Scientific Raises USD655.4 Million in Public Offering of Bonds ....................................................................................... 112
Eurofins Scientific Raises USD464.7 Million in Public Offering of 3.25% Bonds ............................................................................ 113
Eurofins Scientific Raises USD745.3 Million in Public Offering of 2.125% Bonds Due 2024 .......................................................... 114
Eurofins Scientific Raises USD554 Million in Public Offering of 3.375% Bonds Due 2023 ............................................................. 115
Eurofins Scientific Prices USD322 Million in Public Offering of 4.87% Bond Due 2023 ................................................................. 116
Eurofins Scientific Raises USD579 Million in Public Offering of 2.25% Bond Due 2022 ................................................................ 117
Equity Offerings ............................................................................................................................................................................. 118
Eurofins Scientific to Raise up to USD559 Million in Private Placement of Shares ........................................................................ 118
Eurofins Scientific Raises USD347.1 Million in Private Placement of Shares ................................................................................. 120
Eurofins Scientific Raises USD333 Million in Private Placement of Shares .................................................................................... 121
Partnerships ................................................................................................................................................................................... 122
Eurofins Pharma Discovery Enters into Collaboration with Escient Pharma ................................................................................. 122
LifeCodexx Enters into Agreement with LifeCell International ...................................................................................................... 123
LifeCodexx Enters into Research Agreement with Charite - Universitatsmedizin Berlin ............................................................... 124
GATC Biotech Enters into Agreement with University of Konstanz ............................................................................................... 125
Idogen Enters into Research Agreement with Advinus Therapeutics............................................................................................ 126
Transplant Genomics Enters into Agreement with Mayo Clinic Center for Individualized Medicine ............................................ 127
Applied BioCode Enters into Agreement with Diatherix................................................................................................................ 128
Biomnis SELAS Enters into Agreement with DIATHERIX Laboratories ........................................................................................... 129
Transplant Genomics Enters into Clinical Trial Agreement with Astellas Pharma ......................................................................... 130
Quark Pharma Enters into Agreement with Transplant Genomics................................................................................................ 131
Agilent Technologies Enters into Agreement with Eurofins Genomics ......................................................................................... 132
IQuity Labs Enters into Agreement with Diatherix Labs ................................................................................................................ 133
Biomnis Enters into Agreement with ODPM ................................................................................................................................. 134
Diatherix Labs Enters into Research Agreement with Vanderbilt University Medical Center ....................................................... 135
Rubicon Genomics Enters into Distribution Agreeement with Eurofins MWG Operon ................................................................ 136
Qiagen Enters into Agreement with GATC Biotech ....................................................................................................................... 137
Transplant Genomics Enters into Licensing Agreement with Scripps Research Institute and Northwestern University .............. 138
Eurofins Genomics Enters into Co-Marketing Agreement with AmpTec for IVT-RNAs ................................................................. 139
Oxford Gene Enters Co-Development Agreement With Emory Genetics For New CGH Arrays .................................................... 140
Venture Financing .......................................................................................................................................................................... 141
Transplant Genomics Raises USD1.5 Million in Venture Financing ............................................................................................... 141
Transplant Genomics Raises USD1.7 Million in Venture Financing ............................................................................................... 142
Transplant Genomics Raises US$2.8 Million In Venture Financing ................................................................................................ 143
Section 5 – Company’s Recent Developments .............................................................................................................................. 144
Jul 14, 2020: Eurofins publishes robust method to analyse SARS-CoV-2 in wastewater samples, providing early warning of
potential COVID-19 outbreak at a given site ................................................................................................................................. 144
Jun 29, 2020: Eurofins DiscoverX further expands its bioassay certification program with Catalent Biologics ............................ 145
Jun 03, 2020: TGI and Viracor announce Transplant Advisory Board ............................................................................................ 146
Apr 28, 2020: Eurofins Scientific to enable over 20 million COVID-19 tests per month by end May 2020 with multiple new
solutions ......................................................................................................................................................................................... 147
Apr 16, 2020: Eurofins Genomics U.S. launches new SARS-CoV-2 plasmid DNA controls and increases its capacity to produce
probes and primers, all of which being key components of SARS-CoV-2 RT-PCR testing.............................................................. 148
Apr 13, 2020: Eurofins Discovery supports critical COVID-19 drug discovery research with products and accelerated drug
discovery services .......................................................................................................................................................................... 149
Apr 07, 2020: The National Kidney Registry and Viracor Eurofins announce Coronavirus Antibody Testing for Donors and
Recipients....................................................................................................................................................................................... 153

Apr 06, 2020: Eurofins Scientific offers a full range of testing services for Personal Protective Equipment (PPEs) and Medical
Devices used in the fight against the COVID pandemic ................................................................................................................. 154
Mar 30, 2020: Viracor Eurofins launches Labs@HOME, a mobile phlebotomy service for post-transplant patient testing ........ 155
Mar 19, 2020: Eurofins Scientific supports healthcare authorities in Europe, the U.S.A. and Brazil in their fight against the
COVID-19 pandemic with additional testing options and fast growing capacity ........................................................................... 156
Mar 18, 2020: Eurofins Transplant Genomics and Viracor will partner to offer Remote Sample Collection Options to support care
for Kidney Transplant Recipients during COVID-19 Outbreak ....................................................................................................... 157
Mar 16, 2020: The National Kidney Registry and Viracor Eurofins Announce Coronavirus COVID-19 Rapid Turnaround Transplant
Testing for Donors and Recipients ................................................................................................................................................. 158
Mar 14, 2020: Eurofins Scientific Supports SARS-CoV-2 analyses needs in the U.S.A. and in Europe with multiple testing options
....................................................................................................................................................................................................... 160
Mar 04, 2020: Eurofins delivers strong growth again in 2019 ....................................................................................................... 161
Jan 10, 2020: Transplant Genomics appoints Dr. John Holman as VP Medical Affairs .................................................................. 170
Dec 11, 2019: Viracor Eurofins expands its clinical diagnostic footprint to oncology ................................................................... 171
Dec 09, 2019: Laboratory to pay $26.67 million to settle allegations of kickbacks to physicians ................................................. 172
Oct 28, 2019: Eurofins reports strong organic growth (over 6%) in Q3 2019 ................................................................................ 173
Sep 26, 2019: CareDx files patent infringement lawsuit against Eurofins Viracor......................................................................... 177
Aug 29, 2019: Eurofins reports robust financial performance in H1 2019 despite disruptions from the June cyber-attack ........ 178
Section 6 – Appendix ..................................................................................................................................................................... 183
Methodology ............................................................................................................................................................................. 183
Ratio Definitions ........................................................................................................................................................................ 183
About GlobalData ...................................................................................................................................................................... 187
Contact Us ................................................................................................................................................................................. 187
Disclaimer .................................................................................................................................................................................. 187

List of Tables
Eurofins Scientific SE, Key Facts ......................................................................................................................................................... 9
Eurofins Scientific SE, Key Employees .............................................................................................................................................. 10
Eurofins Scientific SE, Key Employee Biographies............................................................................................................................ 12
Eurofins Scientific SE, Major Products and Services ........................................................................................................................ 13
Eurofins Scientific SE, History .......................................................................................................................................................... 14
Eurofins Scientific SE, Subsidiaries ................................................................................................................................................... 21
Eurofins Scientific SE, Key Competitors ........................................................................................................................................... 41
Eurofins Scientific SE, Ratios based on current share price ............................................................................................................. 42
Eurofins Scientific SE, Annual Ratios ................................................................................................................................................ 43
Eurofins Scientific SE, Annual Ratios (Cont...1) ................................................................................................................................ 44
Eurofins Scientific SE, Annual Ratios (Cont...2) ................................................................................................................................ 45
Eurofins Scientific SE, Interim Ratios ............................................................................................................................................... 47
Eurofins Scientific SE, Mergers and Acquisitions Transaction Summary, 2014 to YTD 2020 ........................................................... 55
Eurofins Scientific SE, Strategic Alliances, by Transaction Phase, 2014 to YTD 2020 ...................................................................... 58
Eurofins Scientific SE, Strategic Alliances Transactions Summary, 2014 to YTD 2020 ..................................................................... 59
Eurofins Scientific SE, Venture Capital Transactions, by Stage of Financing 2014 to YTD 2020 ...................................................... 62
Eurofins Scientific SE, Private Equity/Venture Capital Transactions Summary, 2014 to YTD 2020 ................................................. 63
Eurofins Scientific SE, Equity and Debt Offerings Transactions Summary, 2014 to YTD 2020......................................................... 65
Eurofins Scientific SE, Recent Transactions Summary ..................................................................................................................... 66
Currency Codes .............................................................................................................................................................................. 183
Capital Market Ratios..................................................................................................................................................................... 183
Equity Ratios .................................................................................................................................................................................. 184
Profitability Ratios.......................................................................................................................................................................... 184
Cost Ratios ..................................................................................................................................................................................... 185
Liquidity Ratios............................................................................................................................................................................... 185
Leverage Ratios .............................................................................................................................................................................. 186
Efficiency Ratios ............................................................................................................................................................................. 186
List of Figures
Eurofins Scientific SE, Performance Chart (2015 - 2019) ................................................................................................................. 46
Eurofins Scientific SE, Ratio Charts .................................................................................................................................................. 48

Eurofins Scientific SE, Strategic Alliances, by Transaction Phase, 2014 to YTD 2020, Number of Transactions (%)........................ 58
Eurofins Scientific SE, Venture Capital Transactions, by Stage of Financing 2014 to YTD 2020 ,Number of Transactions(%) ........ 61
Eurofins Scientific SE, Venture Capital Transactions, by Stage of Financing 2014 to YTD 2020 ,Transactions Value(%) ................. 61

Section 1 - About the Company

Eurofins Scientific SE - Key Facts
Eurofins Scientific SE, Key Facts
Corporate Address 23 Val Fleuri, Luxembourg City, Ticker Symbol, Exchange ERF [Euronext Paris]
1526, Luxembourg
Telephone +356 26 185320 No. of Employees 47,000
Fax +356 26 185331 Fiscal Year End December
URL www.eurofins.com Revenue (in USD Million) 5,108.2
Industry Energy and Utilities, Metals and Revenue (in EUR Million) 4,562.8
Mining, Pharmaceuticals and
Healthcare
Locations Australia, Belgium, Brazil, Canada, China, Denmark, Finland, Germany, India, Ireland, Italy, Japan,
Luxembourg, Netherlands, South Korea, Spain, Switzerland, Taiwan, Turkey, United Kingdom, United
States
Source: Annual Report, Company Website, Primary and Secondary Research GlobalData

Eurofins Scientific SE - Key Employees

Eurofins Scientific SE, Key Employees
Name Job Title Board Level Since Age
Gilles G. Martin Chairman, Chief Executive Officer Executive Board 57
Valerie Hanote Director Non Executive Board 54

Stuart Anderson Director Non Executive Board 78
Yves-Loic Martin Director Non Executive Board 2015 54
Fereshteh Pouchantchi Director Non Executive Board 66
Patrizia Luchetta Director Non Executive Board
Dirk Bontridder Executive Vice President Senior Management
BioPharma Services and Clinical
Diagnostics Services US
Markus Brandmeier, Ph.D. Executive Vice President Human Senior Management
Resources, Communication and
Marketing
David Besnault Executive Vice President Senior Management
Environment Testing Europe and
Food & Environment Testing - Asia
Pacific
Laurent Lebras Director Administration and Senior Management
Finance
Andreas Konig Chief Information Officer Senior Management
Francois Vigneau Senior Vice President Food and Senior Management
Feed Testing - Western Europe
Gabriel Julia Senior Vice President Clinical Senior Management
Diagnostics - Europe
Timothy S. Oostdyk Executive Vice President Senior Management
BioPharma, Genomics and
Agrosciences Services - North
America
David W. Bryant Senior Vice President Food and Senior Management
Environment Testing - North
America
Brian Williams Executive Vice President Senior Management
Environment Testing Americas,
Latin America and Australia/New
Zealand
Yvoine Remy-McCort Senior Vice President Senior Management
Environment Testing - Europe
Joachim Reichelt Senior Vice President Food & Senior Management
Feed Testing - Europe
Rajesh Saigal Executive Vice President Asia Senior Management
and Middle East
Mark Thys Chief Transformation Officer Senior Management 2019
Christian Wurst Chief Operating Officer Food & Senior Management 2019

Environment Testing

Eurofins Scientific SE - Key Employee Biographies

Eurofins Scientific SE, Key Employee Biographies
Gilles G. Martin Dr. Gilles G. Martin is the Chairman and Chief Executive Officer of the Eurofins.
Job Title: Chairman, Chief Executive Officer Prior to this, he was the President of the French Association of private analytical
laboratories APROLAB, of the North American Technical Committee for Juice
Board Level: Executive Board and Juice Products (TCJJP).
Age: 57
Mr. Andreas Konig has been the Chief Information Officer of the company since
Andreas Konig
2016. Prior to this, he was the Chief Information Officer of ProSiebenSat1 Media
Job Title: Chief Information Officer
AG. Mr. Konig also served as the Chief Information Officer and Chief Operating
Officer of First Data.
Board Level: Senior Management

Eurofins Scientific SE - Major Products and Services

Eurofins is a bioanalytical testing service provider. The key services offered by the company include the following:
Eurofins Scientific SE, Major Products and Services
Services:
Food and Feed Testing
Environment Testing
Pharma Services
Genomic Services
Agroscience Services
REACH Services
Product Testing
Genomic Services

Eurofins Scientific SE - History

Eurofins Scientific SE, History
2020 New Products/Services In March, the company launched GeneScan VIRSeek SARS-CoV-2 RT-PCR
testing solution for the detection of SARS-CoV-2 in swabs of environmental
surfaces.
2020 New Products/Services In May, the company launched the new GSD NovaPrime product to identify
the SARS-CoV-2 virus infections through polymerase chain reaction.
2019 Acquisitions/Mergers/Takeovers In August, the company acquired Iproma, a provider of laboratory testing,
monitoring and consulting services from Grupo Gimeno.
2019 Acquisitions/Mergers/Takeovers In July, the company acquired AQM, a provider of audits, inspection and
brand protection.
2019 Acquisitions/Mergers/Takeovers In June, the company acquired Transplant Genomics Inc., a developer of
molecular diagnostics.
2019 Contracts/Agreements In December, the company collaborated with Medicinal Genomics to develop
a high-density SNP chip for cannabis and hemp genotyping, breeding, and
pathogen testing.
2019 Regulatory Approval In March, the company received approval for Y chromosome assessment to
its maternalfetalscreenSM t1 test by the New York State Department of
Health (NYSDOH).
2018 Acquisitions/Mergers/Takeovers In April, the company acquired Lab Frontier, a firm which provides a suite of
food, environment and cosmetics testing services in South Korea.
2018 Acquisitions/Mergers/Takeovers In August, Eurofins agreed to acquire Nanolab Technologies, a provider of

materials and analytical solutions.
2018 Acquisitions/Mergers/Takeovers In February, the company acquired a medical testing business provider,
NMDL-LCPL.
2018 Acquisitions/Mergers/Takeovers In January, the company acquired Selcia Ltd., a provider of custom
radiolabelling and drug discovery services.
2018 Acquisitions/Mergers/Takeovers In January, the company acquired Tsing Hua Testing & Analysis Co., Ltd.
2018 Acquisitions/Mergers/Takeovers In July, Eurofins acquired Laboratoire de Bromatologie de l’Ouest (LBO), a

Food Testing Laboratory in France.
2018 Acquisitions/Mergers/Takeovers In July, the company completed the the acquisition of Laboratorios Ecosur
SA.
2018 Acquisitions/Mergers/Takeovers In June, Eurofins Scientific acquired VTT Expert Services and Labtium from
VTT Group.
2018 Acquisitions/Mergers/Takeovers In May, the company agreed to acquire Exova's food, water and
pharmaceutical testing business in the UK and Ireland.
2018 Acquisitions/Mergers/Takeovers In May, the company signed an agreement to acquire PHAST GmbH.
2018 Acquisitions/Mergers/Takeovers In October, Eurofins Scientific entered into a contract to acquire TestAmerica
Environmental Services, from JSTI Group.
2018 Acquisitions/Mergers/Takeovers In October, the company acquired EnvironeX Group from Marc Hamilton and
Persistence Capital Partners.
2018 Acquisitions/Mergers/Takeovers In October, the company announced the acquisition of Laboratoire Dermscan
SAS, a provider of cosmetic and personal care products testing services in
Europe.
2018 Acquisitions/Mergers/Takeovers In September, the company announced the acquisition of Clinical Research
Laboratories, LLC.

2018 Contracts/Agreements In April, the company entered into a contract to acquire water and food
testing businesses owned by Protec Group located in France.
2018 Contracts/Agreements In May, the company entered into an agreement to acquire Covance Food
Solutions from LabCorp for US$670 million.
2018 Plans/Strategy In April, the company announced its plan to acquire a majority stake in
Medall Healthcare.
2017 Acquisitions/Mergers/Takeovers In April, the company acquired analytical laboratory business in Finland from
Ramboll Group.
2017 Acquisitions/Mergers/Takeovers In December, Eurofins announced the acquisition of Pasteur Group.
2017 Acquisitions/Mergers/Takeovers In December, the company acquired EAG Laboratories, a global scientific
services company.
2017 Acquisitions/Mergers/Takeovers In July, the company acquired GATC Biotech and 62% stake in LifeCodexx.
2017 Acquisitions/Mergers/Takeovers In June, Eurofins agreed to acquire diagnostics testing provider, Genoma.
2017 Acquisitions/Mergers/Takeovers In June, Eurofins signed an agreement to acquire GATC Biotech AG.
2017 Acquisitions/Mergers/Takeovers In June, the company announced the acquisition of Alphora Research Inc.
2017 Acquisitions/Mergers/Takeovers In June, the company announced the acquisition of Nab Labs Group Oy.
2017 Acquisitions/Mergers/Takeovers In March, the company acquired Gozlem Gyda Kontrol ve Araþtyrma
Laboratuvarlary., a Turkey-based food testing lab.
2017 Acquisitions/Mergers/Takeovers In March, the company announced the acquisition of Denmark-based, VBM
Laboratoriet A/S.
2017 Acquisitions/Mergers/Takeovers In May, the company signed an agreement to acquire MVZ für
Laboratoriumsmedizin am Hygiene-Institut (Hygel).
2017 Acquisitions/Mergers/Takeovers In November, Eurofins Scientific SE acquired Spectro Analytical Labs Ltd.
2017 Acquisitions/Mergers/Takeovers In November, the company acquired signed an agreement to acquire the
Forensics and Security division of LGC Forensics.
2017 Acquisitions/Mergers/Takeovers In October, the company acquired Institut Nehring GmbH, a food testing
laboratory.
2017 Contracts/Agreements In July, Eurofins Scientific signed an agreement to acquire Amatsigroup from
Ekkio Capital for around EUR130 million.
2017 Contracts/Agreements In May, Eurofins Scientific acquired four clinical laboratories, which enables
the company to strengthen its clinical diagnostic footprint in France.
2016 Acquisitions/Mergers/Takeovers In April, Eurofins Scientific, the global leader in bio-analytical testing, and one
of the world leaders in genomic services, acquired PerkinElmer, Inc.'s U.S.
prenatal screening laboratory services business PerkinElmer Labs/NTD.
2016 Acquisitions/Mergers/Takeovers In January, Eurofins Scientific acquired Sinensis Life Sciences.
2016 Acquisitions/Mergers/Takeovers In March, the company agreed to acquire Advantar Laboratories.
2016 Acquisitions/Mergers/Takeovers In March, the company announced the acquisition of ams Laboratories.
2016 Acquisitions/Mergers/Takeovers In September, Eurofins Scientific acquired VRL Laboratories, expanding its
clinical diagnostics footprint.
2016 Acquisitions/Mergers/Takeovers In September, the company acquired Megalab SA for a value at

approximately EUR40 million.
2016 Commercial Operation In January, Biomnis and a subsidiary of Eurofins Scientific launched a protocol
for pharmacogenetics tests after the creation of a cancer treatment

partnership with Onco Drug Personalized Medicine.
2016 Contracts/Agreements In December, Eurofins Scientific entered into an agreement to acquire

Villapharma Research SL to expand its footprint in discovery pharmacology.
2016 Corporate Changes/Expansions In February, Eurofins Microbiology opened a new, state-of-the-art, ISO 17025
accredited laboratory in Louisville, Kentucky, the U.S.
2016 Corporate Changes/Expansions In March, Eurofins Scientific opened its new state-of-the-art manufacturing
and services facility in Louisville, Kentucky, the U.S.
2016 Financing Agreements In September, the company raised EUR296 million in private placement of
shares.
2016 Plans/Strategy In June, the company plans to expand its Dungarvan, Ireland campus to
advance its laboratory services.
2015 Acquisitions/Mergers/Takeovers In February, Eurofins Scientific completed the acquisition of Boston Heart
Diagnostics Corporation.
2015 Acquisitions/Mergers/Takeovers In June, the company had signed an agreement to acquire Diatherix
Laboratories, Inc. for approximately US$50 million.
2015 Acquisitions/Mergers/Takeovers In May, Eurofins Scientific entered into an agreement to acquire 65% stake in
Sac Ky Hai Dang.
2015 Acquisitions/Mergers/Takeovers In May, Eurofins Scientific SE acquired QC Laboratories(QC Inc), and changed
QC Laboratories name to Eurofins QC Inc.
2015 Acquisitions/Mergers/Takeovers In May, the company acquired Experchem Laboratories.
2015 Contracts/Agreements In February, Eurofins Scientific acquired BioDiagnostics Inc.
2015 Contracts/Agreements In June, Eurofins Scientific signed an agreement, to acquire a controlling

interest in the Emory Genetics Laboratory (EGL).
2015 Contracts/Agreements In June, the company entered into an agreement with Financiere Bio Alfras
SAS to acquire Biomnis Group for purchase consideration of EUR220 million.
2015 Contracts/Agreements In June, the company signed an agreement, to develop Bio-Access/Labazur

clinical laboratories together with its founder and the medical biologists.
2015 Financing Agreements In December, Eurofins Scientific SE announced a private placement of

1,000,000 shares of its common stock.
2014 Acquisitions/Mergers/Takeovers In February, the company acquired KBBL, one of the leading food and water
testing service companies in The Netherlands.
2014 Acquisitions/Mergers/Takeovers In January, the company acquired discovery and development solutions
business of Merck KGaA.
2014 Acquisitions/Mergers/Takeovers In January, the company acquired IDmyk, a laboratory specialized in the
areas of detection, identification and molecular typing of microorganisms.
2014 Acquisitions/Mergers/Takeovers In July, Eurofins entered into an agreement to acquire Analytical Technology,
one of the leading environmental testing service companies in Brazil.
2014 Acquisitions/Mergers/Takeovers In July, Eurofins Scientific acquired Viracor-IBT Labs For USD255 Million.
2014 Acquisitions/Mergers/Takeovers In July, the company entered into an agreement to acquire Analytical
Technology.
2014 Acquisitions/Mergers/Takeovers In March, the company acquired Applus Agrofood Testing, a leading food and
agro-environmental testing provider in Spain.
2014 Acquisitions/Mergers/Takeovers In March, the company acquired the food and environmental testing
laboratory of Maintpartner Group.
2014 Acquisitions/Mergers/Takeovers In March, the company signed an agreement to acquire the consumer and
municipal water testing business of UL (Underwriters Laboratories).

2014 Acquisitions/Mergers/Takeovers In May, Eurofins signed an agreement to acquire Calscience Environmental

Laboratories, Inc. in the US.
2014 Acquisitions/Mergers/Takeovers In May, the company acquired Applus Agrofood Testing, a leading food and
agro-environmental testing provider in Spain.
2014 Acquisitions/Mergers/Takeovers The company sets plans to acquire Viracor-IBT Labs for US$255 million.
2014 Corporate Changes/Expansions In September, Eurofins opened new state-of-the-art quarantine facility in
Toowoomba, Queensland.
2014 New Products/Services In November, Eurofins introduced rapidust, the first on-site test system for
mycotoxins, including representative sampling of grain lots and rapid
analysis.
2014 Other In June, Eurofins combined its competencies to provide the most
comprehensive suite of genomics services in the market.
2014 Plans/Strategy In November, the company planned to acquire SF Analytical Laboratories to

strengthen its position in US.
2013 Acquisitions/Mergers/Takeovers In February, Eurofins Discovery Services Luxembourg Holding acquired over
50% of the share capital of Cerep S.A.
2013 Acquisitions/Mergers/Takeovers In February, the company completed the acquisition of AROS Applied
Biotechnology A/S (AROS).
2013 Acquisitions/Mergers/Takeovers In January, the company acquired 80% majority stake in mgt-LabMark.
2013 Acquisitions/Mergers/Takeovers In January, the company acquired Laboratorium Zeeuws-Vlaanderen (LZV).
2013 Acquisitions/Mergers/Takeovers In July, the company acquired BLGG Groep BV, the leading agribusiness
testing service companies in The Netherlands.
2013 Acquisitions/Mergers/Takeovers In March, the company entered into an agreement to acquire a 52% stake in
GCL/Fundacion Chile (GCL).
2013 Acquisitions/Mergers/Takeovers In September, the company announced the acquisition of 81% stake in
Agrisearch Services.
2013 Contracts/Agreements In August, the company entered into a milestone outsourcing agreement
with Danone.
2013 Contracts/Agreements In March, the company was selected as the main industry laboratory
participant in a European Commission-sponsored research project.
2013 New Products/Services In June, the company introduced a high-resolution LC-MS-based screening
method for 100 antibiotics and antiparasitics in meat and fish.
2013 Official Trials/Tests In December, the company introduced a research breakthrough in genetic
discrimination between identical monozygotic twins.
2012 Acquisitions/Mergers/Takeovers In April, the company completed the acquisition of ALAC.
2012 Acquisitions/Mergers/Takeovers In April, the company entered into an agreement to acquire a 52.6% majority
stake in Nihon Kankyo K.K.
2012 Acquisitions/Mergers/Takeovers In December, the company completed the acquisition of Cerep.
2012 Acquisitions/Mergers/Takeovers In December, the company entered into an agreement to acquire a 92.5%
majority stake in Viljavuuspalvelu Oy.
2012 Acquisitions/Mergers/Takeovers In July, the company acquired New Zealand Laboratory Services (NZ Labs).
2012 Acquisitions/Mergers/Takeovers In July, the company planned to acquire MWH Laboratories (MWH Labs).
2012 Acquisitions/Mergers/Takeovers In March, Eurofins completed the acquisitions of LabCo and Envirocontrol.
2012 Acquisitions/Mergers/Takeovers In September, the company entered into an agreement to acquire the Pan

Labs pharmacology unit.
2012 Contracts/Agreements In November, Eurofins Eaton Analytical was selected by the US

Environmental Protection Agency (EPA) to offer water quality testing services
to communities below 10,000 people.
2012 New Products/Services In March, the company launched its Webinar services catering the food and
feed industry.
2012 Plans/Strategy In March, the company planned to acquire the Quality Trait Analysis (QTA)
business of BASF Corporation.
2012 Plans/Strategy In October, the company completed its laboratory expansion plan for 2012.
2011 Acquisitions/Mergers/Takeovers In April, the company acquired 100% of Lancaster Laboratories, Inc.
2011 Acquisitions/Mergers/Takeovers In November, the company acquired a 67% majority stake in each of the two
subsidiaries of the Fondation Institut Pasteur de Lille (IPL), namely IPL Invest
and IPL Santé Environnement Durable Nord.
2011 Corporate Changes/Expansions In September, the company inaugurated a 3,000 m2 extension to its
laboratory in Nantes, France.
2011 Other In July, the company transferred its experience in radioactivity analysis of
food and water to its new laboratory for Radioactive Material Analysis (RMA)
in Japan.
2009 Contracts/Agreements In January, DLG Group agreed to outsource its laboratory testing activities
and part of its daily quality control to Eurofins Steins in Denmark.
2008 Contracts/Agreements In July, the company entered into an outsourcing agreement with Raisio
Yhtyma Oyj.
2008 Corporate Changes/Expansions In April, the company opened a new pharmaceutical laboratory in Suzhou,
China.
2007 Acquisitions/Mergers/Takeovers In November, the company acquired three companies engaged in the
production of genomic services in Germany, Japan and the US.
2007 Acquisitions/Mergers/Takeovers In October, the company completed the acquisition of Lantmannen Analycen
AB.
2007 Corporate Changes/Expansions In May, the company launched a new laboratory in the Fitzsimons Biotech
Park in Aurora, Colorado, the US.
2007 Corporate Changes/Expansions In November, the company established a new microbiology laboratory in
Acton, the UK
2006 Acquisitions/Mergers/Takeovers In July, the company acquired Steins Laboratorium A/S, a company in
Denmark and Sweden specialized in laboratory testing of food, feed and
agriculture.
2006 Acquisitions/Mergers/Takeovers In November, the company acquired several mid-size companies in Germany,
Italy and France.
2005 Acquisitions/Mergers/Takeovers In August, the company acquired Ginger SA's LEM laboratories.
2005 Acquisitions/Mergers/Takeovers In June, the company acquired the Scandinavian environmental laboratories
Steins A/S.
2005 Acquisitions/Mergers/Takeovers In November, the company completed the acquisition of AvTech

Laboratories, Inc.
2005 Contracts/Agreements In March, the company secured an outsourcing contract from SITA
Netherlands.
2005 Corporate Changes/Expansions In May, the company completed establishing the first phase of a food
analysis center.
1997 Stock Listings/IPO The company was issued its IPO on the French stock exchange.

1987 Incorporation/Establishment The company was founded in 1987.

Eurofins Scientific SE - Company Statement
The Vision and Mission statement of Eurofins Scientific SE is given below. It has been taken from the company's website.
Our Vision
Our long-term aspiration
To be the Global Leader in Testing for Life.
Our Mission:
Why we are here - the cause/purpose of our business
To contribute to a safer and healthier world by providing our customers with innovative and high quality laboratory, research and advisory
services whilst creating opportunities for our employees and generating sustainable shareholder value.

Eurofins Scientific SE - Locations And Subsidiaries

Head Office
Eurofins Scientific SE
23 Val Fleuri
Luxembourg City
1526
Luxembourg
Tel: +356 26 185320
Fax: +356 26 185331
Other Locations & Subsidiaries
Eurofins Scientific SE, Subsidiaries
Eurofins Viracor Inc GATC Biotech AG

Jakob-Stadler-Platz 7
1001 NorthWest Technology Drive Constance
Lee's Summit Baden-Wurttemberg
78467
MO
Germany
64086 Tel: +49 7531 81600
United States Fax: +49 7531 816081
Url: www.gatc-biotech.com/en
Tel: +1 816 3470113
Fax: +1 816 3470143
Url: www.viracor-eurofins.com
GeneScan Europe AG DIATHERIX Laboratories Inc

Engesserstrasse 4 Suite 4208
Freiburg 601 Genome Way
Baden-Wurttemberg Huntsville
79108 AL
Germany 35806
Tel: +49 761 5038100 United States
Fax: +49 761 5038 211 Tel: +1 866 9794242
Url: www.genescan.de Url: www.diatherix.com
Eurofins Advinus Ltd Eurofins Medigenomix GmbH

No. 21 and 22 Anzinger Strasse 7a
Phase II, Peenya Industrial Area Ebersberg
Bangalore Bayern
Karnataka 85560
560058 Germany
India Tel: +49 8092 8289200
Tel: +91 80 28394959 Fax: +49 8092 8289201
Fax: +91 80 28394015 Url: www.eurofins.com
Url: www.advinus.com
Eurofins Optimed SAS Eurofins Amatsigroup NV

1 Rue Des Essarts Industriepark Zwijnaarde 7B
Gieres Ghent
Rhone Alpes Flandre Occidentale
38610 9052
France Belgium
Tel: +33 4 38372740 Tel: +32 92 411104
Fax: +33 4 38372741 Url: www.amatsigroup.com
Url: www.eurofins.com

Eurofins Alphora VBM Laboratoriet A/S

Suite 2001 Denmark
2395 Speakman Drive
Mississauga
ON
L5K 1B3
Canada
Tel: +1 905 4030477
Fax: +1 905 4038744
Url: www.alphoraresearch.com
Biomnis SELAS Eurofins NTD LLC

17-19 Avenue Tony Garnier Suite 1
Lyon 80 Ruland Road
69007 Melville
France NY
Tel: +33 4 72801010 11747
Url: www.eurofins-biomnis.com United States
Tel: +1 631 4250800
Url: www.ntd-eurofins.com
Eurofins Viralliance Inc Eurofins AvTech Laboratories Inc

United States 712 Abbott Road
East Lansing
MI
48823
United States
Url: www.avtechlabs.com
Eurofins Forensic Services Eurofins MWG Operon LLC

Queens Road 12701 Plantside Drive
Teddington Louisville
Middlesex KY
TW11 0LY 40299
United Kingdom United States
Tel: +44 20 89437000 Fax: +1 502 3710613
Fax: +44 20 89432767 Url: www.eurofinsgenomics.com
Url: www.eurofins.co.uk
Lancaster Laboratories Inc Eurofins Medinet BV

2425 New Holland Pike Bergschot 71
Lancaster PO Box 5510
PA Breda
17605 Noord-Brabant
United States 4801 PA
Tel: +1 717 6562300 Netherlands
Fax: +1 717 6562681 Tel: +31 76 5737518
Fax: +31 76 5737777
BioDiagnostics Inc Met Laboratories Inc.

507 Highland Drive 914 W. Patapsco Ave.
River Falls Baltimore
WI 21230
54022 United States
United States Tel: +1 410 3543300
Tel: +1 715 4260246 Fax: +1 410 3543313
Fax: +1 715 4260251 Url: www.metlabs.com
Url: www.biodiagnostics.net

Eurofins NSC US Inc ID MYK SA

2425 New Holland Pike Bât 4B - 1, rue des Vergers
Lancaster Limonest
PA Rhone Alpes
17605 69760
United States France
Url: www.eurofinsus.com Tel: +33 4 37499351
Fax: +33 4 37499362
Url: www.idmyk.com
Laboratoire Dermscan Eurofins LC2

114 Boulevard du 11 Novembre 1918 10 Rue de l'Aqueduc, Z.A. of Charpenay
Lyon Lentilly
Auvergne Rhone Alpes
69100 69210
France France
Url: www.dermscan.com Tel: +33 4 74721777
Fax: +33 4 74721760
Url: www.eurofins.com/contact-us/worldwide-interactive-
map/france/lc2-pharmaceuticals/
Eurofins Scientific Italia srl Advantar Laboratories Inc

Via Vinca 6 3030 Bunker Hill Street
San Giorgio di Piano Suite 101
Bologna San Diego
Emilia-Romagna CA
I 40016 92109
Italy United States
Tel: +39 51 6650637 Tel: +1 858 2287788
Fax: +39 51 6655119 Url: www.advantarlabs.com
Url: www.eurofins-agrisearch.com
Integrated Petroleum Expertise Co Eurofins Analytics France SAS

69/71 - Botafogo, Rua Dezenove de Fevereiro France
Rio de Janeiro
Rio de Janeiro
Brazil
Tel: +55 21 36229500
Fax: +55 21 36229513
Eurofins Agroscience Services France SAS Eurofins GSC France SAS

France France
Eurofins Food Testing UK Holding Ltd Eurofins Analytik GmbH

United Kingdom Germany
Eurofins Food Denmark Holding A/S Eurofins GSC LUX SARL

Denmark 10A rue Henri Schnadt
Luxembourg
L 2530
Luxembourg
Tel: +352 26185341
Fax: +352 26185330
Eurofins Genomics LUX Holding SARL Eurofins Hydrologie France LUX Holding SARL
Luxembourg Luxembourg
Eurofins Genomics GmbH Eurofins Product Testing Hong Kong Ltd

Anzinger Str. 7a Hong Kong
Ebersberg

Bayern
85560
Germany
Tel: +49 8092 82890
Fax: +49 8092 21084
Url: www.eurofinsgenomics.eu
Nihon Kankyo K.K. Boston Heart Diagnostics Corp

http://www.n-kankyo.com/english/moreinfo/ Suite 100
TKY 175 Crossing Boulevard
Japan Framingham
MA
01702
United States
Tel: +1 508 8778711
Fax: +1 508 8778707
Url: www.bostonheartdiagnostics.com
Eurofins Scientific Inc Eurofins Eaton Analytical

2200 Rittenhouse Street United States
Suite 175
Des Moines
IA
50321
United States
Tel: +1 515 280 8378
Fax: +1 515 280 7068
Eurofins Panlabs Inc Eurofins ams Laboratories Pty Ltd

22011 30th Drive SE Bothell 8 Rachael Close
Bothell Silverwater
WA NSW
98021 2128
United States Australia
Tel: +1 800 7265229 Tel: +61 297 042300
Url: www.eurofinspanlabs.com Fax: +61 297 379425
Url: www.amslabs.com.au
Eurofins Sinensis Emory Genetics Laboratory

Archimedesweg 23 2165 North Decatur Road
Decatur
Leiden GA
Netherland Antilles 30033
2333 CM United States
Netherlands Tel: +1 404 7788499
Tel: +31 71 5244080 Fax: +1 404 7788559
Url: www.sinensislifesciences.com Url: www.genetics.emory.edu
VRL Laboratories Transplant Genomics Inc

Suite 205 Suite 102
6665 S Kenton Street 905 South Main Street
Centennial Mansfield
CO MA
80111 02048
United States United States
Fax: +1 303 7991584 Tel: +1 508 3376200
Url: www.vrlden.com Url: www.transplantgenomics.com
Eurofins Forensics Belgium BVBA Eurofins Scientific Services NV

Lieven Bauwensstraat 4-6 Chaussee de Malines, 455

Brugge Kraainem
B 8200 Brabant Flamand
Belgium 1950
Belgium
Eurofins Product Testing Services Ltd Eurofins Consumer Product Testing GmbH
D3 Broadoak Business Park Germany
Ashburton Road West Trafford Park

Mancheste
M17 1RW
United Kingdom
Eurofins Umwelt West GMBH Eurofins QC, Inc.

Germany
Labtium Ltd Eurofins Pharma Services LUX Holding SARL

Tekniikantie 2 Switzerland
Espoo
+2150
Finland
Eurofins Genomics BV Eurofins International Support Services LUX SARL

Netherlands Luxembourg
Eurofins International Holdings LUX SARL Eurofins Finance NV

Luxembourg Belgium
Eurofins Bioanalytics UK Clinical Research Laboratories LLC

90 Park Drive Suite #100
Abingdon 371 Hoes Lane
Oxfordshire Piscataway
OX14 4RY NJ
United Kingdom 08854
Fax: +44 1235 444199 Tel: +1 732 9811616
Url: www.eurofins.com Fax: +1 732 9810520
Url: crlresearchlabs.com
Eurofins Lancaster Laboratories Inc Eurofins Bioanalytical Services UK Ltd

2425 New Holland Pike 90 Park Dr, Milton
Lancaster Abingdon
PA Oxfordshire
17601 OX144RY
United States United Kingdom
Tel: +1 717 6562300 Tel: +44 1235 444100
Url: www.lancasterlabs.com Fax: +44 1235 444199
Cerep Drug Discovery Services Co, Ltd. NDSM Limited

326 Aidisheng (Edison) Road North Yorkshire
B 302-1 United Kingdom
Shanghai
SHA
201203
China
IPROMA Eurofins Digital Product Testing UK Limited

CNO. the Raya 46 i54 Business Park
Castellon Wolverhampton

Spain United Kingdom

Tel: +34 964 251 072 Tel: +44 1179 8961 00
Fax: +34 964 210 476 Fax: +44 1179 8961 01
Url: www.iproma.com Url: www.eurofins-digitaltesting.com
Eurofins GeneScan GmbH Evans Analytical Group LLC

Engesserstrasse 4, <br> Freiburg 79108, Germany 810 Kifer Road
Engesserstrasse 4 Sunnyvale
Freiburg CA
Baden-Wurttemberg United States
Germany Tel: +1 408 530 3500
Tel: +49 761 5038 200 Fax: +1 408 530 3501
Url: www.genescan.de Url: www.eaglabs.com
Eurofins Eaton Analytical, Inc. Eurofins Agroscience Services, Inc.

750 Royal Oaks Drive #100 6100 Thornton Avenue
Monrovia Suite 220
CA Des Moines
United States IA
Fax: +1 626 386 1101 Tel: +1 515 280 8378
Url: www.eatonanalytical.com Fax: +1 515 280 7075
Url: www.eurofinsagro.com
Megalab S.A. Biomnis Group

Calle Alfonso XII, 42 - 1 17/19 Avenue Tony Garnier
MAD Lyon
Spain Rhone Alpes
Tel: +34 914 296 287 France
Url: www.megalab.es Tel: +33 8 00061814
Url: www.biomnis.com
Gozlem Gyda Kontrol ve Araþtyrma Laboratuvarlary Nab Labs Group Oy

Istanbul
Istanbul-I (Thrace)
34742
Turkey
Spectro Analytical Labs Limited Pasteur Group

Andhra Pradesh Av. Meritxell, 84
India Andorra la Vella
Url: www.spectro.in Brazil
Tel: +55 376 800970
Fax: +55 376 800978
Url: pasteurgroup.com
Tsing Hua Testing & Analysis Co., Ltd. NMDL-LCPL

Taiwan Visseringlaan 25
Rijswijk
Zuid-Holland
2288
Netherlands
Tel: +1 88 2350235
Fax: +1 88 2350236
Url: www.nmdl-lcpl.nl
Eurofins Food Testing Laboratory Eurofins Agroscience Services GmbH

3F YoungLin Bldg, 60 Germany
Anyangcheondong-ro, Dongan-gu, Anyang-si
14042

South Korea
Tel: +82 31 4609000
Url: www.labfrontier.com
Laboratoire de Bromatologie de l’Ouest Laboratorios Ecosur S.A.

46 rue Ernest Renan Castillo de Aledo
Rosporden Poligono Industrial San Martin S/N
29140 Lorqui
France MUR
Tel: +33 2 98 59 80 60 30564
Fax: +33 2 98 59 91 22 Spain
Url: www.lbo.fr Tel: +34 968 676 842
Url: www.laboratoriosecosur.es
Eurofins BioPharma Product Testing Netherlands BV Eurofins Australia New Zealand Holding Pty Ltd
Middenkampweg 19 6 Monterey Road
Nijmegen Melbourne
Gelderland VIC
6545 Australia
Netherlands
Tel: +31 24 3715280
Url: www.sinensislifesciences.com
Eurofins BioPharma Product Testing Ireland Ltd AQM (France)

IDA Industrial Estate France
Url: www.aqm-textile.com
Dungarvan
Munster
X35 Y326
Ireland
Tel: +353 58 48300
Url: www.eurofins.ie
Eurofins Genomics LLC Eurofins GeneScan Technologies GmbH

12701 Plantside Drive Engesser Strasse 4
Louisville Freiburg
KY D 79108
40299 Germany
United States Tel: +49 761 50 38 20 0
Tel: +1 800 6882248 Fax: +49 761 50 38 11 1
Fax: +1 502 3710613 Url: www.eurofins.com
Url: www.eurofinsgenomics.com

Section 2 – Company Analysis

Company Overview
Eurofins Scientific SE (Eurofins) is a life sciences company, which provides analytical testing services to clients in various industries. The
company offers food and feed testing, biopharma services, pharma discovery services, pharma early development, pharma central laboratory,
biopharma product testing, agroscience services, product testing, forensic services and environmental testing. Its analytical methods help in
evaluating the safety, identity, composition, origin, authenticity and purity of biological products and substances. It harnesses its expertise in
logistics and information technology to deliver a range of services. The company operates across Western Europe, North America, and Rest of
the World. Eurofins is headquartered in Luxembourg.

Eurofins Scientific SE - Business Description

Eurofins Scientific SE (Eurofins) provides a range of analytical testing services. It offers food, environment and pharmaceutical products testing
and laboratory services.
The company’s major services include food and feed testing; biopharma services; biopharma product testing; genomic services; medical
device testing and biocides testing; agroscience services; consumer product testing; forensic services; and environmental testing services.
R&D efforts focus on the latest developments in the field of biotechnology and analytical chemistry to develop and offer a comprehensive
range of testing methods. The company has several internal and collaborative R&D projects including projects with the European Union.
It offers testing portfolio of over 200,000 tests and operates more than 800 laboratories in 50 countries.

Product Category: Agroscience Services

Agroscience Services - Overview
Offers global field studies, worker exposure studies, ecotoxicology, analytical services, physico-chemical property testing, environmental fate
laboratory and field studies.
Product Category: Biopharma Services

Biopharma Services - Overview
Its services include in vitro pharmacology profiling/screening services.
-It also offers in vivo screening models across therapeutic categories including infectious diseases, cardiovascular, central nervous system,
gastro intestinal, inflammation, allergy, metabolic, endocrine, oncology and respiratory.
Product Category: Clinical Diagnostics

Clinical Diagnostics - Overview
Develops clinically validated non-invasive diagnostic tests based on molecular analytical method.
Product Category: Consumer Product Testing

Consumer Product Testing - Overview
Services include testing, certification, and consulting on the quality and safety of products.
-It provides the services to manufacturers, distributors and retailers.
Product Category: Environmental Testing

Environmental Testing - Overview
Offers services including water testing, soil testing, fuel testing, building materials, waste testing, air testing and pollution testing.
Product Category: Food and Feed Testing

Food and Feed Testing - Overview
Offers food and feed testing services by using state-of-the-art analytical techniques. Its serves various industries such as poultry, meat,
farming, fishing, dairy, fruits and vegetables, spice, sweets, tea and tobacco.
-Key services include allergen testing, authenticity testing, carbohydrates testing, dioxins and pops testing, food irradiation testing, food law
and labelling, GMO testing, grain testing, heavy metals testing, identity preservation, meat testing, melamine testing, microbiology testing,
molecular biology & immunology testing, mycotoxins testing.
-Other services include nano material testing, nutritional analyses, organic contaminants, packaging/migration, pesticides testing, rapidust
testing, residual DNA testing, sensory analyses, veterinary drug residues testing, vitamins testing.

Product Category: Genomics Services

Genomics Services - Overview
Offers DNA sequencing services, genotyping services, DNA synthesis products and bioinformatics services catering to pharmaceutical,
diagnostics, agriculture, food, biotechnological and research markets.
Product Category: REACH Services

REACH Services - Overview
Offers consultancy and regulatory support; generates test data in areas such as physico chemical properties, ecotoxicology, toxicology and
chemical analysis and substance identification.
Geographical Segment: Europe

Europe - Performance
Reported revenue of EUR2,500.6 million for FY2019, which grew 13.2% YoY. Europe accounted for 54.8% of the company's revenue in FY2019.

Eurofins Scientific SE, Europe, Revenue Performance EUR (m)

Year Revenue
2018 2,209.90
2019 2,500.60

Geographical Segment: North America

North America - Performance
Reported revenue of EUR1,677.2 million for FY2019, which grew 33.5% YoY. North America accounted for 36.8% of the company's revenue in
FY2019.

Eurofins Scientific SE, North America, Revenue Performance EUR (m)

Year Revenue
2015 643.20
2016 803.60
2017 902.80
2018 1,256.70
2019 1,677.20

Geographical Segment: Rest of the World

Rest of the World - Performance
Reported revenue of EUR385.0 million for FY2019, which grew 22.4% YoY. Rest of World accounted for 8.4% of the company's revenue in
FY2019.

Eurofins Scientific SE, Rest of the World, Revenue Performance EUR (m)
Year Revenue
2017 459.50
2018 314.50
2019 385

Eurofins Scientific SE - SWOT Analysis

SWOT Analysis - Overview
Eurofins Scientific SE (Eurofins) capitalizes on its leading market position, research and development capabilities to improve its operational
performance. Decline in working capital can be an area for concern to the company. Intense competition, integration risks and intellectual
property risk pose a threat to the company. However, Eurofins could benefit from its strategic acquisitions, initiatives and increasing
opportunities in testing field.
Eurofins Scientific SE - Strengths

Strength - Dominant Position
Eurofins is a leading player in the food and pharmaceutical testing. According to estimates of the company it company holds the number one
position in the field of environmental laboratory services. Lancaster Environmental Testing is the laboratory of choice for several leading
companies in the US. It is one of the market leaders worldwide in agroscience, genomics, discovery pharmacology and central laboratory
services. The company holds one of the leading positions in the food and food testing market offering a comprehensive range of services
covering agricultural production and product development, production and retail and distribution. Eurofins is a market leader in the pharma
product testing and discovery pharmacology services spanning the entire drug development cycle. It also holds a leading position in the
environment testing market.
Strength - Operational Performance
Eurofins capitalizes on its growing businesses, which enable it to improve its operational performance. In FY2019, Eurofins reported revenue
of EUR4,563 million, reflecting an increase of 20.7% over revenue for FY2018. The company benefits substantially from its food testing
business. It reported strong growth owing to regulations in the US, increased food testing in Europe, increased trade and wealth in emerging
markets, or outsourcing activities. In pharmaceutical testing, the company’s pharma product testing business continues to grow due to its
stable operational and geographical presence. Its genomics business continues to report growing demand especially for its new range of
services. Such activities enabled the company to post strong growth and continued profitability.
Strength - Research and Development Capabilities
The company undertakes research and development activities to develop and deploy new analytical methods. Eurofins conducts several
internal and collaborative research and development projects including development activities with European Union. The majority of research
projects led to successful application of new analytical methods. The company capitalizes on the latest development in biotechnology and
analytical chemistry to offer unique solutions to its clients. Eurofins’ expertise in R&D enabled it to offer a portfolio of 200,000 reliable
analytical methods. The company operates over 400 laboratories across 50 countries. Eurofins continues to develop and acquire state-of-the-
art analytical technologies to support its clients’ growing stringent quality and safety standards and the demands of regulatory authorities
across the world. The company leverages its proprietary technologies for proof of origin, virus phenotyping and authenticity testing. It has
extensive expertise in local regulations in all major markets, and acts as a one-stop contact for compliance in multiple countries.

Eurofins Scientific SE - Weaknesses

Weakness - Decline in Working Capital
Eurofins reported a decline in its working capital in FY2019, which could cause financial instability and make it difficult for the company to
meet its short-term obligations. For the FY2019, the working capital stood at EUR23 million, as compared to EUR255 million in the previous
year. The company reported current assets of EUR1,604 million, reflecting a year-on-year decline of 5.9%. Cash and cash equivalents also
declined by 41.3%. Such decline could render the company borrow short-term financing in the case of additional unforeseen indirect costs, in
turn increasing its interest liabilities.

Eurofins Scientific SE - Opportunities

Opportunity - Growth Drivers
Eurofins could benefit substantially from the growing demand in the food testing market, pharma testing market and environmental testing
market. The growth drivers of food testing market include food scares and crisis, globalization, increased food safety awareness among
consumers and outsourcing. These factors strengthen the industry’s testing programs; create the need for new tests; increase regulations on
food control; prioritize transparency and traceability; and increase the pressure on manufacturers to invest in testing. All these factors would
drive the demand for high quality, state-of-the-art facilities and an international network of laboratories. In the pharma testing market, the
need to expand pipeline drugs and rapid technological changes are driving the growth in this industry. The increase in the complexity of
clinical trials; regulations; and spending per drug trial will boost the likelihood of using contract research organizations. The environmental
testing market continues to grow with the rise in issues related to contamination and pollution. This trend is driven by increasing demand by
people for clean environment; regulations; toxic products; need for more sophisticated analysis and equipments. This compels companies to
improve testing and outsource internal lab functions.
Opportunity - Strategic Acquisitions
Eurofins follows an acquisition strategy to secure market leadership or expand into high growth niche markets to leverage its existing
competencies. The company acquired Transplant Genomics Inc. to expand transplantation testing. Eurofins acquired Labo Van Poucke (LVP).
This acquisition provides the company an entry platform into the clinical testing market in Belgium and a license to operate and sell its
specialties in this market. It significantly strengthens Eurofins’ growing footprint in the specialty clinical diagnostics testing market in Europe.
In the same month, Eurofins acquired NMDL-LCPL, a specialized medical testing business providing molecular diagnostics and pathology
laboratory services. The acquisition provides Eurofins a first entry platform for further growth into the clinical diagnostics market in the
Netherlands.
Opportunity - Growing Healthcare and Pharmaceuticals Market
The company can leverage on the growing healthcare and pharmaceutical market to accelerate future growth. According to the estimates, the
global healthcare market is valued at nearly US$5.7 billion and is growing at a rate of 6% every year; and is estimated to grow to US$20 billion
in volumes by 2030. The key factors that accelerate the market growth include aging population, technological advances and stronger
purchasing power. According to the World Health Organization, the average will grow by approximately 20% by 2030. As older people have
frequent health issues, the prescription volume has been rising. According to Federal Ministry of Economics and Technology, the spending in
healthcare market is increasing. The Organization for Economic Cooperation and Development (OECD) countries are set to triple spending on
healthcare to over US$10 trillion by 2020, which accounts for 16% of gross domestic product (GDP) on average. Healthcare spending in most
European Union countries is growing faster than their GDP. According to the US government’s Center for Medicare and Medicaid Services
(CMS), healthcare expenditure in the country rose recently 6.8% to surpass US$2 trillion and represented 16% of the country’s GDP. According
to the Congressional Budget Office, if the growth in healthcare spending continues at its current pace, CMS spending and private health costs
will increase from the current 16% of GDP to 25% in 2025. The increase in cost is due to increased demand amid aging population and
changes in lifestyle.

Eurofins Scientific SE - Threats

Threat - Competition
Eurofins operates in the conformity assessment solutions domain, which is characterized by intense competition. The major geographical
markets in which the company operates are highly competitive and in recent years, competition intensified considerably due to highly
maturing and saturating markets. Competition increased during the economic downturn, leading to consolidation of businesses. Eurofins
competes with major global players, some of which are market leaders in their respective home countries. Few of its competitors include
Bureau Veritas SA., R-Biopharm AG, bioMerieux SA and SGS SA. The main factors for competition include price, service quality, brand
reputation and customer service, among others. Decreasing barriers to entry in different regions intensified the competition further. If the
company is not able to maintain its service quality and consumer loyalty, rising competition may force the company to reduce its prices, which
may affect its margins adversely.
Threat - Intellectual Property Risk
Eurofins’s intellectual property rights could be challenged, invalidated, or infringed by its competitors. The company has strong R&D activity,
which allows it to develop several new technologies. The company’s intellectual property includes patents and trademarks, among others.
Currently, the company has several issued and pending patent applications worldwide. Failure to meet the requirement in securing its
technology could hamper the company’s competitive position. Similarly, the company can face infringement claims and incur increased costs
that would affect its profitability.
Threat - Integration Risks
The company’s strategy is to acquire other companies, laboratories and technologies in order to gain expertise in technologies and
consolidate its market position in Europe, North America and Asia among others. Possible integration problems could result in a wide range of
cost burden. It could significantly or completely devalue the acquisitions and result in significant burden on the company. Acquisitions also
carry the risk of unforeseen liabilities or affect its image due to the unprofessional or lower quality business activities of the acquired
businesses. Acquisitions can represent a substantial business risk, which can have a significant effect on the profitability and continued
existence of the company.
NOTE:
* Sector average represents top companies within the specified sector
The above strategic analysis is based on in-house research and reflects the publishers opinion only

Eurofins Scientific SE - Key Competitors

Eurofins Scientific SE, Key Competitors
Name Headquarters Revenue (US$ m)
bioMerieux SA France 2,995
Bureau Veritas SA France 5,659
Intertek Group Plc United Kingdom 3,735
R-Biopharm AG Germany
SGS SA Switzerland 6,644

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios
Eurofins Scientific SE, Ratios based on current share price
Key Ratios 16-Jul-2020
P/E (Price/Earnings) Ratio 51.88

EV/EBITDA (Enterprise Value/Earnings Before Interest, Taxes, Depreciation and Amortization) 12.56
Enterprise Value/Sales 2.94
Enterprise Value/Operating Profit 23.43
Enterprise Value/Total Assets 1.72
Dividend Yield 0.51
Note: Above ratios are based on share price as of 16-Jul-2020, the above ratios are absolute numbers

Financial Ratios - Annual Ratios

Eurofins Scientific SE, Annual Ratios
Key Ratios Unit/Currency 2015 2016 2017 2018 2019
Equity Ratios
EPS (Earnings per Share) EUR 8.20 11.11 14.61 16.82 16.69
Dividend per Share EUR 1.45 2 2.40 2.88 3.45
Dividend Cover Absolute 5.65 5.55 6.09 5.84 4.84
Book Value per Share EUR 62.21 96.15 138.47 150.36 158.55
Cash Value per Share EUR 38.41 18.91 37.81 27.13 0.20
Profitability Ratios
Gross Margin % 18.50 18.91 18.74 19.04 20.40
Operating Margin % 13.55 14.10 13.45 13.77 12.57
Net Profit Margin % 4.48 6.86 7.30 5.92 4.28
Profit Markup % 22.70 23.32 23.06 23.51 25.62
PBT Margin (Profit Before Tax) % 11.62 12.17 12.01 12.19 10.46
Return on Equity % 9.12 10.69 8.87 8.39 6.88
Return on Capital Employed % 9.04 10.46 9.12 9.05 9.19
Return on Assets % 3.13 4.44 4.35 3.44 2.60
Return on Working Capital % 40.71 41.13 106.64 204.43 2,548.89
Growth Ratios
Sales Growth % 38.28 30.08 17.14 27.25 20.67
Operating Income Growth % 39.21 35.29 11.73 30.33 10.13
EBITDA Growth % 38.54 32.93 16.08 29.30 29.29

Eurofins Scientific SE, Annual Ratios (Cont...1)

Net Income Growth % 10.38 99.27 24.58 3.31 -12.79
EPS Growth % 3.50 35.52 31.54 15.12 -0.74
Working Capital Growth % 282.94 33.89 -56.90 -32.01 -91.17
Cost Ratios
Operating Costs (% of Sales) % 86.45 85.90 86.55 86.23 87.43
Liquidity Ratios
Current Ratio Absolute 1.84 2.22 1.26 1.18 1.01
Quick Ratio Absolute 1.79 2.17 1.22 1.13 0.96
Cash Ratio Absolute 1.02 1.16 0.57 0.35 0.19
Leverage Ratios
Debt to Equity Ratio % 1.78 0.85 0.81 1.04 1.14
Net Debt to Equity Absolute 0.96 0.34 0.57 0.99 1.14
Debt to Capital Ratio % 0.64 0.46 0.45 0.51 0.53
Efficiency Ratios
Asset Turnover Absolute 0.70 0.65 0.60 0.58 0.61
Fixed Asset Turnover Absolute 5.19 5.43 4.98 4.44 3.49
Inventory Turnover Absolute 51.15 53.39 52.87 51.81 49.87
Current Asset Turnover Absolute 1.91 1.69 1.74 2.14 2.76
Capital Employed Turnover Absolute 0.67 0.74 0.68 0.66 0.73
Working Capital Turnover Absolute 3 2.92 7.93 14.84 202.79

Eurofins Scientific SE, Annual Ratios (Cont...2)

Revenue per Employee EUR 96,207
Net Income per Employee EUR 4,118
Capex to Sales % 8.67 7.87 8.27 9.64 9.32

Performance Chart
Eurofins Scientific SE, Performance Chart (2015 - 2019)
Financial Performance
The company reported revenues of (Euro) EUR4,562.8 million for the fiscal year ended December 2019 (FY2019), an increase of 20.7% over
FY2018. In FY2019, the company’s operating margin was 12.6%, compared to an operating margin of 13.8% in FY2018. In FY2019, the
company recorded a net margin of 4.3%, compared to a net margin of 5.9% in FY2018.

Financial Ratios - Interim Ratios

Eurofins Scientific SE, Interim Ratios
Key Ratios Unit/Currency ------ ----- ---- Jun-2019 Dec-2019
Interim EPS (Earnings per Share) EUR 7.16 9.53

Dividend per Share EUR 3.45
Book Value per Share EUR 150.71 158.55
Gross Margin % 19.14 21.54
Operating Margin % 11.57 13.47
Net Profit Margin % 2.72 5.70
Profit Markup % 23.67 27.45
PBIT Margin (Profit Before Interest & Tax) % 13.15
PBT Margin (Profit Before Tax) % 9.47 11.35
Operating Costs (% of Sales) % 88.43 86.53
Interest Costs (% of Sales) % 2.22
Current Ratio Absolute 0.78 1.01
Quick Ratio Absolute 0.74 0.96
Debt to Equity Ratio % 1.32 1.25
Net Debt to Equity Absolute 1.21 1.14
Debt to Capital Ratio % 0.62 0.57
Interest Coverage Ratio Absolute 592.82

Financial Ratios - Ratio Charts

Eurofins Scientific SE, Ratio Charts
EPS Operating Margin
Return on Equity Return on Assets
Debt to Equity Ratio Current Ratio

Section 4 – Company’s Mergers & Acquisitions, Capital Raising and Alliances

Eurofins Scientific SE, Transactions by Year, 2014 to YTD 2020
Note: Deals include all announced deals from 2014 onwards, deal values included wherever disclosed. GlobalData
Above data is extracted from GlobalData’s Deals and Alliances Profile.
Eurofins Scientific SE reported three deals worth $1,214.59 million in YTD 2020. The company’s deal volume decreased from seven deals in
2018 to two deals in 2019.
YEAR No. of Deals Deal Value (US$ million)
2014 11 259.50
2015 14 1,996.95
2016 16 332.85
2017 16 2,547.35
2018 7 845.00
2019 2 NA
YTD 2020 3 1,214.59
Note: Deals include all announced deals from 2014 onwards, deal values included wherever disclosed. Above data is extracted GlobalData
from GlobalData’s Deals and Alliances Profile.

Eurofins Scientific SE, Transactions by Type, 2014 to YTD 2020

Note: Deals include all announced deals from 2014 onwards, deal values included wherever disclosed.
Above data is extracted from GlobalData’s Deals and Alliances Profile. GlobalData
Eurofins Scientific SE’s deals activity has been reportedly focusing on acquisition with 34 deals during the period 2014 to YTD 2020.
Deal type No. of Deals Deal Value (US$ million)
Acquisition 34 2,630.49
Partnerships 19 0.00
Debt Offerings 6 3,320.71
Equity Offerings 3 1,239.05
Asset Transactions 3 0.00
Venture Financing 3 6.00
Contract Service Agreement 1 0.00

Eurofins Scientific SE, Transactions by Region, 2014 to YTD 2020

Eurofins Scientific SE, deals activity has been reportedly focusing on North America with 32 deals worth $2,176 million during
the period 2014 to YTD 2020.
Region No. of Deals Deal Value (US$ million)
North America 32 2,176.00

Europe 31 4,958.09
Asia-Pacific 8 62.16
South and Central America 3 NA
Middle East and Africa 1 NA

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Transaction By Therapy Area, 2014 to
YTD 2020
Eurofins Scientific SE, Pharmaceuticals & Healthcare, Transaction By Therapy Area, 2014 to YTD 2020
Eurofins Scientific SE pharmaceuticals & healthcare deals activity has been reportedly focusing on Oncology with two deals followed by
Ophthalmology with one deal during the period 2014 to YTD YTD 2020
Eurofins Scientific SE, Pharmaceuticals & Healthcare, Transaction By Therapy Area, 2014 to YTD 2020
Market Name No. of Deals Deal Value (US$ million)
Oncology 2 62.16
Ophthalmology 1 62.16
Genito Urinary System And Sex 1 62.16
Genito Urinary System And Sex Hormones 1 62.16
Infectious Disease 1 255.00

Eurofins Scientific SE, Medical Devices Transaction, 2014 to YTD 2020

Eurofins Scientific SE Medical Devices deals activity has been reportedly focusing on In Vitro Diagnostics with 12 deals followed by Healthcare
IT with two deals during the period 2014 to YTD YTD 2020
Market Name No. of Deals Deal Value (US$ million)
In Vitro Diagnostics 12 709.76

Healthcare IT 2 NA
Cardiovascular Devices 1 200.00
Diagnostic Imaging 1 NA

Eurofins Scientific SE, Mergers and Acquisitions Transactions, 2014 to YTD 2020
Eurofins Scientific SE's Mergers and Acquisitions Transactions activity reported one deal worth undisclosed deal value in YTD 2020. In 2019,
there was one deal worth undisclosed deal value.
2014 6 255.00
2015 6 540.19
2016 6 NA
2017 10 990.30
2018 7 845.00
2019 1 NA
YTD 2020 1 NA

Eurofins Scientific SE, Mergers and Acquisitions Transaction Summary, 2014 to YTD 2020
Eurofins Scientific SE, Mergers and Acquisitions Transaction Summary, 2014 to YTD 2020
Deal Date Deal type Deal Status Acquirer/Investor/ Target/Issuer/Part Vendor Deal Value (US $
Licensor ners/Licensee million
05-Feb-2020 Asset Transactions Completed Eurofins Advinus Ltd Gomti Life Sciences Gomti Life
India Private Limited Sciences India
- Assets Private Limited
25-Jun-2019 Acquisition Completed Eurofins Scientific SE Transplant
Genomics Inc
01-Oct-2018 Acquisition Announced Eurofins Scientific SE TestAmerica Jsti Group 175.00
Environmental
Services, LLC
01-Aug-2018 Acquisition Completed Eurofins Scientific SE Covance Inc Laboratory Corp 670.00
of America
Holdings
01-Jun-2018 Acquisition Completed Eurofins Scientific SE Labtium Ltd , VTT Technical
VTT Expert Services Research Centre
Ltd of Finland Ltd
09-May-2018 Acquisition Announced Eurofins Scientific SE Phast GmbH
03-Apr-2018 Acquisition Completed Eurofins Scientific SE Eurofins Food
Testing Laboratory
26-Feb-2018 Acquisition Completed Eurofins Scientific SE NMDL-LCPL
25-Jan-2018 Acquisition Completed Eurofins Scientific SE Selcia Ltd
21-Dec-2017 Acquisition Completed Eurofins Scientific SE Pasteur Group
04-Dec-2017 Acquisition Completed Eurofins Scientific SE EAG Laboratories Odyssey 780.00
Investment
Partners, LLC
20-Oct-2017 Acquisition Completed Eurofins Pharma Eurofins Advinus Ltd Rallis India Ltd , 62.16
Services LUX Holding Tata Industries
SARL Limited , Tata
Sons Pvt Ltd ,
Undisclosed
Angel Investors
31-Jul-2017 Acquisition Announced Eurofins Scientific SE DiscoveRx Corp
25-Jul-2017 Acquisition Completed Eurofins Scientific SE Amatsigroup SAS Ekkio Capital 148.14
(Inactive)
05-Jul-2017 Acquisition Completed Eurofins GSC LUX Ana Laboratories,
SARL Inc.
26-Jun-2017 Acquisition Announced Eurofins Scientific SE Genoma Group Srl
13-Jun-2017 Acquisition Completed Eurofins Scientific SE Eurofins Alphora
02-Jun-2017 Acquisition Announced Eurofins Scientific SE GATC Biotech AG
04-May-2017 Acquisition Announced Eurofins Scientific SE MVZ fur
Laboratoriumsmediz
in Koblenz
29-Dec-2016 Acquisition Announced Eurofins Scientific SE Villapharma
Research SL

01-Sep-2016 Acquisition Completed Eurofins Scientific SE VRL Laboratories

19-May-2016 Asset Transactions Announced Eurofins Scientific SE Testing Business Exova Group Plc
30-Apr-2016 Acquisition Completed Eurofins Scientific SE Advantar
Laboratories Inc
11-Mar-2016 Acquisition Completed Eurofins Scientific SE Eurofins ams
Laboratories Pty Ltd
13-Jan-2016 Acquisition Completed Eurofins Scientific SE Eurofins Sinensis
14-Oct-2015 Acquisition Completed Eurofins Scientific SE Biomnis SELAS Financiere Bio 250.19
Alfras SAS
01-Sep-2015 Acquisition Completed Eurofins Scientific SE Emory Genetics Emory University 40.00
Laboratory School of
Medicine
31-Jul-2015 Acquisition Completed Eurofins Scientific SE DIATHERIX 50.00
Laboratories Inc
11-May-2015 Acquisition Completed Eurofins Scientific SE Experchem
Laboratories Inc
05-May-2015 Acquisition Completed Eurofins Scientific SE QC LABORATORIES, PBM Capital
INC. Group, LLC
02-Feb-2015 Acquisition Completed Eurofins Scientific SE Boston Heart Bain Capital 200.00
Diagnostics Corp Ventures LLC ,
Cherrystone
Angel Group
06-Nov-2014 Acquisition Announced Eurofins Scientific SE SF Analytical
Laboratories
21-Oct-2014 Acquisition Completed Eurofins Genomics VBC-Biotech Service
GmbH GmbH
30-Sep-2014 Acquisition Completed Innolab do Brasil Integrated PetroRio SA
Ltda Petroleum Expertise
Co
01-Jul-2014 Acquisition Completed Eurofins Scientific SE Eurofins Viracor Inc Ampersand 255.00
Capital Partners ,
Undisclosed Co
30-Apr-2014 Asset Transactions Completed Eurofins Scientific SE Discovery and Merck Millipore
Development Corp
Solutions
16-Jan-2014 Acquisition Completed Eurofins Scientific SE ID MYK SA

Eurofins Scientific SE, Strategic Alliances Transactions, 2014 to YTD 2020

Eurofins Scientific SE's Strategic alliances activity reported zero deals in YTD 2020. In 2019, there was one deal worth undisclosed deal value.
2014 3 NA
2015 3 NA
2016 9 NA
2017 3 NA
2018 0 NA
2019 1 NA
YTD 2020 0 NA

Eurofins Scientific SE, Strategic Alliances, by Transaction Phase, 2014 to YTD 2020
Eurofins Scientific SE, Strategic Alliances, by Transaction Phase, 2014 to YTD 2020, Number of Transactions (%)
Eurofins Scientific SE's Strategic Alliances, by Transactions Phase reported one deal worth undisclosed deal value in Phase III. In Discovery,
there was one deal worth undisclosed deal value.
Eurofins Scientific SE, Strategic Alliances, by Transaction Phase, 2014 to YTD 2020
Phase No. of Deals Deal Value (US$ million)
Preclinical 2 NA
Discovery 1 NA
Phase III 1 NA

Eurofins Scientific SE, Strategic Alliances Transactions Summary, 2014 to YTD 2020
Eurofins Scientific SE, Strategic Alliances Transactions Summary, 2014 to YTD 2020
Deal Date Phase Deal Status Acquirer/Investor/ Target/Issuer/Part Vendor Deal Value (US $
28-Oct-2019 Preclinical Completed Escient

Pharmaceuticals Inc
, Eurofins Pharma
Discovery Services
21-Nov-2016 Discovery Completed Eurofins Advinus Ltd
, Idogen AB
21-Nov-2016 Preclinical Completed Eurofins Advinus Ltd
, Idogen AB
14-Apr-2016 Phase III Completed Quark
Pharmaceuticals Inc
, Transplant
Genomics Inc

Eurofins Scientific SE, Private Equity/Venture Capital Transactions, 2014 to YTD 2020
Eurofins Scientific SE's Private Equity/Venture Capital segment reported zero deals in YTD 2020. In 2019, there were zero deals.
2014 2 4.50
2015 1 1.50
2016 0 NA
2017 0 NA
2018 0 NA
2019 0 NA
YTD 2020 0 NA

Eurofins Scientific SE, Venture Capital Transactions, by Stage of Financing 2014 to YTD 2020
Eurofins Scientific SE, Venture Capital Transactions, by Stage of Financing 2014 to YTD 2020 ,Number of Transactions(%)
Eurofins Scientific SE, Venture Capital Transactions, by Stage of Financing 2014 to YTD 2020 ,Transactions Value(%)

Eurofins Scientific SE's Venture Capital Transactions, by Stage of Financing reported one deal worth $2.80 million in Start-up. In Growth
Capital/Expansion, there were two deals worth $3.20 million.
Eurofins Scientific SE, Venture Capital Transactions, by Stage of Financing 2014 to YTD 2020
Stage No. of Deals Deal Value (US$ million)
Growth Capital/Expansion 2 3.20

Start-up 1 2.80

Eurofins Scientific SE, Private Equity/Venture Capital Transactions Summary, 2014 to YTD
2020
Eurofins Scientific SE, Private Equity/Venture Capital Transactions Summary, 2014 to YTD 2020
28-May-2015 Venture Financing Completed Undisclosed Transplant 1.50

Investor(s) Genomics Inc
24-Nov-2014 Venture Financing Completed Undisclosed Transplant 1.70
21-Mar-2014 Venture Financing Completed Undisclosed Transplant 2.80

Eurofins Scientific SE, Equity and Debt Offerings, 2014 to YTD 2020
Eurofins Scientific SE's Equity and Debt Offerings reported two deals worth $1,214.59 million in YTD 2020. In 2019, there were zero deals.
2014 0 NA
2015 3 1,455.26
2016 1 332.85
2017 3 1,557.06
2018 0 NA
2019 0 NA
YTD 2020 2 1,214.59

Eurofins Scientific SE, Equity and Debt Offerings Transactions Summary, 2014 to YTD 2020
Eurofins Scientific SE, Equity and Debt Offerings Transactions Summary, 2014 to YTD 2020
18-May-2020 Equity Offerings Announced Undisclosed Eurofins Scientific SE 559.14

Investor(s)
06-May-2020 Debt Offerings Completed Eurofins Scientific SE 655.46
06-Nov-2017 Debt Offerings Completed Eurofins Scientific SE 464.70
31-Oct-2017 Equity Offerings Completed Undisclosed Angel Eurofins Scientific SE 347.06
Investors
18-Jul-2017 Debt Offerings Completed 745.30
08-Sep-2016 Equity Offerings Completed Undisclosed Eurofins Scientific SE 332.85
Investor(s)
24-Jul-2015 Debt Offerings Completed Undisclosed Eurofins Scientific SE 554.04
Investor(s)
23-Apr-2015 Debt Offerings Pricing Eurofins Scientific SE 322.19
20-Jan-2015 Debt Offerings Completed Eurofins Scientific SE 579.03

Eurofins Scientific SE, Recent Transactions Summary
Eurofins Scientific SE, Recent Transactions Summary
Deal Date Deal type Deal Status Deal Headline Deal Value (US $
million
18-May-2020 Equity Offerings Announced Eurofins Scientific to Raise up to USD559 Million in 559.14
Private Placement of Shares
06-May-2020 Debt Offerings Completed Eurofins Scientific Raises USD655.4 Million in Public 655.46
Offering of Bonds
05-Feb-2020 Asset Transactions Completed Eurofins Advinus Acquires Assets of Gomti Life
Sciences
28-Oct-2019 Partnerships Completed Eurofins Pharma Discovery Enters into Collaboration
with Escient Pharma
25-Jun-2019 Acquisition Completed Eurofins Scientific Acquires Transplant Genomics
01-Oct-2018 Acquisition Announced Eurofins Scientific to Acquire TestAmerica 175.00
Environmental Services from JSTI Group
01-Aug-2018 Acquisition Completed Eurofins Acquires Covance from LabCorp 670.00
01-Jun-2018 Acquisition Completed Eurofins Scientific Acquires VTT Expert Services and
Labtium from VTT Technical Research Centre of
Finland
09-May-2018 Acquisition Announced Eurofins Scientific to Acquire PHAST
03-Apr-2018 Acquisition Completed Eurofins Scientific Acquires Lab Frontier
26-Feb-2018 Acquisition Completed Eurofins Scientific Acquires NMDL-LCPL
25-Jan-2018 Acquisition Completed Eurofins Scientific Acquires Selcia
21-Dec-2017 Acquisition Completed Eurofins Scientific Acquires Pasteur
04-Dec-2017 Acquisition Completed Eurofins Acquires EAG Laboratories from Odyssey 780.00
Investment Partners
06-Nov-2017 Debt Offerings Completed Eurofins Scientific Raises USD464.7 Million in Public 464.70
Offering of 3.25% Bonds
31-Oct-2017 Equity Offerings Completed Eurofins Scientific Raises USD347.1 Million in Private 347.06
Placement of Shares
20-Oct-2017 Acquisition Completed Eurofins Pharma Services Acquires Majority Stake in 62.16
Advinus Therapeutics
31-Jul-2017 Acquisition Announced Eurofins Scientific to Acquire DiscoverX
25-Jul-2017 Acquisition Completed Eurofins Scientific Acquires Amatsigroup from Ekkio 148.14
Capital
18-Jul-2017 Debt Offerings Completed Eurofins Scientific Raises USD745.3 Million in Public 745.30
Offering of 2.125% Bonds Due 2024
05-Jul-2017 Acquisition Completed Eurofins GSC Lux Acquires ANA Laboratories
26-Jun-2017 Acquisition Announced Eurofins Scientific to Acquire Genoma Group
13-Jun-2017 Acquisition Completed Eurofins Scientific Acquires Alphora Research
07-Jun-2017 Partnerships Completed LifeCodexx Enters into Agreement with LifeCell
International
02-Jun-2017 Acquisition Announced Eurofins Scientific to Acquire GATC Biotech

04-May-2017 Acquisition Announced Eurofins Scientific to Acquire MVZ fur

Laboratoriumsmedizin
11-Apr-2017 Partnerships Completed LifeCodexx Enters into Research Agreement with
Charite - Universitatsmedizin Berlin
31-Mar-2017 Partnerships Completed GATC Biotech Enters into Agreement with University
of Konstanz
29-Dec-2016 Acquisition Announced Eurofins Scientific to Acquire Villapharma Research
21-Nov-2016 Partnerships Completed Idogen Enters into Research Agreement with Advinus
Therapeutics
08-Sep-2016 Equity Offerings Completed Eurofins Scientific Raises USD333 Million in Private 332.85
Placement of Shares
01-Sep-2016 Acquisition Completed Eurofins Scientific Acquires VRL Laboratories
27-Jun-2016 Partnerships Completed Transplant Genomics Enters into Agreement with
Mayo Clinic Center for Individualized Medicine
16-Jun-2016 Partnerships Completed Applied BioCode Enters into Agreement with
Diatherix
13-Jun-2016 Partnerships Completed Biomnis SELAS Enters into Agreement with
DIATHERIX Laboratories
19-May-2016 Asset Transactions Announced Eurofins Scientific to Acquire Testing Business from
Exova
02-May-2016 Partnerships Completed Transplant Genomics Enters into Clinical Trial
Agreement with Astellas Pharma
30-Apr-2016 Acquisition Completed Eurofins Scientific Acquires Advantar Laboratories
14-Apr-2016 Partnerships Completed Quark Pharma Enters into Agreement with
Transplant Genomics
11-Mar-2016 Acquisition Completed Eurofins Scientific Acquires ams Laboratories
10-Mar-2016 Partnerships Completed Agilent Technologies Enters into Agreement with
Eurofins Genomics
24-Feb-2016 Partnerships Completed IQuity Labs Enters into Agreement with Diatherix
Labs
13-Jan-2016 Acquisition Completed Eurofins Scientific Acquires Sinensis Life Sciences
12-Jan-2016 Partnerships Completed Biomnis Enters into Agreement with ODPM
04-Dec-2015 Partnerships Completed Diatherix Labs Enters into Research Agreement with
Vanderbilt University Medical Center
29-Oct-2015 Partnerships Completed Rubicon Genomics Enters into Distribution
Agreeement with Eurofins MWG Operon
14-Oct-2015 Acquisition Completed Eurofins Scientific Acquires Biomnis for USD250 250.19
Million
01-Sep-2015 Acquisition Completed Eurofins Scientific Acquires 75% Stake in Emory 40.00
Genetics Lab for USD40 Million
31-Jul-2015 Acquisition Completed Eurofins Scientific Acquires Diatherix Labs for USD50 50.00
Million
24-Jul-2015 Debt Offerings Completed Eurofins Scientific Raises USD554 Million in Public 554.04
Offering of 3.375% Bonds Due 2023
28-May-2015 Venture Financing Completed Transplant Genomics Raises USD1.5 Million in 1.50
Venture Financing

11-May-2015 Acquisition Completed Eurofins Acquires Experchem

05-May-2015 Acquisition Completed Eurofins Scientific Acquires QC Laboratories (QCL)
23-Apr-2015 Debt Offerings Pricing Eurofins Scientific Prices USD322 Million in Public 322.19
Offering of 4.87% Bond Due 2023
01-Apr-2015 Contract Service Completed Bionure Enters API Manufacturing Agreement with
Agreement Advinus for BN-201
19-Mar-2015 Partnerships Completed Qiagen Enters into Agreement with GATC Biotech
02-Feb-2015 Acquisition Completed Eurofins Scientific Acquires Boston Heart Diagnostics 200.00
20-Jan-2015 Debt Offerings Completed Eurofins Scientific Raises USD579 Million in Public 579.03
Offering of 2.25% Bond Due 2022
24-Nov-2014 Venture Financing Completed Transplant Genomics Raises USD1.7 Million in 1.70
Venture Financing
06-Nov-2014 Acquisition Announced Eurofins Scientific to Acquire SF Analytical Labs
21-Oct-2014 Acquisition Completed Eurofins Genomics Acquires VBC-Biotech
30-Sep-2014 Acquisition Completed Innolab do Brasil Completes Acquisition Of Integrated
Petroleum Expertise From HRT Participacoes
14-Jul-2014 Partnerships Completed Transplant Genomics Enters into Licensing
Agreement with Scripps Research Institute and
Northwestern University
01-Jul-2014 Acquisition Completed Eurofins Scientific Completes Acquisition of Viracor- 255.00
IBT Labs For USD255 Million
01-Jul-2014 Partnerships Completed Eurofins Genomics Enters into Co-Marketing
Agreement with AmpTec for IVT-RNAs
30-Apr-2014 Asset Transactions Completed Eurofins Scientific Acquires Assets of Discovery and
Development Solutions Business of Merck
21-Mar-2014 Venture Financing Completed Transplant Genomics Raises US$2.8 Million In 2.80
Venture Financing
11-Mar-2014 Partnerships Completed Oxford Gene Enters Co-Development Agreement
With Emory Genetics For New CGH Arrays
16-Jan-2014 Acquisition Completed Eurofins Scientific Acquires IDmyk

Acquisition
Eurofins Scientific Acquires Transplant Genomics
Eurofins Scientific Acquires Transplant Genomics
Deal Type Acquisition Deal Sub Type 100% Acquisition
Deal in Brief
Eurofins Scientific, a scientific provider of bioanalytical testing, has closed the acquisition of Transplant Genomics Inc., a molecular
diagnostics company committed to improving organ transplant outcomes with non-invasive serial monitoring guided by
genomics.Transplant Genomics’ non-invasive tests for the management of patients with silent inflammation and rejection following kidney
transplants will strengthen and complement Eurofins’ global Transplant Diagnostics offering, which includes VRL, Inc., a pre-transplant
laboratory in the US and Viracor, Inc., a post-transplant clinical laboratory in the US.This acquisition expands Eurofins Scientific's
transplantation testing footprint.
Deal Rationale
This acquisition expands Eurofins Scientific's transplantation testing footprint.
Deal Information
Deal Status Completed
Completed Date 25-Jun-2019
% Acquired 100
Companies Information
Acquirer Company Information
Company Name Eurofins Scientific SE
Business Description
company offers food and feed testing, biopharma services, pharma discovery services, pharma early development, pharma central
laboratory, biopharma product testing, agroscience services, product testing, forensic services and environmental testing. Its analytical
methods help in evaluating the safety, identity, composition, origin, authenticity and purity of biological products and substances. It
harnesses its expertise in logistics and information technology to deliver a range of services. The company operates across Western
Europe, North America, and Rest of the World. Eurofins is headquartered in Luxembourg.
Target Company Information
Company Name Transplant Genomics Inc Parent Eurofins Scientific SE
Transplant Genomics Inc (TGI) is a part of Eurofins Scientific., is a biotech company. It carries out performing organ
transplantation using non-invasive serial monitoring under the guidance of genomics. It aims in detecting early signs of graft
injury by conducting molecular diagnostic tests, enabling in differentiating among various actionable causes and also
enabling optimizing the therapy. Transplant Genomics carries out the transplantation of organs such as the kidney, liver,
lungs, pancreas, and intestines through genomics supervision. The company has its operational presence in the US. TGI is
headquartered in Mansfield, Massachusetts, the US.
Source: GlobalData

Eurofins Scientific to Acquire TestAmerica Environmental Services from JSTI Group

Eurofins Scientific to Acquire TestAmerica Environmental Services from JSTI Group
Deal Type Acquisition Deal Sub Type Majority Acquisition
Deal in Brief
Eurofins Scientific SE, has signed an agreement with the JSTI Group, to acquire TestAmerica Environmental Services LLC, a US-based
environmental testing firm that provides total access, source air testing, shale oil and gas, industrial hygiene, defense, air, vapor, and other
specialty services.Eurofins Scientific is a Luxembourg based provider of various analytical testing services whereas JSTI Group provides
engineering consultancy services in China.The agreed acquisition price is US$175 million on a cash free debt free basis.TestAmerica should
generate revenues of over US$230 million in 2018 and employs over 2,000 staff.The transaction is expected to close in the fourth quarter
of 2018 subject to the fulfilment of regulatory and customary closing conditions.
Deal Rationale
The acquisition will allow Eurofins Scientific to expand its geographic footprint and technical offering restructuring of either business is
expected to be minimal, the focus being on further enhancement of consolidated service offering to the market, and scale economies with
respect to rare tests, R&D, operational costs and operational optimization of sites to improve efficiencies.
Deal Information
Deal Status Announced
Announced Date 01-Oct-2018
Deal Financials
Deal Value (US$ m) 175
Vendor Company Information
Company Name Jsti Group
JSTI Group (JSTI) is a provider of integrated services. The company is specialized in providing engineering, procurement and construction
(EPC) consultation, planning and design, research and testing, project management and supervision, consulting services to various roads,
municipal projects, water systems, city rails, railways, and construction, environment projects. It also provides urban planning,
architectural services and environmental protection services. In addition, the company is involved in a smart city, energy-saving,
examination for difficult cases, and judicial identification services. JSTI is headquartered in Nanjing, China.
Company Name TestAmerica Environmental Parent Jsti Group
Services, LLC
Source: GlobalData

Eurofins Acquires Covance from LabCorp

Eurofins Acquires Covance from LabCorp
Deal in Brief
Eurofins Scientific SE (Eurofins) has acquired Covance Inc (Covance), a US-based subsidiary of LabCorp, a drug development company that
offers contract research and manufacturing services from Laboratory Corp of America Holdings (LabCorp), for an all-cash purchase price of
USD670 million.Eurofins is a Luxembourg-based life sciences company, which provides a range of analytical testing services to clients in
various industries.The price includes the significant favorable tax benefits of an acquisition of assets in the US.LabCorp is a provider of
clinical laboratory services and end-to-end drug development support.Wells Fargo Securities acted as financial adviser, while, Kelley Drye &
Warren LLP and Hogan Lovells International LLP acted as legal advisor to LabCorp.Deal History:Approval: On June 21, 2018, Eurofins
Scientific received U.S. Antitrust Clearance to acquire Covance Inc (Covance) from Laboratory Corp of America Holdings (LabCorp), for an
all-cash purchase price of USD670 million.Announced: On April 30, 2018, Eurofins agreed to acquire Covance, from LabCorp, for an all-cash
purchase price of USD670 million.
Deal Rationale
The transaction will allow Eurofins to offer and supports mission to deliver the most innovative and highest quality food testing and
development services in the world.
Deal Information
Announced Date 30-Apr-2018
Completed Date 01-Aug-2018
Deal Financials
Company Name Laboratory Corp of America
Holdings
Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It
focuses on the development and commercialization of a range of diagnostic technologies and testing services. The company offers clinical
diagnostics laboratory services such as core testing, genomic and esoteric testing. Its services include general and specialty laboratory
testing, bone marrow and human leukocyte antigen (HLA) testing, clinical trials services, drug testing services, deoxyribonucleic acid (DNA)
identification services, forensic identity services, insurance health plan services, paternity testing services, patient services, personalized
medicine and hospital services. It also offers drug development services through Covance. It offers services to managed care organizations,
physicians, hospitals, government agencies and biotechnology and pharmaceutical companies through a network of primary laboratories
and patient service centers. The company has operations across the US, Belgium, China, Singapore, the UK and other countries. LabCorp is
headquartered in Burlington, North Carolina, the US.
Company Name Covance Inc Parent Laboratory Corp of America
Holdings
Covance Inc (Covance), a subsidiary of Laboratory Corporation of America Holdings, is a contract research company that offer drug
development and manufacturing services. The company’s services include research, lead optimization, analysis services, safety assessment
and drug safety testing, consulting and partnering, clinical development, informatics, clinical testing, commercialization and manufacturing

support, among others. It offers solutions in various therapeutic areas such as cardiovascular; diabetes, endocrinology and nephrology;
immuno-oncology; infectious diseases; inflammation; neuroscience; non-alcoholic steatohepatitis; oncology; rare disease and orphan
drugs; and pediatrics. Covance also offers laboratory testing services for agrochemical and chemical industries. The company operates
across the US, Europe, Latin America, Africa and Asia-Pacific. Covance is headquartered in Princeton, New Jersey, the US.
Advisor Information
Company Being Advised Legal Advisor
Laboratory Corp of America Kelley Drye & Warren LLP
Holdings
Company Being Advised Financial Advisor
Laboratory Corp of America Wells Fargo Securities LLC
Holdings
Hogan Lovells International LLP
Source: GlobalData

Eurofins Scientific Acquires VTT Expert Services and Labtium from VTT Technical Research
Centre of Finland
Eurofins Scientific Acquires VTT Expert Services and Labtium from VTT Technical Research Centre of Finland
Deal in Brief
Eurofins Scientific SE has acquired VTT Expert Services Ltd, a provider of testing, certification, and approval services and Labtium Ltd, a
provider of laboratory and expert services to industry, research and development, from VTT Technical Research Centre of Finland Ltd, an
operator of contract research company. VTT Expert Services, Labtium and VTT Technical Research Centre are based in Finland.Eurofins
Scientific is a Luxembourg-based life sciences company, which provides a range of analytical testing services to clients in various industries.
As part of the transaction, VTT Expert Services will become the part of Eurofins Group.Following the transaction, VTT Expert Services will
continue with its operations name contact information and VAT will remain the same.Deal History:Announced: On January 1, 2018 Eurofins
Scientific agreed to acquire VTT Expert Services and Labtium from VTT Technical Research Centre of Finland.
Deal Rationale
The transaction of VTT Expert Services and Labtium will enable Eurofins Scientific to strengthen its environment testing.
Deal Information
Announced Date 01-Jan-2018
Company Name VTT Technical Research Centre
of Finland Ltd
VTT Technical Research Centre of Finland Ltd (VTT) is a research and technology center that promotes sustainable development,
employment and well-being. The center offers services to increase the competitiveness of its customers’ businesses; promote the creation
of new business and improve and speed up research and development. It provides research services on bioeconomy and circular economy,
health and wellbeing, digital society, low carbon energy, smart industry, sustainable and smart city, business development, pilot plants,
and research and development infrastructure. VTTalso offers technology and business foresight, strategic research, product and service
development, IPR and licensing, assessment and testing, inspection and certification, and technology and innovation management. VTT is
headquartered in Espoo, Finland.
Company Name VTT Expert Services Ltd Parent VTT Technical Research Centre
of Finland Ltd
Company Name Labtium Ltd Parent Eurofins Scientific SE
Source: GlobalData

Eurofins Scientific to Acquire PHAST

Eurofins Scientific to Acquire PHAST
Deal in Brief
Eurofins Scientific SE, a company focused on biopharmaceutical product testing services, has signed an exclusive agreement to acquire
PHAST Gesellschaft fur Pharmazeutische Qualitatsstandards mbH, a provider of pharmaceutical services.The transaction will enable
Eurofins to complement its biopharma product testing capabilities and expand its geographical footprint in these markets.The transaction
is expected to be completed in the next few weeks and is subject to the fulfilment of regulatory and customary closing conditions.
Deal Rationale
The transaction will enable Eurofins to complement its biopharma product testing capabilities and expand its geographical footprint in
these markets.
Deal Information
Announced Date 09-May-2018
% Acquired 100
Company Name Phast GmbH
Source: GlobalData

Eurofins Scientific Acquires Lab Frontier

Eurofins Scientific Acquires Lab Frontier
Deal in Brief
Eurofins Scientific SE, a Luxembourg-based provider of various bio-analytical testing services, has acquired Lab Frontier Co., Ltd., a South
Korea-based provider of food, environment and cosmetics testing services.Y.S. Kang is the chief executive officer (CEO) Lab Frontier.
Deal Rationale
The acquisition would enable Eurofins Scientific to expand its analytical testing market footprint in Asia Pacific and to extend its significant
organic and inorganic growth.
Deal Information
Completed Date 03-Apr-2018
Company Name Eurofins Food Testing Parent Eurofins Scientific SE
Laboratory
Source: GlobalData

Eurofins Scientific Acquires NMDL-LCPL

Eurofins Scientific Acquires NMDL-LCPL
Deal in Brief
Eurofins Scientific Inc., a bio-analytical testing company, has acquired NMDL-LCPL, a medical testing business providing molecular
diagnostics and pathology laboratory services. NMDL-LCPL is comprised of the Nederlands Moleculair Diagnostisch Laboratorium (NMDL)
and the Leids Cytologisch Pathologisch Laboratorium (LCPL).This transaction provides Eurofins Scientific an entry platform for further
growth into the clinical diagnostics market in the Netherlands.
Deal Rationale
This transaction provides Eurofins Scientific an entry platform for further growth into the clinical diagnostics market in the Netherlands.
Deal Information
Completed Date 26-Feb-2018
% Acquired 100
Company Name NMDL-LCPL Parent Eurofins Scientific SE
Advisor Information
Eurofins Scientific SE Houthoff Buruma Cooperatief
U.A
Source: GlobalData

Eurofins Scientific Acquires Selcia

Eurofins Scientific Acquires Selcia
Deal in Brief
Selcia Limited, a global provider of custom radiolabelling and integrated drug discovery services, has been acquired by Eurofins Scientific, a
provider of analytical testing and pharma discovery services.The acquisition of Selcia provides Eurofins with an entry into the custom
radiolabelling and innovative pre-clinical, integrated drug discovery services markets.InterPharmaLink facilitated the transaction. Birketts
LLP acted as legal advisor to shareholders of Selcia.
Deal Rationale
The acquisition of Selcia provides Eurofins with an entry into the custom radiolabelling and innovative pre-clinical, integrated drug
discovery services markets.
Deal Information
Completed Date 25-Jan-2018
% Acquired 100
Company Name Selcia Ltd
Selcia Ltd (Selcia), formerly SCYNEXIS Europe Ltd is a contract research provider that offers drug discovery services. The company offers
drug discovery operations, incorporating proprietary fragment screening, and supply of custom 14C radiochemicals. It also provides radio
labelling and chemistry, and analytic services. Selcia’s drug discovery services comprise medicinal chemistry, natural product chemistry and
structural biology, assay development and screening, ADME and PK, PPIase profiling services, and disease expertise services. The company
serves chemicals, pharmaceutical, crop protection and biocides, biotechnology, food and nutrition sectors. Selcia is headquartered in
Ongar, Essex, the UK.
Advisor Information
Selcia Ltd Birketts LLP
Selcia Ltd InterPharmaLink AG
Source: GlobalData

Eurofins Scientific Acquires Pasteur

Eurofins Scientific Acquires Pasteur
Deal in Brief
Eurofins Scientific SE, a Luxembourger a life sciences company, has acquired Pasteur Group, a company engaged in clinical diagnostics.The
acquisition enables Eurofins Scientific to a new business line in Latin America, and provides a platform with significant organic and
inorganic growth potential, and Pasteur Group will gain access to the full range of services, companies and knowledge of the Eurofins
Scientific, which should strengthen their analytical portfolio for the benefit of the patients and medical practitioners it serves.
Deal Rationale
The acquisition enables Eurofins Scientific to a new business line in Latin America, and provides a platform with significant organic and
inorganic growth potential, and Pasteur Group will gain access to the full range of services, companies and knowledge of the Eurofins
Scientific, which should strengthen their analytical portfolio for the benefit of the patients and medical practitioners it serves.
Deal Information
Completed Date 21-Dec-2017
% Acquired 100
Company Name Pasteur Group Parent Eurofins Scientific SE
Source: GlobalData

Eurofins Acquires EAG Laboratories from Odyssey Investment Partners

Eurofins Acquires EAG Laboratories from Odyssey Investment Partners
Deal in Brief
Eurofins Scientific, a bioanalytical testing company, announces the successful closing of the transaction to acquire EAG Laboratories, a
scientific services company providing analytical testing and consulting solutions to a diverse and demanding set of end markets, from
affiliates of Odyssey Investment Partners.The agreed transaction price is USD780 million on a cash free debt free basis and the transaction
should be immediately margin accretive for Eurofins after closing.Siddhartha Kadia, president and CEO of EAG Laboratories.
Deal Rationale
The transaction allows Eurofins to entry into the dynamic and growing Materials and Engineering Sciences markets.
Deal Information
Deal Financials
Company Name Odyssey Investment Partners,
LLC
Company Name EAG Laboratories
EAG Laboratories (EAG), formerly Chemir Analytical Services is a scientific services company that offers clinical research and
technology solutions. The company provides analytical testing, product development, custom synthesis, litigation support,
and consulting services to its clients. Its analytical testing services include deformulation, customized investigations,
materials testing and ID, contaminant identification, failure analysis, polymer analysis, method development and chemical
analysis. EAG’s product development offers idea generation, formulation development, product feasibility, performance
testing, scale-up and manufacturing support and raw material suppliers. The company serves pharmaceuticals, veterinary
drugs, generic drugs, and crop protection. It offers its services to clients in the UK, Germany, France, Mexico, Peru,
Venezuela, Brazil, Belgium and Austria. EAG is headquartered in Maryland Heights, Missouri, the US.
Source: GlobalData

Eurofins Pharma Services Acquires Majority Stake in Advinus Therapeutics

Eurofins Pharma Services Acquires Majority Stake in Advinus Therapeutics
Deal in Brief
Eurofins Pharma Services LUX Holding SARL, a life sciences company and a subsidiary of Eurofins Scientific SE, has acquired Advinus
Therapeutics Ltd., a contract research organization, from Tata Sons Ltd., Tata Industries Ltd. and Rallis India Ltd., along with individual
shareholders.This acquisition will enable Eurofins Pharma Services to expand its business.Deal History:Announced: On July 20, 2017,
Eurofins Pharma a subsidiary of Eurofins Scientific entered into a definitive agreement to acquire Advinus from Tata Sons, Tata Industries
and Rallis India along with individual shareholders.Under the terms, the deal will be valued between INR3,500 million (USD54.37 million)
and INR4,000 (USD62.14 million). Rallis India will sell its entire shareholding consisting of 1,82,86,000 equity shares with 13.68% stake in
Advinus Therapeutics to Eurofins Pharma Services for a consideration of INR9.47 (USD0.14) per share, aggregating INR173.2 million
(USD2.69 million). Tata Sons holds a 67.31% stake in Advinus Therapeutics, according to its 2015-2016 annual report. Advinus Therapeutics
is expected to complement the existing capabilities of Eurofins Pharma Services and expand its presence in India.
Deal Rationale
This acquisition will enable Eurofins Pharma Services to expand its business.
Deal Information
Announced Date 20-Jul-2017
Completed Date 20-Oct-2017
% Acquired 80.99
Deal Financials
Deal Value - Estimated
Minimum Value (US$ m) 54.39 Maximum Value (US$ m) 62.16
Company Name Eurofins Pharma Services LUX Parent Eurofins Scientific SE
Holding SARL
Company Name Tata Sons Pvt Ltd
Tata Sons Pvt Ltd (Tata Sons) is an investment holding company and promoter of Tata companies. It's group companies operates in the
field of agrochemical, consultancy, power, logistics, automotive, steel, communication, trading and distribution, beverage, air conditioning
and engineering service, infrastructure, financial service, hotel, auto component, insurance, retail, digital infrastructure, telecom, and retail
store businesses. The company's product portfolio includes construction equipment, chemical, consumer products; composite products for
the aerospace, defence and industrial industries, drugs, steel products, material handling equipment, automobiles, telecom products, and
others. It offers services such as business research, legal services, management consulting, management training, outsourced customer
care and allied services, agricultural services, engineering services, financial services, investment services, IT and IT-enabled services, legal
services, and management consulting, among others. The company operates in India, the UK, Spain, China, Australia, South Africa, and
others. Tata Sons is headquartered in Mumbai, Maharashtra, India.
Company Name Rallis India Ltd Parent Tata Chemicals Ltd
Rallis India Ltd (Rallis), a subsidiary of Tata Chemicals Ltd, is an agri-solutions service provider. The company’s business portfolio includes
domestic crop protection, international business, contract manufacturing, seeds, plant growth nutrients and agri services. Its products
portfolio includes geogreen, mopu, samrudha krishi, sprayers, fungicides, herbicides, insecticides, pco-pesticides, gluco beta, ralligold,
solubor, tata bahaar, tata uphaar and tracel among others. Rallis Rallis’ domestic crop protection division provides seed treament
chemicals, pesticides, and household products. The company's seeds business division offers hybrid BT cotton, hybrid paddy, hybrid pearl
millet, hybrid maize, mustard and wheat. It operates in Bangalore, Chandigarh, Kolkata and Secunderabad, India. Rallis is headquartered in
Mumbai, Maharashtra, India.
Company Name Tata Industries Limited Parent Tata Teleservices (Maharashtra)
Ltd

Company Name Eurofins Advinus Ltd Parent Eurofins Scientific SE

Eurofins Advinus Ltd (Advinus), formerly Advinus Therapeutics Ltd is a research and development services company that
supports the discovery and development of compounds. It develops small molecules drugs for metabolic, inflammatory,
neurodegenerative and neglected diseases. Its services comprise drug discovery, drug development, agrochemical discovery
and development, biologics testing and reach support services. Its agrochemical discovery and development services
comprise process chemistry, analytical studies for crop protection agents and toxicology of crop protection agents. Advinus
offers drug development services such as chemistry, manufacturing and control; bio-analytical services, DMPK, safety
assessment and regulatory service. The company caters to pharmaceuticals, biologicals, agrochemicals, nutraceuticals and
cosmetic industries. It operates in Bangalore and Pune. Advinus is headquartered in Bangalore, Karnataka, India.
Source: GlobalData

Eurofins Scientific to Acquire DiscoverX

Eurofins Scientific to Acquire DiscoverX
Deal in Brief
Eurofins Scientific SE, a life sciences company, has entered into an agreement to acquire DiscoverX Corp., a provider of reagents.Following
the acquisition, the combination of Eurofins Pharma Discovery Services and DiscoverX provides the pharmaceutical and biotech industries
with a partner of choice for end-to-end drug discovery services, enabling customers to improve research productivity and effectiveness of
their screening, lead optimization and structure-activity relationships (SAR) campaigns, thus accelerating the discovery and development of
new drugs. In addition, DiscoverX’s KINOMEscan platform and epigenetics services, combined with Eurofins Pharma Discovery’s kinase
profiling services would result in the largest available portfolio of kinase products and services in the market. Furthermore, it provides
researchers with a comprehensive technology platform for assessment of drugs to kinases, the most widely evaluated drug target.This
acquisition will enable Eurofins Scientific to expand its offering and footprint in drug discovery services.The transaction is expected to be
completed in the coming weeks, upon fulfillment of customary closing conditions.
Deal Rationale
This acquisition will enable Eurofins Scientific to expand its offering and footprint in drug discovery services.
Deal Information
% Acquired 100
Company Name DiscoveRx Corp Parent Eurofins Pharma Discovery
Services
DiscoveRx Corp (DiscoveRx), a subsidiary of Eurofins Pharma Discovery Services develops, manufactures, and commercializes of reagents,
cell-based assay kits. The company’s products include cell-based assay kits, ligands and inhibitors, detection reagents, biochemical and
messenger assays, reagents, consumables, cell culture kits, retroviruses, cloning vectors and others. Its services include custom assay
development services, drug discovery services, and custom formulation and bulk services. The company serves therapeutic areas including
cancer, digestive and renal, reproductive, inflammation, dermatology, metabolic, ontology, pain and addiction. The company has
operational presence in the US and the UK. DiscoveRx is headquartered in Fremont, California, the US.
Advisor Information
DiscoveRx Corp DLA Piper LLP
Source: GlobalData

Eurofins Scientific Acquires Amatsigroup from Ekkio Capital

Eurofins Scientific Acquires Amatsigroup from Ekkio Capital
Deal in Brief
Eurofins Scientific SE, a provider of biopharmaceutical products testing and genomic services, has completed the acquisition of
Amatsigroup SAS, a contract development and manufacturing organization (CDMO), from Ekkio Capital, a private equity firm, for a
purchase consideration of approximately EUR130 million (USD148.14 million) plus some residual debt at completion.Amatsigroup provides
preclinical and clinical phase services for the development of drugs. It is one of the multi-specialist platforms in Europe with a proposal for
specialty and biopharma clients, including biopharmaceutical analysis, formulation development and manufacturing, biological research &
development, among other services. It employs about 450 staff and plans to generate over EUR60 million (USD68.51 million) revenues in
2017 on a pro forma basis, with an EBITDA margin already above Eurofins overall group target.This transaction strengthens the Eurofins
Scientific's biopharma product testing biopharmaceutical service offering, and strengthen its presence in the field of formulation,
development and manufacturing of new drugs.Willkie Farr & Gallagher LLP acted as legal advisor to Ekkio Capital for the transaction.Deal
History:Announced: On July 10, 2017, Eurofins Scientific entered into agreement to acquire the Amatsigroup from Ekkio Capital for a
purchase consideration of approximately EUR130 million (USD148.14 million) plus some residual debt at completion.
Deal Rationale
This transaction strengthens the Eurofins Scientific's biopharma product testing biopharmaceutical service offering, and strengthen its
presence in the field of formulation, development and manufacturing of new drugs.
Deal Information
Completed Date 25-Jul-2017
% Acquired 100
Deal Financials
Minimum Value (US$ m) 148.14
Company Name Amatsigroup SAS (Inactive)
Amatsigroup SAS (Amatsigroup) is a contract development manufacturing organization that offers human and veterinary pharmaceutical
development through preclinical and clinical phases. The organization provides services such as bioservices, clinical trial supply,
formulation development and manufacturing, management of drug product development and pharmaceutical analysis solutions, among
others. It provides bioservices in bioanalysis and life studies. Amatsigroup offers clinical trial supply services such as logistics, packaging,
and QP release. The organization has its presence in Belgium, France and the US, among others. Amatsigroup is headquartered in
Fontenilles, France.
Vendor Firm Information
Firm Name Ekkio Capital
Ekkio Capital is a private equity firm.
Advisor Information


Ekkio Capital Willkie Farr & Gallagher LLP
Ekkio Capital Rothschild & Co SCA
Source: GlobalData

Eurofins GSC Lux Acquires ANA Laboratories

Eurofins GSC Lux Acquires ANA Laboratories
Deal in Brief
Eurofins GSC Lux SARL, a Luxembourg based group of laboratories providing testing and support services to the pharmaceutical, food,
environmental and consumer products industries and to governments, has acquired ANA Laboratories Inc., a US-based laboratory
providing testing and analysis of biodiesel and other alternative fuels.
Deal Rationale
The transaction would allow Eurofins Scientific to expand its environment testing footprint into industrial fluid analysis in the US.
Deal Information
Company Name Eurofins GSC LUX SARL Parent Eurofins Scientific SE
Company Name Ana Laboratories, Inc. Parent Eurofins GSC LUX SARL
ANA Laboratories is an industry leader in the testing and analysis of biodiesel and other alternative fuels.
Source: GlobalData

Eurofins Scientific to Acquire Genoma Group

Eurofins Scientific to Acquire Genoma Group
Deal in Brief
Eurofins Scientific SE, a company engaged in bio-analytical testing and genomic services, has entered into an agreement to acquire
Genoma Group Srl (Genoma), a provider of diagnostics testing.Genoma has 20 years of clinical testing innovation. It offers a range of
specialty diagnostic testing services, molecular biology and cytogenetics. Specifically, the company is into non-invasive pre-natal testing
(NIPT) in Italy, and leads the industry in innovative diagnostic tests in oncology. Genoma employs about 100 staff across its 2 main sites in
Rome and Milan, and generates annual revenues in excess of EUR20 million. It serves hospitals, physicians and other laboratories which
outsource the more complex diagnostic tests to Genoma.This transaction provides Eurofins Scientific an entry platform into the clinical
testing market in Italy, and strengthens its footprint in the specialty diagnostic testing market in Europe.The transaction is subject to
customary closing conditions and is expected to be completed in next few weeks.
Deal Rationale
This transaction provides Eurofins Scientific an entry platform into the clinical testing market in Italy, and strengthens its footprint in the
specialty diagnostic testing market in Europe.
Deal Information
Announced Date 26-Jun-2017
% Acquired 100
Company Name Genoma Group Srl
Source: GlobalData

Eurofins Scientific Acquires Alphora Research

Eurofins Scientific Acquires Alphora Research
Deal in Brief
Eurofins Scientific SE, a company engaged in biopharmaceutical testing, has acquired Alphora Research Inc., a contract research,
development and manufacturing organization (CRDMO) for complex and niche small molecule active pharmaceutical ingredients
(APIs).This transaction strengthens Eurofins Scientific position in the biopharmaceutical testing market.Torreya Partners LLC acted as
financial advisor to Alphora Research for the transaction.
Deal Rationale
This transaction strengthens Eurofins Scientific's position in the biopharmaceutical testing market.
Deal Information
% Acquired 100
Company Name Eurofins Alphora Parent Eurofins Scientific SE
Eurofins Alphora (Alphora) is a research center that provides active pharmaceutical ingredient technology development services. The
center offers services such as early stage development, late stage development, process chemistry, stability testing, gram to kilogram
synthesis, cGMP chromatography purification, technology transfer services, and high potency and cytotoxic services. It provides analytical
development services including method development, supply chain development for key raw materials and intermediates, genotoxic
impurity controls, method validation, API characterization and impurity control, pharmaceutical specification development and method
transfer. The center caters to pharmaceutical and biotechnology companies. It operates in Mississauga and Oakville, Ontario, Canada.
Alphora is headquartered in Mississauga, Ontario, Canada.
Advisor Information
Eurofins Alphora Osler, Hoskin & Harcourt LLP
Eurofins Alphora Torreya Partners LLC
Source: GlobalData

Eurofins Scientific to Acquire GATC Biotech

Eurofins Scientific to Acquire GATC Biotech
Deal in Brief
Eurofins Scientific SA, an international group of laboratories involved in providing testing and support services to the pharmaceutical, food,
environmental and consumer products based in Luxembourg, has signed an agreement to acquire GATC Biotech AG, a German specialists
in DNA sequencing.The company employs 140 staff across 2 sites, and serves over 10,000 institutional and academic customers, generating
annual revenues of about EUR20 million (USD22.5 million).The transaction is subject to the fulfilment of customary closing conditions. The
transaction will advance Eurofins Scientific in gene sequencing and will drive innovations not only in clinical diagnostics, but in the broader
bioanalytical testing market.
Deal Rationale
The transaction will advance Eurofins Scientific in gene sequencing and will drive innovations not only in clinical diagnostics, but in the
broader bioanalytical testing market.
Deal Information
Company Name GATC Biotech AG Parent Eurofins Scientific SE
Source: GlobalData

Eurofins Scientific to Acquire MVZ fur Laboratoriumsmedizin

Eurofins Scientific to Acquire MVZ fur Laboratoriumsmedizin
Deal in Brief
Eurofins Scientific SE, a bioanalytical testing service provider, has agreed to acquire MVZ fur Laboratoriumsmedizin am Hygiene-Institut
GmbH (Hygel), a provider of clinical diagnostics service.The transaction will allow Eurofins to enter into the clinical diagnostic testing
market in Germany, and reinforces its footprint to serve healthcare professionals in Europe.Hygel has 370 employees across its three main
sites, as well as in labs that it operates for four local hospitals. It generated more than EUR35 million (USD38.3 million) revenues in
2016.The transaction is subject to the fulfilment of customary closing conditions.
Deal Rationale
The transaction will allow Eurofins to entry into the clinical diagnostic testing market in Germany, and reinforces its footprint to serve
healthcare professionals in Europe.
Deal Information
% Acquired 100
Company Name MVZ fur Laboratoriumsmedizin
Koblenz
Source: GlobalData

Eurofins Scientific to Acquire Villapharma Research

Eurofins Scientific to Acquire Villapharma Research
Deal in Brief
Eurofins Scientific SE, a life sciences company, has agreed to acquire Villapharma Research SL, a biopharmaceutical company.Villapharma
Research expects to generate more than EUR6 million (USD6.26 million) of revenues in 2016 with EBITDA margins compatible with group
objective.This acquisition will enable Eurofins Scientific to reinforce its footprint in discovery pharmacology.The acquisition is expected to
completed in February 2017, upon fulfilment of customary closing conditions.
Deal Rationale
This acquisition will enable Eurofins Scientific to reinforce its footprint in discovery pharmacology.
Deal Information
Announced Date 29-Dec-2016
% Acquired 100
Company Name Villapharma Research SL
Villapharma Research SL (VillaPharma) is a developer of molecules based on novel scaffolds. The company’s production
technology is dependent on rapid parallel synthesis. It offers drug discovery services in the areas of high-throughput
chemistry, tailor made libraries, hit to lead libraries, lead optimisation, procurement of tailor-made arrays of third parties
compounds for HTS, NMR service for the scientific community, and high capacity in analysis and purification. The company
also partners with research groups and conducts research and development activities in the initial stages of drug discovery
and field of contract synthesis based on proprietary high value chemical projects. VillaPharma is headquartered in Murcia,
Spain.
Source: GlobalData

Eurofins Scientific Acquires VRL Laboratories

Eurofins Scientific Acquires VRL Laboratories
Deal in Brief
Eurofins Scientific SE, a bioanalytical testing service provider, has acquired VRL Laboratories, a provider of pre-transplant testing for the
eligibility determination for donors of human cells, tissues, and cellular and tissue-based product.This acquisition enables VRL to expand
Eurofins’ footprint in clinical testing services.
Deal Rationale
This acquisition enables VRL to expand Eurofins’ footprint in clinical testing services.
Deal Information
Completed Date 01-Sep-2016
% Acquired 100
Company Name VRL Laboratories Parent Eurofins Scientific SE
Source: GlobalData

Eurofins Scientific Acquires Advantar Laboratories

Eurofins Scientific Acquires Advantar Laboratories
Deal in Brief
Eurofins Scientific S.E., a provider of analytical testing services for the pharmaceutical, food, environmental and consumer products
industries, has acquired Advantar Laboratories, Inc., a good laboratory practice (GLP) and current good manufacturing practice (cGMP)
contract analytical laboratory specializing in analytical development and formulation services for large molecule and small molecule
programs. Deal History:Announced: On March 31, 2016, Eurofins has signed an agreement to acquire Advantar.
Deal Information
Announced Date 31-Mar-2016
% Acquired 100
Company Name Advantar Laboratories Inc Parent Eurofins Scientific SE
Source: GlobalData

Eurofins Scientific Acquires ams Laboratories

Eurofins Scientific Acquires ams Laboratories
Deal in Brief
Eurofins Scientific S.E., a biopharmaceutical products testing company, has acquired ams Laboratories Pty Ltd. (ams Laboratories), a
provider of analytical and cGMP Quality Control (QC) services for biopharmaceutical products and medical devices in Australia.ams
Laboratories employs about 45 staff and generates annual revenues of about EUR5 million for the fiscal year 2015.In return, ams
Laboratories will benefit from access to the complete range of Eurofins' portfolio of services as the global reference in biopharmaceutical
testing, which will enable it to expand its service offering and its footprint in the biopharmaceutical.
Deal Information
Completed Date 11-Mar-2016
% Acquired 100
Company Name Eurofins ams Laboratories Pty Parent Eurofins Scientific SE
Ltd
Source: GlobalData

Eurofins Scientific Acquires Sinensis Life Sciences

Eurofins Scientific Acquires Sinensis Life Sciences
Deal in Brief
Eurofins Scientific, SE, a pharmaceutical company, has acquired Sinensis Life Sciences B.V., a provider of pharmaceutical product testing
and cGMP Quality Control (QC) services. Sinensis is the reference laboratory for both microbiology and chemistry testing for
biopharmaceutical products in the domestic market. The company is also active in biosafety testing and biological R&D, chemical R&D, and
in cGMP manufacturing. This acquisition enables Eurofins Scientific to further strengthens its position in the pharmaceutical products
testing market.
Deal Rationale
This acquisition enables Eurofins Scientific to further strengthens its position in the pharmaceutical products testing market.
Deal Information
% Acquired 100
Company Name Eurofins Sinensis Parent Eurofins Scientific SE
Eurofins Sinensis (Eurofins), formerly Sinensis Life Sciences BV, a subsidiary of Eurofins Scientific SE, is a provider of
pharmaceutical services that offers laboratory testing and manufacturing services. The company offers QC testing services
such as QC release testing, biosafety testing, microbial identification, stability testing, validation, and import testing services.
It also provides GMP manufacturing services including drug substance compounding, aseptic fill and finish, labelling and
packaging, QC and QP release, and supporting services. Eurofins provides methods and solutions for the characterization of
raw materials, pharmaceutical drug substances and drug products. The company serves various industries such as
pharmaceuticals, biotech, medical device, hospital and pharmacies. It operates in Leiden, Etten-Leur and Oss, the
Netherlands. Eurofins is headquartered in Leiden, the Netherlands.
Source: GlobalData

Eurofins Scientific Acquires Biomnis for USD250 Million

Eurofins Scientific Acquires Biomnis for USD250 Million
Deal in Brief
Eurofins Scientific SE, a bio-analytical testing company, has acquired Biomnis Group, a provider of diagnostic testing services, from
Financiere Bio Alfras SAS, for a purchase consideration of EUR220 million (USD250.19 million). Pursuant to the transaction, Biomnis
provides Eurofins a strong platform on which to deploy the competencies in specialty clinical diagnostic testing that has obtained, and
continues to develop, at its recently-acquired laboratories in the US. In return, Biomnis will have access to the full range of Eurofins'
growing esoteric testing portfolio to further expand its position in clinical diagnostic testing market in France, and more widely in Europe.
Eurofins intends to offer other prominent groups of laboratory networks in the clinical biology testing market in France the option to co-
invest in Biomnis in the future. This planned partnership is in line with Eurofins' intention to closely collaborate with all the stakeholders in
the French medical laboratories sector to support them in fulfilling their objective of contributing to world-class patient care in France.This
acquisition enables Eurofins Scientific to strengthen its pharmaceutical and genomic services.Deal History: Announced: On June 22, 2015,
Eurofins Scientific agreed to acquire Biomnis Group, from Financiere Bio Alfras for a purchase consideration of EUR220 million (USD249.63
million).
Deal Rationale
This acquisition enables Eurofins Scientific to strengthen its pharmaceutical and genomic services.
Deal Information

% Acquired 100
Deal Financials
Deal Value (EUR million) 220 Deal Value (US$ m) 250.19
Company Name Financiere Bio Alfras SAS
Company Name Biomnis SELAS Parent Eurofins Scientific SE
Biomnis SELAS (Biomnis), a subsidiary of Eurofins Scientific SE, is a provider of medical laboratory testing services. The
company offers laboratory tests in the areas of generics, biochemistry, immunology, cytogenics, assisted reproductive
technology-embrology-sperm science, onco-haemotology, analytical chemistry, genetic fingerprinting, molecular biology,
infectiology, and others. Biomnis also provides pathological anatomy and cytology test for the treatment and management of
cancers and others diseases. PAC laboratory serves its services to various hospital, pharmaceutical companies, and medical
biology laboratories. The company has its operations in France, Ireland and the UK. Biomnis is headquartered in Lyon, France.
Source: GlobalData

Eurofins Scientific Acquires 75% Stake in Emory Genetics Lab for USD40 Million
Eurofins Scientific Acquires 75% Stake in Emory Genetics Lab for USD40 Million
Deal in Brief
Eurofins Scientific SE, a bio-analytical testing company, has completed the acquisition of 75% stake in Emory Genetics Laboratory (EGL), a
provider of genetic services, from Emory University School of Medicine, a research university, for a purchase consideration of USD40
million in cash, subject to standard closing adjustments.EGL provides molecular, biochemical and cytogenetic testing for rare and common
genetic diseases and disorders. EGL founded in 1970, employs around 100 staff at its laboratory in Atlanta, Georgia, and serves over 400
institutional clients hospitals and other commercial laboratories across the US. The company is a part of the Department of Human
Genetics and provides testing services for hospitals and other institutional clients. It specializes in next-generation sequencing testing,
especially for rare genetic disorders. It expects to generate revenues in excess of USD15 million in 2015. EGL's competencies advance
Eurofins' footprint in the genetics and genomic segment of the specialty clinical diagnostic testing market. Its expertise in genetic diseases
and cancer testing fully complements Eurofins leading position in infectious diseases, achieved through the acquisition of ViraCor-IBT and
Diatherix, and in cardiovascular diseases with that of Boston Heart. With this acquisition, Eurofins further strengthens both its
pharmaceutical and genomic service offering and reinforces its development into a leading presence in the specialty clinical testing services
for hospitals, clinicians and pharmaceutical companies. Following the transaction, EGL has been renamed as EGL Genetic Diagnostics, LLC, a
joint venture company of Eurofins and Emory University.This transaction enables Eurofins Scientific to strengthen its footprint in the
specialty clinical diagnostics market; and provides the group a truly unique platform to leverage its renowned competence in genomic
testing to better serve the global healthcare community.Deal History:Announced: On June 29, 2015, Eurofins Scientific agreed to acquire
75% stake in Emory Genetics Laboratory (EGL) for a purchase consideration of USD40 million in cash, subject to standard closing
adjustments.
Deal Rationale
This transaction enables Eurofins Scientific to strengthen its footprint in the specialty clinical diagnostics market; and provides the group a
truly unique platform to leverage its renowned competence in genomic testing to better serve the global healthcare community.
Deal Information

% Acquired 75
Deal Financials
Deal Payment
Cash (US$ m) 40
Company Name Emory University School of Parent Emory University
Medicine
The Emory University School of Medicine is the Graduate Medical School of Emory University and a component of Emory’s Robert W.
Woodruff Health Sciences Center.
Company Name Emory Genetics Laboratory Parent Eurofins Scientific SE

Source: GlobalData

Eurofins Scientific Acquires Diatherix Labs for USD50 Million

Eurofins Scientific Acquires Diatherix Labs for USD50 Million
Deal in Brief
Eurofins Scientific SE, a bio-analytical testing company, has acquired Diatherix Laboratories, Inc., a provider of multiplex molecular
diagnostic services, for a purchase consideration of USD50 million, plus an earn-out upon achievement of pre-defined revenue and
profitability targets.Diatherix provides molecular diagnostic testing services to hospitals and physicians using proprietary TEM-PCR (Target
Enriched Multiplex Polymerase Chain Reaction) technology for precise detection of infectious diseases at high levels of sensitivity and
specificity, and at very short turnaround times. Employing around 100 staff, Diatherix serves close to 7,000 healthcare providers across the
US and expects to generate revenues of about USD40 million in 2015. Through this acquisition, Eurofins strengthens both its
pharmaceutical and genomic service offering and reinforces its development into a leading presence in the specialty clinical testing services
for hospitals, clinicians and pharmaceutical companies.This transaction enables Eurofins Scientific to strengthen its pharmaceutical,
genomic testing, and specialty clinical offerings.Deal History:Announced on:June 1, 2015, Eurofins agreed to Acquire Diatherix for USD50
million plus an earn-out upon achievement of certain revenue and profitability targets.
Deal Rationale
This transaction enables Eurofins Scientific to strengthen its pharmaceutical, genomic testing, and specialty clinical offerings.
Deal Information
% Acquired 100
Deal Financials
Minimum Value (US$ m) 50
Deal Payment
Cash (US$ m) 50
Company Name DIATHERIX Laboratories Inc Parent Eurofins Scientific SE
Source: GlobalData

Eurofins Acquires Experchem

Eurofins Acquires Experchem
Deal in Brief
Eurofins Scientific SE, a Luxembourg-based provider of food and biopharma laboratory testing services, has agreed to acquire Experchem
Laboratories Inc., a company providing consulting and analytical laboratory testing services.Experchem, employs about 95 staff at its
laboratory in Toronto, Canada and generates revenue in excess of CAD10 million (USD8.3 million).
Deal Information
Completed Date 11-May-2015
% Acquired 100
Company Name Experchem Laboratories Inc Parent Eurofins Scientific SA
Source: GlobalData

Eurofins Scientific Acquires QC Laboratories (QCL)

Eurofins Scientific Acquires QC Laboratories (QCL)
Deal in Brief
Eurofins Scientific SE, a Luxembourg-based provider of food and biopharma laboratory testing services, has acquired QC Laboratories, Inc
(QCL), a US-based analytical testing company.QCL has generated revenue of approximately USD20 million and has workforce of 200
employees. Following the completion of the acquisition, QCl integrates with Eurofins and new company known as Eurofins QC.QCL is a
portfolio company of PBM Capital Group, LLC, a private investment firm.
Deal Rationale
The acquisition of QCL enables Eurofins Scientific to expand its food and environment testing business footprint in the US.
Deal Information
Company Name QC LABORATORIES, INC. Parent Sintavia LLC
Firm Name PBM Capital Group, LLC
Source: GlobalData
Eurofins Scientific Acquires Boston Heart Diagnostics

Eurofins Scientific Acquires Boston Heart Diagnostics
Deal in Brief
Eurofins Scientific SE, a bio-analytical testing company, has completed the acquisition of Boston Heart Diagnostics Corporation, a provider
of cardiac diagnostic tests and disease management information and a portfolio company of Bain Capital Ventures LLC and Cherrystone
Angel Group, for initial purchase consideration of USD140 million, plus an earn-out payment that is expected to be in excess of USD60
million upon achievement of certain milestones. Following the transaction, the company will continue to be known as Boston Heart
Diagnostics Corporation. Eurofins will retain Boston Heart's high quality workforce of nearly 350 employees.Boston Heart is an innovative
heart health management company that provides a leading, advanced diagnostics platform to help identify and reduce the risk of
cardiovascular disease, diabetes, and other chronic conditions which impose large costs upon the US healthcare system.This transaction
enables Eurofins Scientific to strengthen its clinical testing and genomic service offerings.Lazard Ltd acted as financial advisor to Boston
Heart Diagnostics for the transaction.Deal History: Announced: On December 8, 2014, Eurofins Scientific agreed to acquire Boston Heart
Diagnostics, for initial purchase consideration of USD140 million, subject to post-closing adjustments, plus an earn-out payment that is
expected to be in excess of USD60 million upon achievement of certain milestones.
Deal Rationale
This transaction enables Eurofins Scientific to strengthen its clinical testing and genomic service offerings.
Deal Information
Announced Date 08-Dec-2014

% Acquired 100
Deal Financials
Minimum Value (US$ m) 140 Maximum Value (US$ m) 200
Company Name Boston Heart Diagnostics Corp Parent Eurofins Scientific SE
Firm Name Bain Capital Ventures LLC Parent Bain Capital LP
Bain Capital Ventures LLC (Bain Capital) is an affiliate of Bain Capital, operates as an asset management company. The company performs
its activities through various sectors such as commerce technology, SaaS and data services, FinTech, infrastructure software, healthcare
and consumer. It performs its financial services operations through Liason, OpenFin, Nomis Solutions and AvidXchange. Bain Capital is
headquartered in Boston, Massachusetts, the US.
Firm Name Cherrystone Angel Group
Advisor Information
Boston Heart Diagnostics Corp Lazard Ltd
Source: GlobalData
Eurofins Scientific to Acquire SF Analytical Labs

Eurofins Scientific to Acquire SF Analytical Labs
Deal in Brief
Eurofins Scientific, SE, a pharmaceutical company, has agreed to acquire SF Analytical Laboratories (SFA Labs), a testing laboratory.
Following the transaction, SFA Labs will become part of the global services of Eurofins, adding Wisconsin and the Upper Great Lakes Region
to the multiple services offered. SFA will retain the 114 year old Wisconsin brand which will now be called 'Eurofins SF Analytical' and its
established relationships and recognition will be seamless to clients and the community. People will still work with their employees as they
have for decades in New Berlin and the Milwaukee area. At the same time, the lab will now be able to serve more clients with greatly
expanded capabilities on a regional and national level as part of the Eurofins network of laboratories in the US.SFA Labs is an independent
commercial testing laboratory with multiple testing disciplines including food microbiology, food chemistry, consultative analysis, and
environmental chemistry. The laboratory offers a complete range of chemistry, nutrition, allergen, and microbiological testing for food
processors and manufacturers, in addition to environmental and water testing. The acquisition will enable Eurofins to strengthen its
growing presence in the US, as well as expand the current base of operations in the Midwestern US; and allows SFA Labs to offer full range
of services available from Eurofins' group of more than 200 laboratories around the world. The transaction is expected to be completed at
the end of November, 2014.
Deal Rationale
The acquisition will enable Eurofins to strengthen its growing presence in the US, as well as expand the current base of operations in the
Midwestern US; and allows SFA Labs to offer full range of services available from Eurofins' group of more than 200 laboratories around the
world.
Deal Information
Announced Date 06-Nov-2014
% Acquired 100
Company Name SF Analytical Laboratories
Source: GlobalData
Eurofins Genomics Acquires VBC-Biotech

Eurofins Genomics Acquires VBC-Biotech
Deal in Brief
Eurofins Genomics Inc., a provider of DNA sequencing services and subsidiary of Eurofins Group, has acquired VBC-Biotech Service GmbH, a
provider of oligonucleotide synthesis and DNA sequencing services.Following the transaction, VBC-Biotech's services are integrated into
the Eurofins Genomics business units and Eurofins Genomics will establish an Austrian subsidiary named as Eurofins Genomics AT, located
in Vienna. This transaction enables Eurofins Genomics to extend its genomic business into Austria and Czech Republic.
Deal Rationale
This transaction enables Eurofins Genomics to extend its genomic business into Austria and Czech Republic.
Deal Information
% Acquired 100
Company Name Eurofins Genomics GmbH Parent Eurofins Scientific SE
Eurofins Genomics GmbH (Eurofins Genomics) provides genomic services. The company is a part of Eurofins Scientific Group. It provides
next generation sequencing services, genotyping and gene expression services, custom (deoxyribonucleic acid) DNA sequencing services,
oligonucleotides, siRNA (ribonucleic acid) and gene synthesis. It also offers genomics services for plant breeding, seed production, crop
protection, livestock breeding, industrial biotechnology and basic research. The company operates in Germany, India, the US and Japan.
Eurofins Genomics is headquartered in Ebersberg, Germany.
Company Name VBC-Biotech Service GmbH Parent Eurofins Genomics GmbH
Source: GlobalData
Innolab do Brasil Completes Acquisition Of Integrated Petroleum Expertise From HRT

Participacoes
Innolab do Brasil Completes Acquisition Of Integrated Petroleum Expertise From HRT Participacoes
Deal in Brief
Innolab do Brasil Ltda, a Brazilian subsidiary of Eurofins Scientific SE, completed the acquisition of Integrated Petroleum Expertise Co.
(IPEX), a provider of geophysics, geochemistry and chemical analysis services to the oil and gas industry, from HRT Participacoes em
Petroleo SA (HRT), an oil and gas company.IPEX is a geological and geophysical service company equipped with technology to support the
petroleum exploration and production industry. Its activities include geology, geophysics, geochemistry, petroleum system modeling,
biostratigraphy, environmental monitoring and licensing, chemical analyses, remote sensing, piston core sampling and heat flow
measurement, oil seepage detection systems, and E&P databases.The transaction is a part of HRT’s strategy to divest non-core assets to
reduce corporate costs and focus on its core business. The transaction enables Eurofins to expand its service offerings portfolio in
Brazil.Milton Franke, CEO of HRT said, "We are satisfied with the execution of this agreement, given that the sale of IPEX will reduce
corporate costs related to laboratory maintenance. It also continues the program, initiated in 2013, to divest non-core assets, enabling HRT
to become increasingly focused on its core business, pursuing new opportunities to invest in production assets, as well as prioritizing new
partnerships in exploration assets."Deal historyCompleted: In September 2014, Innolab do Brasil completed the acquisition of Integrated
Petroleum Expertise from HRT Participacoes em Petroleo.Announced: On September 17, 2014, Innolab do Brasil agreed to acquire
Integrated Petroleum Expertise from HRT Participacoes em Petroleo.
Deal Rationale
The transaction enables Eurofins to expand its service offerings portfolio in Brazil.
Deal Information
Announced Date 17-Sep-2014
% Acquired 100
Company Name Innolab do Brasil Ltda
Company Name PetroRio SA Parent HRT Oil & Gas Ltd
PetroRio SA (PetroRio), formerly HRT Participacoes em Petroleo SA, a subsidiary of HRT Oil & Gas Ltd, is oil and gas company. It offers
investment and recovering of oil production assets. The company provides development of solid growth platforms aiming to generate
value to its shareholders by increasing its production through the acquisition of production assets. It operates several oil blocks in South of
the Campos Basin, in Rio de Janeiro and also operates the Polvo Field. In addition, the company also offers acquisition of assets, efficient
management, cost reduction, project optimization, positioning and other programs. It operates reserves for natural gas. PetroRio is
headquartered in Rio de Janeiro, Brazil.
Company Name Integrated Petroleum Expertise Parent Eurofins Scientific SE
Co
Source: GlobalData
Eurofins Scientific Completes Acquisition of Viracor-IBT Labs For USD255 Million

Eurofins Scientific Completes Acquisition of Viracor-IBT Labs For USD255 Million
Deal in Brief
Eurofins Scientific, SE, a pharmaceutical company, completed the acquisition of Viracor-IBT Laboratories, Inc., a clinical diagnostic and
research laboratory, from Ampersand Capital Partners, a majority-owned private equity firm, and other shareholders, for a purchase
consideration of approximately USD255 million. Following the transaction, the company continue to be known as ViraCor-IBT Laboratories,
Inc.Viracor-IBT Labs provides biologic and large molecular biomarker support, along with molecular testing (qPCR/sequencing) to hospitals,
physicians and biotech/pharmaceutical companies. The company serves 550 institutional clients and over 4,000 affiliated clinicians as well
as 12 leading pharmaceutical companies across the US.This acquisition enables Eurofins Scientific to strengthens its both pharmaceutical
and genomic service offering; and to establish its presence in the specialty clinical testing services. Lazard Ltd acted as financial advisor to
Ampersand Capital Partners for the transaction.Deal History:Announced: On May 9, 2014, Eurofins Scientific agreed to acquire Viracor-IBT
Labs from Ampersand Capital Partners and other shareholders, for a purchase consideration of approximately USD255 million, subject to
post-closing adjustments.Rumor: On March 10, 2014, Ampersand Capital Partners rumored to sell Viracor-IBT Labs, reported by Dow Jones
citing the people familiar with the situation. The transaction is estimated to be valued more than USD200 million.
Deal Rationale
This acquisition enables Eurofins Scientific to strengthens its both pharmaceutical and genomic service offering; and to establish its
presence in the specialty clinical testing services.
Deal Information
% Acquired 100
Deal Financials
Company Name Eurofins Viracor Inc Parent Eurofins Scientific SE
Eurofins Viracor Inc (Eurofins Viracor), formerly Viracor-IBT Laboratories Inc, a subsidiary of Eurofins Scientific SE, is a clinical-stage
biopharmaceutical company that conducts clinical testing services. The company offers kits for diagnostic testing such as single, regular,
dual and medium kits, live cell kits, bio-hazard specimen bags. It offers speciality testing for infectious disease, immunology, allergy and
transplants. The company provides clinical trial testing services such as molecular infectious disease testing and monitoring, immune
response and monitoring, allergy and hypersensitivity testing, project management, and information technology. It provides its testing
services to transplant teams, medical professionals, reference labs and biopharmaceutical companies. Viracor-IBT is headquartered in Lee's
Summit, Missouri, the US.
Firm Name Ampersand Capital Partners
Ampersand Capital Partners (Ampersand Capital) is a middle market private equity firm focused on growth-oriented investments in the
healthcare sector. The company's investments focus on EBITDA-positive companies that provide products or services including laboratory
testing services, laboratory products, contract manufacturing, specialty pharma and healthcare services. Its portfolio companies include
Avista Pharma Solutions Inc, Brammer Bio LLC, Confluent Medical Technologies Inc, Genewiz Inc, Genoptix Inc, Talecris Biotherapeutics Inc,
and Viracor-IBT Laboratories Inc. The company operates in the US and Netherlands. Ampersand Capital is headquartered in Wellesley,
Massachusetts, the US.
Advisor Information
Ampersand Capital Partners Lazard Ltd
Source: GlobalData
Eurofins Scientific Acquires IDmyk

Eurofins Scientific Acquires IDmyk
Deal in Brief
Eurofins Scientific SE, a bioanalytical testing company, acquired IDmyk S.A., a laboratory specialized in the areas of detection, identification
and molecular typing of microorganisms for the pharmaceutical industry.
This acquisition reinforces Eurofins Scientific’s pharmaceutical quality control offering, and complements its existing capabilities in
microbiological analysis.
Deal Rationale
This acquisition enables Eurofins to strengthen its presence in the pharmaceutical quality control offering, and complements its existing
capabilities in microbiological analysis.
Deal Information
% Acquired 100
Company Name ID MYK SA Parent Eurofins Scientific SE
Source: GlobalData
Asset Transactions
Eurofins Advinus Acquires Assets of Gomti Life Sciences
Eurofins Advinus Acquires Assets of Gomti Life Sciences
Deal Type Asset Transactions
TransactionType Acquisition
Deal in Brief
Eurofins Advinus Ltd, a preclinical contract research organization, has acquired the assets of Gomti Life Sciences India Private Limited, a
manufacturer of drugs. Both companies involved in the transaction are based in India.The assets include a fully equipped state-of-the-art
manufacturing facility located in Bidadi industrial area, Bangalore, India, with cGMP pilot plant, intermediate area and ISO class 8 clean
rooms and a total reactor capacity of about 45 KL.Eurofins Advinus is a subsidiary of Eurofins Scientific, a Luxembourg-based testing
laboratories company which provides testing and support services.
Deal Rationale
The acquisition will allow Eurofins to manufacture RSM's, intermediates, API's and NCE's.
Deal Information
Eurofins Advinus Ltd (Advinus), formerly Advinus Therapeutics Ltd is a research and development services company that supports the
discovery and development of compounds. It develops small molecules drugs for metabolic, inflammatory, neurodegenerative and
neglected diseases. Its services comprise drug discovery, drug development, agrochemical discovery and development, biologics testing
and reach support services. Its agrochemical discovery and development services comprise process chemistry, analytical studies for crop
protection agents and toxicology of crop protection agents. Advinus offers drug development services such as chemistry, manufacturing
and control; bio-analytical services, DMPK, safety assessment and regulatory service. The company caters to pharmaceuticals, biologicals,
agrochemicals, nutraceuticals and cosmetic industries. It operates in Bangalore and Pune. Advinus is headquartered in Bangalore,
Karnataka, India.
Company Name Gomti Life Sciences India Private Parent Eurofins Advinus Ltd
Limited
Gomti Life Sciences India Private Limited is a drug manufacturing company.
Asset Information
Gomti Life Sciences India Private Limited - Assets
Asset Description The acquired assets belongs to Gomti Life Sciences India Private Limited, a manufacturer of
drugs.
Source: GlobalData
Eurofins Scientific to Acquire Testing Business from Exova

Eurofins Scientific to Acquire Testing Business from Exova
Deal in Brief
Eurofins Scientific, a provider of bioanalytical testing, has signed an agreement to acquire Exova's food, water and pharmaceutical testing
business in the UK & Ireland, comprising 10 laboratories, for approximately GBP18 million.Collectively, the 10 laboratories employ more
than 300 staff and are expected to generate revenues in excess of EUR20 million in 2016. Of the 10 laboratories, 3 are for food testing, 5
for water testing, and 2 for pharmaceutical products testing.The transaction also includes the acquisition of 2 cGMP laboratories offering
quality control (QC) analytical services to medium to large pharmaceutical clients.This transaction provides Eurofins with an entry platform
to deploy its market- biopharmaceutical products testing capabilities to support the pharmaceutical and biotechnology industries in the
UK.The transaction is subject to customary closing conditions.
Deal Rationale
This transaction provides Eurofins with an entry platform to deploy its market-leading biopharmaceutical products testing capabilities to
support the pharmaceutical and biotechnology industries in the UK.
Deal Information
Company Name Exova Group Plc Parent Element Materials Technology
Group Holdings Ltd
Exova Group Plc (Exova Group) is a laboratory-based testing company. The company carries out analysis of drinking water, waste water,
soil and hazardous waste for both organic and inorganic contaminants. It also carries out reaction to fire and fire resistance testing, fire
engineering, training, consultancy and associated certification for all international fire standards. The company provides technical
laboratory-based testing, calibration and related services for aerospace, construction, defence, environmental, fire, building products and
certification, food, industrials, oil and gas, pharmaceuticals, and transportation sectors. Exova Group operates in the UK and the US. Exova
Group is headquartered in Eccles, the UK.
Asset Information
Testing Business
Asset Description Food, water and pharmaceutical testing business in the UK & Ireland.
Source: GlobalData
Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of

Merck
Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of Merck
Deal in Brief
Eurofins Scientific, SE, a pharmaceutical company, agreed to acquire the assets of the Discovery and Development Solutions (DDS) business
of Merck Millipore (EMD Millipore Corporation/ Millipore Corporation), a life science division of Merck KgaA, under a new division known
as Eurofins Pharma BioAnalytical Services. Under the acquisition, the manufacturing operations at two facilities in the UK, in Dundee,
Scotland and Oxford, England will be transferred to Eurofins Scientific, while the company will also take responsibility for a facility in St.
Charles, Missuori, which would be leased from Merck who will continue to own it. Eurofins Scientific will retain DDS' workforce and
leadership, and the business will continue to be led by Christina Shasserre. Shasserre will be president of Eurofins Pharma BioAnalytical
Services. This transaction enables Eurofins to strengthen its presence in the early stage discovery solutions market while adding the most
advanced expertise in high-quality bioanalytical services. White & Case LLP is acting as legal advisor to Merck for the transaction.Gilles
Martin, CEO of Eurofins, said, "The addition of DDS into the Eurofins network reinforces our leading position in the discovery pharmacology
market, and expands our large molecules bioanalytical service capability to meet the growing needs of our pharmaceutical and
biopharmaceutical clients. The transaction reflects Eurofins' commitment to provide the best laboratory services and client support to its
customers, and the highest level of analytical testing technology available in the industry."The transaction is expected to close within 90
days, subject to standard closing conditions.
Deal Rationale
This transaction enables Eurofins to strengthen its presence in the early stage discovery solutions market while adding the most advanced
expertise in high-quality bioanalytical services.
Deal Information
Announced Date 09-Jan-2014
Company Name Merck Millipore Corp Parent Merck KGaA
Asset Information
Discovery and Development Solutions
Asset Description Discovery and Development Solutions is a provider of bioanalytical testing and early stage discovery
services and products to the biopharmaceutical market. DDS provides industry-leading expertise in
bioanalytical testing to support clinical trials.
Country United Kingdom
Advisor Information
Merck Millipore Corp White & Case LLP
Source: GlobalData
Contract Service Agreement

Bionure Enters API Manufacturing Agreement with Advinus for BN-201
Bionure Enters API Manufacturing Agreement with Advinus for BN-201
Deal Type Contract Service Agreement
Deal in Brief
Bionure has entered into an API manufacturing agreement with Advinus for BN-201 product
Deal Rationale
This agreement enables Advinus to provide API manufacturing services to Bionure for BN-201
Deal Information
Karnataka, India.
Company Name Bionure Farma SL
Bionure Farma SL (Bionure) is a healthcare service provider that provides treatment for ophthalmological diseases that
concentrates on multiple sclerosis and glaucoma. The company concentrates on two conditions of vision impairment such as
optic neuritis and neuromyelitis optica. Its lead candidate BN201 is being developed for the treatment of multiple sclerosis
and other neurological and ophthalmological diseases. Bionure also identifies biomarkers to diagnose the disease and to be
used in prognostic and predictive tests. The company partners with Fundacio GAEM, Reig Jofre, National Multiple Sclerosis
Society, and Myelin Repair Foundation. It operates in the US and Spain. Bionure is headquartered in Barcelona, Spain.
Source: GlobalData
Debt Offerings
Eurofins Scientific Raises USD655.4 Million in Public Offering of Bonds
Eurofins Scientific Raises USD655.4 Million in Public Offering of Bonds
Deal Type Debt Offering Deal Sub Type Public Offering
Deal in Brief
Eurofins Scientific SE, a life sciences company that provides analytical testing services, has raised EUR600 million in a public offering
through an issue of senior unsecured Euro bond.The bonds will mature on July 17, 2026 (have a 6.2 years maturity) and will bear an annual
fixed rate of 3.75%.Eurofins Scientific plans to the launch of tender offers to repurchase its EUR500 million 2.250% bonds (ISIN:
XS1174211471) due January 27, 2022 and its EUR500 million 3.375% bonds (ISIN: XS1268496640) due January 30, 2023.Eurofins Scientific
intends to use the proceeds to proactively manage the refinancing of its outstanding bonds and increase the average life of its financing
instruments.Deal History:Planning: On May 5, 2020, Eurofins Scientific has announced its intention to issue new Euro-denominated bonds,
for gross proceeds of EUR500 million.
Deal Rationale
Eurofins Scientific intends to use the proceeds to proactively manage the refinancing of Eurofins' outstanding bonds and increase the
average life of its financing instruments.
Deal Information
Deal Financials
Securities Type Offered Bonds
Interest Rate (%) 3.75
Maturity Date 17-Jul-2026
Eurofins Scientific SE (Eurofins) is a life sciences company, which provides analytical testing services to clients in various
industries. The company offers food and feed testing, biopharma services, pharma discovery services, pharma early
development, pharma central laboratory, biopharma product testing, agroscience services, product testing, forensic services
and environmental testing. Its analytical methods help in evaluating the safety, identity, composition, origin, authenticity and
purity of biological products and substances. It harnesses its expertise in logistics and information technology to deliver a
range of services. The company operates across Western Europe, North America, and Rest of the World. Eurofins is
headquartered in Luxembourg.
Source: GlobalData
Eurofins Scientific Raises USD464.7 Million in Public Offering of 3.25% Bonds

Eurofins Scientific Raises USD464.7 Million in Public Offering of 3.25% Bonds
Deal in Brief
Eurofins Scientific SE, a life sciences company, has completed the public offering of 3.25% international bonds, for gross proceeds of
EUR400 million (USD464.71 million). The offering was over-subscribed more than 8x times.The bonds issued has no specified maturity, and
is accounted for as 100% equity according to international financial reporting standards (IFRS). It is callable at par by the company on the
8th year (Perp NC8, first call date in November 2025) and is structured for optimum equity qualification by rating agencies should the
company opt for a credit rating in the next 3 years. It will bear a fixed annual coupon of 3.25% for the first 8 years. Settlement date for the
issue is on the November 13, 2017, and the first call date for the instrument is on November 13, 2025.The company intends to use the
proceeds for general corporate purposes, including the funding of growth opportunities.BNP Paribas, Bank of America Merrill Lynch, HSBC
and UniCredit acted as global coordinators and together with BayernLB and Danske Bank acted as joint lead managers to the company for
the offering.
Deal Rationale
The company intends to use the proceeds for general corporate purposes, including the funding of growth opportunities.
Deal Information
Completed Date 06-Nov-2017
Deal Financials
Advisor Information
Company Being Advised Under Writer
Eurofins Scientific SE UniCredit Bank AG
Bayerische Landesbank
BNP Paribas SA
Danske Bank AS
Bank of America Merrill Lynch
Source: GlobalData
Eurofins Scientific Raises USD745.3 Million in Public Offering of 2.125% Bonds Due 2024
Eurofins Scientific Raises USD745.3 Million in Public Offering of 2.125% Bonds Due 2024
Deal in Brief
Eurofins Scientific SE, a life sciences company, has completed the public offering of 2.125% senior unsecured bond due 25 July 2024, for
gross proceeds of EUR650 million (USD745.3million). The offering was over-subscribed more than 4x times.The company intends to use the
proceeds for general corporate purposes, including refinancing some of its existing debt instruments, as well as to fund any further growth
opportunity in-line with the Group’s strategy and objectives; and to further improves its liquidity position by lengthening its debt maturity
profile.Bank of America Merrill Lynch and BNP Paribas SA acted as coordinators, while Credit Agricole CIB SA, Natixis SA and UniCredit Bank
AG acted as joint book runners to the company for the offering.Deal History: Announced: On July 17, 2017, Eurofins Scientific announced a
public offering of senior unsecured bond due 2024, to raise gross proceeds of EUR500 million (USD573.46 million).
Deal Rationale
The company intends to use the proceeds for general corporate purposes, including refinancing some of its existing debt instruments, as
well as to fund any further growth opportunity in-line with the Group’s strategy and objectives; and to further improves its liquidity
position by lengthening its debt maturity profile.
Deal Information
Deal Financials
Maturity Date 25-Jul-2024
Advisor Information
Company Being Advised Book Runner
Eurofins Scientific SE UniCredit Bank AG
Natixis SA
Credit Agricole CIB SA
Company Being Advised Under Writer
Eurofins Scientific SE BNP Paribas SA
Bank of America Merrill Lynch
Source: GlobalData
Eurofins Scientific Raises USD554 Million in Public Offering of 3.375% Bonds Due 2023
Eurofins Scientific Raises USD554 Million in Public Offering of 3.375% Bonds Due 2023
Deal in Brief
Eurofins Scientific, SE, a pharmaceutical company, has completed a public offering of 3.375% senior unsecured euro bonds, due January 30,
2023, for gross proceeds of EUR500 million (USD554 million). The issue was more than 2x times over-subscribed. The bonds will be listed
from their issue date (30 July 2015) on the regulated market of the Luxembourg stock exchange The company to use the proceeds of the
issuance for general corporate purposes, including refinancing some of existing debt instruments, as well as to fund any further growth
opportunity in-line with the group's strategy and objectives. The new bond further improves Eurofins' liquidity position by lengthening its
debt maturity profile.BNP Paribas FS LLC, HSBC France, S.A and Societe Generale Corporate & Investment Banking (SG CIB), acted as joint
book-runners for the offering.
Deal Rationale
The company to use the proceeds of the issuance for general corporate purposes, including refinancing some of existing debt instruments,
as well as to fund any further growth opportunity in-line with the group's strategy and objectives. The new bond further improves Eurofins'
liquidity position by lengthening its debt maturity profile.
Deal Information
Deal Financials
Maturity Date 23-Jan-2023
Advisor Information
Eurofins Scientific SE HSBC France SA
BNPP FS LLC
Societe Generale Corporate &
Investment Banking
Source: GlobalData
Eurofins Scientific Prices USD322 Million in Public Offering of 4.87% Bond Due 2023
Eurofins Scientific Prices USD322 Million in Public Offering of 4.87% Bond Due 2023
Deal in Brief
Eurofins Scientific, SE, a pharmaceutical company, has priced public offering of a new hybrid bond due 2023, to raise gross proceeds of
EUR300 million (USD322 million). The bonds bear an interest rate of 4.875% per annum and will mature in April 2023. The company
intends to use the proceeds for general corporate purposes, including funding of both organic and external growth, as part of its mid-term
development plan with the objective to achieve revenues of EUR2 billion (USD2.3 billion) by 2017, as well as to secure its longer-term
leading position in the markets where it is active; and for balance sheet optimization to lengthen average maturity of its debt whilst
reducing its average cost of capital.The offering is expected to close on or about April 29, 2015. HSBC France, S.A., BNP Paribas FS LLC and
Societe Generale Corporate & Investment Banking (SG CIB) are acting as joint book-runners to the company for the offering.
Deal Rationale
The company intends to use the proceeds for general corporate purposes, including funding of both organic and external growth, as part of
its mid-term development plan with the objective to achieve revenues of EUR2 billion (USD2.3 billion) by 2017, as well as to secure its
longer-term leading position in the markets where it is active; and for balance sheet optimization to lengthen average maturity of its debt
whilst reducing its average cost of capital.
Deal Information
Deal Status Pricing
Announced Date Apr 23, 2015
Deal Financials
Maturity Date 29-Apr-2023
Advisor Information
Eurofins Scientific SE BNPP FS LLC
Source: GlobalData
Eurofins Scientific Raises USD579 Million in Public Offering of 2.25% Bond Due 2022
Eurofins Scientific Raises USD579 Million in Public Offering of 2.25% Bond Due 2022
Deal in Brief
Eurofins Scientific, SE, a pharmaceutical company, has completed a public offering of senior unsecured euro bond, for gross proceeds of
EUR500 million (USD579 million). The bonds bear an interest rate of 2.25% per annum and will maturity on January 27, 2022.The company
intends to use the proceeds for general corporate purposes as part of its mid-term development plan with the objective to achieve
revenues of EUR2 billion (USD2.3 billion) by 2017, as well as to secure its longer-term leading position in the markets where it is active; and
for balance sheet optimization to lengthen average maturity of its debt whilst reducing its average cost of capital.HSBC France, S.A., BNP
Paribas FS LLC and Societe Generale Corporate & Investment Banking (SG CIB) acted as joint book-runners for the offering.
Deal Rationale
The company intends to use the proceeds for general corporate purposes as part of its mid-term development plan with the objective to
achieve revenues of EUR2 billion (USD2.3 billion) by 2017, as well as to secure its longer-term leading position in the markets where it is
active; and for balance sheet optimization to lengthen average maturity of its debt whilst reducing its average cost of capital.
Deal Information
Deal Financials
Maturity Date 27-Jan-2022
Advisor Information
Eurofins Scientific SE HSBC France SA
BNPP FS LLC
Societe Generale Corporate &
Investment Banking
Source: GlobalData
Equity Offerings
Eurofins Scientific to Raise up to USD559 Million in Private Placement of Shares
Eurofins Scientific to Raise up to USD559 Million in Private Placement of Shares
Deal Type Equity Offerings Deal Sub Type PIPE
Deal in Brief
Eurofins Scientific SE, a life sciences company that provides analytical testing services, has announced the private placement of 900,000
new ordinary shares at an assumed price of EUR574.4 per share, to raise gross proceeds of approximately EUR517 million. The placement
will subscribe to by institutional investors.The new ordinary shares would represent 5% of the existing issued share capital.The company
intends to use the proceeds to fund investments and net working capital needs in conjunction with the build-up of its capacity in COVID-19
related PCR tests, serologic tests and internal manufacturing of kits, probes and primers.Berenberg and Credit Suisse are acting as joint
bookrunners for the offering.
Deal Rationale
The company intends to use the proceeds to fund investments and net working capital needs in conjunction with the build-up of its
capacity in COVID-19 related PCR tests, serologic tests and internal manufacturing of kits, probes and primers.
Deal Information
Deal Financials
Minimum Value (US$ m) 559.14
Shares Issued 900,000
Advisor Information
Eurofins Scientific SE NautaDutilh NV
White & Case LLP
Allen & Overy LLP
Eurofins Scientific SE Berenberg Bank
Credit Suisse
Share Price Information
Share Price Before 30 Days 490.78
(US$)
Share Price Before 1 Day (US$) 621.21
Financial Information (Eurofins Scientific SE)
(Trailing Twelve Months Ended 31-Dec-2019)
Number of Employees 47,427
Financial Ratios Information
Operating Margin(%) 12.57
EV/Revenues 2.86
EV/Operating Profit 22.74
EV/EBITDA 11.59
EV/Total Assets 1.67
Cash Value Per Share (US$) 0.24
Net Assets Per Share Ratio (US$) 186.99
Earnings per share (US$ ) 12.87
Price Earnings Ratio 50
Source: GlobalData
Eurofins Scientific Raises USD347.1 Million in Private Placement of Shares

Eurofins Scientific Raises USD347.1 Million in Private Placement of Shares
Deal in Brief
Eurofins Scientific SE, a life sciences company, has completed the private placement of 550,000 shares, at a price of EUR543 (USD630.28)
per share, for gross proceeds of approximately EUR299 million (USD347.06 million). The placement was subscribed to by institutional
investors.The company intends to use the net proceeds to identified potential acquisition targets.Berenberg and Jefferies acted as joint
book-runners to the company for the offering.Deal History: Announced: On October 30, 2017, Eurofins Scientific announced the private
placement of approximately 500,000 new ordinary shares by way of an accelerated book building offering.
Deal Rationale
The company intends to use the net proceeds to identified potential acquisition targets.
Deal Information
Announced Date 30-Oct-2017
Deal Financials
Maximum Value (US$ m) 347.06
Advisor Information
Eurofins Scientific SE Berenberg and Jefferies
(US$)
EV/Revenues 4.15
EV/EBITDA 19.19
Price Earnings Ratio 53.84
Source: GlobalData
Eurofins Scientific Raises USD333 Million in Private Placement of Shares

Eurofins Scientific Raises USD333 Million in Private Placement of Shares
Deal in Brief
Eurofins Scientific SE, a provider of bio-analytical testing services, has completed the private placement of 800,000 shares of its common
stock at a price of EUR370 (USD416) per share, for gross proceeds of EUR296 million (USD332.85 million). The placement was subscribed to
by institutional investors. The issue price represents a discount of 1.8% to the closing price on September 7, 2016, and a discount of 0.8%
to the one-month volume weighted average price (VWAP).The company intends to use the proceeds to fund the identified potential
acquisition targets. Berenberg Private Banking and Jefferies LLC acted as joint book-runners to the company for the offering.
Deal Rationale
The company intends to use the proceeds to fund the identified potential acquisition targets.
Deal Information
Deal Financials
Offer Price (Local) 370
Offer Price (US$) 416.06
Advisor Information
Eurofins Scientific SE Jefferies LLC
Berenberg Wealth Management
(US$)
EV/Revenues 3.64
EV/EBITDA 16.59
Price Earnings Ratio 68.90
Source: GlobalData
Partnerships
Eurofins Pharma Discovery Enters into Collaboration with Escient Pharma
Eurofins Pharma Discovery Enters into Collaboration with Escient Pharma
Deal Type Partnership Deal Sub Type Co-Development
Deal in Brief
Eurofins Discovery, a provider of services and products to the drug discovery industry, announced a collaboration with Escient
Pharmaceuticals.Eurofins Discovery has collaborated with clients in integrated drug discovery programs and has a strong record of
accomplishment of preclinical candidate delivery. The integrated services are marketed under the brand name of DiscoveryOne.Escient is
leveraging Eurofins' expertise in assay development and GPCR drug discovery to identify novel therapeutics targeting Mas-Related G-
Protein Receptors (Mrgpr).Under the terms of the ongoing collaboration, Eurofins will support in vitro preclinical discovery efforts for
Escient's programs by providing expertise and services.
Deal Information
Partner Company Information
Company Name Escient Pharmaceuticals Inc
Escient Pharmaceuticals Inc (Escient Pharmaceuticals) is an independent biotechnology company that strives to discover, develop and
commercialize drugs targeting G protein-coupled receptor (GPCRs) for unmet medical needs. The company aims to develop therapies for
neuro-immuno-inflammatory and autoreactive diseases. It is funded by Osage University Partners, The Column Group and 5AM Ventures.
Escient Pharmaceuticals is headquartered in San Diego, California, the US.
Company Name Eurofins Pharma Discovery Parent Eurofins Panlabs Inc
Services
Source: GlobalData
LifeCodexx Enters into Agreement with LifeCell International

LifeCodexx Enters into Agreement with LifeCell International
Deal Type Partnership Deal Sub Type Other
Deal in Brief
LifeCodexx AG, a non-invasive prenatal DNA testing, has entered into an agreement with LifeCell International Pvt Ltd., a mother & baby
preventive health care provider, to bring PrenaTest qNIPT testing in India.Under the agreement, LifeCell will be able to perform the
licensed qNIPTTM PrenaTest at LifeCell’s laboratories.This agreement enables LifeCodexx and LifeCell International to launch non-invasive
prenatal DNA testing (NIPT) in India.
Deal Rationale
This agreement enables LifeCodexx and LifeCell International to launch non-invasive prenatal DNA testing (NIPT) in India.
Deal Information
Company Name LifeCell International Pvt Ltd
LifeCell International Pvt Ltd (LifeCell) is a medical service provider that offers preventive care, stem cell banking and therapeutic care
services. The company's services include prenatal screening, umbilical cord stem cell banking and newborn screening. Its also offers
services pregnancy and You, baby mania and doctor's Deck. LifeCell’s pregnancy services include due date calculator, nutrition and fitness
and pregnancy care. The company offers services such as matching probability, stem cell access, immediate availability, stem cells sharing
services, menstrual blood stem cell banking and cellular therapy solutions, among others. It offers therapeutic solutions for vascular,
orthopedic, cardiovascular and other diseases using stem cells. LifeCell is headquartered in Chennai, Tamil Nadu, India.
Company Name LifeCodexx AG Parent GATC Biotech AG
Source: GlobalData
LifeCodexx Enters into Research Agreement with Charite - Universitatsmedizin Berlin

LifeCodexx Enters into Research Agreement with Charite - Universitatsmedizin Berlin
Deal in Brief
LifeCodexx AG, a developer of innovative and clinically validated non-invasive molecular genetic tests, has entered into a research
agreement with Charite - Universitatsmedizin Berlin, a clinical research university, to intensify R&D of a novel molecular genetic-based
assay for the early detection of pre-eclampsia, a severe disorder in pregnancy characterized by hypertension and proteinuria after the 20th
week of gestation.It is the cause of approximately 16% of all maternal deaths in developed countries and up to 25% of the total perinatal
mortality. The collaboration builds on an ongoing research partnership between LifeCodexx and the University Hospital Wuerzburg in
which the partners recently demonstrated in a successful clinical proof-of principle that the proprietary qPCR-based assay developed by
LifeCodexx clearly distinguishes between patients affected with preeclampsia and non-affected patients.This agreement enables
LifeCodexx and Charite - Universitatsmedizin Berlin to predict pre-eclampsia at an early stage of pregnancy.
Deal Rationale
This agreement enables LifeCodexx and Charite - Universitatsmedizin Berlin to predict pre-eclampsia at an early stage of pregnancy.
Deal Information
Company Name Charite University Hospital of
Berlin
Charite University Hospital of Berlin (Charity) is a research institute that provides education and treatment services. The institute offers
research in areas of immunological sciences, cardiovascular and metabolism, neurosciences, oncology, rare diseases and genetics, and
regenerative therapies. It provides Charity Center for health and human sciences, basic sciences, dental, oral and maxillary medicine,
therapy and research, diagnostic laboratory and preventive medicine. Charity offers diagnostic and interventional radiology and nuclear
medicine, anesthesiology, operating-room management and intensive care medicine, surgery, traumatology and reconstructive surgery
and Charity comprehensive cancer center. The institute also provides degree programs, advice, international students, and scholarships
and funding. Charity is headquartered in Berlin, Germany.
Company Name LifeCodexx AG Parent GATC Biotech AG
Source: GlobalData
GATC Biotech Enters into Agreement with University of Konstanz

GATC Biotech Enters into Agreement with University of Konstanz
Deal in Brief
GATC Biotech AG, a DNA and RNA sequencing services provider, has entered into agreement with The Konstanz Research School Chemical
Biology of the University of Konstanz, an educational institute, for developing next generation sequencing.The agreement aims to establish
an alliance for sequence and transcript analysis (ASTRA) in order to further develop and expand modern sequencing processes. The co-
operation was established during a mutual workshop for both partners, mediated by the BioLAGO life science network. The ASTRA alliance
combines the infrastructure of GATC Biotech with University of Konstanz research projects whose main focus is on chemical biology.This
agreement enables GATC Biotech to expand and exhilarate research in chemical biology and transform the technological advantage into
scientific and financial success.
Deal Rationale
This agreement enables GATC Biotech to expand and exhilarate research in chemical biology and transform the technological advantage
into scientific and financial success.
Deal Information
Company Name University of Konstanz
University of Konstanz (UOK) is an educational institution that offers education and research services. The institute provides
undergraduate, postgraduate, doctorate courses and research programs. It offers study programs in the field of mathematics
and natural sciences, humanities and politics, law and economics. UOK’s subjects include mathematics and statistics,
computer and information science, physics, chemistry, biology, psychology, philosophy, history, sociology, literature and
politics, and public administration, among others. The institute also offers research studies in the field of cultural studies, life
sciences, nanoscience and material sciences and decision sciences. UOK is headquartered in Konstanz, Germany.
Source: GlobalData
Idogen Enters into Research Agreement with Advinus Therapeutics

Idogen Enters into Research Agreement with Advinus Therapeutics
Deal in Brief
Idogen AB, a developer of tolerogenic vaccines, has entered into a research agreement with Advinus Therapeutics Ltd, a contract research
organization, for synthesis of zebularine for future pre-clinical and clinical trials.Zebularine in GMP-quality is required for preclinical safety
studies of the company’s tolerogenic dendritic cells and for the upcoming clinical trial, which the company estimates to commence during
2018.This agreement enables Idogen and Advinus Therapeutics to develop zebularine, for the patients with severe hemophilia A and
antibodies to factor VIII.
Deal Rationale
This agreement enables Idogen and Advinus Therapeutics to develop zebularine, for the patients with severe hemophilia A and antibodies
to factor VIII.
Deal Information
Karnataka, India.
Company Name Idogen AB
Idogen AB (Idogen) is a biotechnology company that develops tolerogenic vaccines which reprogram the immune system of
paitents. The company provides product portfolio such as antibodies for autoimmune diseases, organ rejection after
transplantation and several other disease conditions. It develops anti-drug antibodies against critical treatment with
coagulation factor VIII (factor VIII). Idogen utilizes its platform technology to facilitate the development of tolerogenic
vaccines in several areas such as hemophilia A, rheumatoid arthritis, and transplantation for type-1 diabetes. The company
technology comprises a small number of dendritic cells and is treated with zebularine and the disease specific antigens. It
carries out collaboration with Oxford University to develop novel therapeutic strategies for the treatment of rheumatoid
arthritis. Idogen is headquartered in Lund, Sweden.
Source: GlobalData
Transplant Genomics Enters into Agreement with Mayo Clinic Center for Individualized
Medicine
Transplant Genomics Enters into Agreement with Mayo Clinic Center for Individualized Medicine
Deal in Brief
Transplant Genomics Inc. (TGI), a molecular diagnostics company, has entered into a multi-year agreement with Mayo Clinic Center for
Individualized Medicine, a research institute and wholly-owned subsidiary of Mayo Foundation for Medical Education and Research, to
develop, validate and commercialize diagnostic tests enabling personalized immunosuppression for solid organ transplant recipients.Under
the agreement, the partners will perform a multi-year assessment of TGI's TruGraf test for renal transplant monitoring at Mayo campuses
in Minnesota, Arizona, and Florida. They will also co-develop new tests for other types of organ and will launch exploratory studies of heart
and liver transplantation monitoring. Mayo Clinic will also make an investment in Transplant Genomics.This agreement enables TGI and
Mayo Clinic Center to develop diagnostic tests to help detect whether a patient may reject transplanted kidneys.
Deal Rationale
This agreement enables TGI and Mayo Clinic Center to develop diagnostic tests to help detect whether a patient may reject transplanted
kidneys.
Deal Information
Company Name Mayo Clinic Center for Parent Mayo Clinic
Individualized Medicine
Source: GlobalData
Applied BioCode Enters into Agreement with Diatherix

Applied BioCode Enters into Agreement with Diatherix
Deal in Brief
Applied BioCode, Inc., a developer of Barcoded Magnetic Beads (BMB) and detection systems, has entered into an agreement with
Diatherix Laboratories, Inc., a molecular diagnostic laboratory, to develop multiplex molecular diagnostic panels for laboratory
testing.Under the agreement, Diatherix will utilize its TEM-PCR technology with Applied BioCode's BMB technology and detection systems
to develop highly sensitive multiplex molecular diagnostic panels for infectious disease laboratory testing.This agreement enables Applied
BioCode and Diatherix to provide solution for multiplexing of molecular diagnostic infectious disease tests.
Deal Rationale
This agreement enables Applied BioCode and Diatherix to provide solution for multiplexing of molecular diagnostic infectious disease tests.
Deal Information
Company Name Applied BioCode Inc
Applied BioCode Inc (Applied BioCode) is a medical device company that develops, manufactures, and commercializes
multiplex testing products. The company provides a digital multiplexing molecular platform that delivers multiplex analysis
for the research of moleculars and proteins. It offers BioCode MDx 3000 System, an automated molecular diagnostic system
that automates the PCR amplification, hybridization, and detection steps of molecular testing; and BioCode 2500 Analyzer, a
system for multiplex applications. Applied BioCode offers BioCode gastrointestinal pathogen panel for common
gastrointestinal pathogen including viruses, bacteria, and parasites that cause infectious diarrhea; and BioCode sexually
transmitted infections (STI) panel for the detection of common infectious agents causing STDs. The company also provides a
multiplex cytokine and chemokine detection panel to identify biomarkers; mouse cytokine and chemokine multiplex kits that
allow users to pick and choose their own analytes panels; pre-mixed and custom multiplex kits; barcoded magnetic beads for
bioassay applications; calibration beads to coupling kits; and assay development, AgBio application, and multiplex ELISA
assay services. Applied BioCode is headquartered in Santa Fe Springs, California, the US.
Source: GlobalData
Biomnis SELAS Enters into Agreement with DIATHERIX Laboratories

Biomnis SELAS Enters into Agreement with DIATHERIX Laboratories
Deal in Brief
Biomnis SELAS, a medical testing company, has entered into partnership with DIATHERIX Laboratories, Inc., a medical device company, for
panel-based molecular diagnostics for infectious diseases.Under the agreement, Biomnis will make use of Diatherix's scientific and
technological know-how to accelerate the development of new tests and panels for molecular diagnostics that can be offered to all of its
clients. This agreement enables Biomnis and DIATHERIX to develop panel based diagnostics for infectious diseases.
Deal Rationale
This agreement enables Biomnis and DIATHERIX to develop panel based diagnostics for infectious diseases.
Deal Information
Biomnis SELAS (Biomnis), a subsidiary of Eurofins Scientific SE, is a provider of medical laboratory testing services. The
company offers laboratory tests in the areas of generics, biochemistry, immunology, cytogenics, assisted reproductive
technology-embrology-sperm science, onco-haemotology, analytical chemistry, genetic fingerprinting, molecular biology,
infectiology, and others. Biomnis also provides pathological anatomy and cytology test for the treatment and management of
cancers and others diseases. PAC laboratory serves its services to various hospital, pharmaceutical companies, and medical
biology laboratories. The company has its operations in France, Ireland and the UK. Biomnis is headquartered in Lyon, France.
Source: GlobalData
Transplant Genomics Enters into Clinical Trial Agreement with Astellas Pharma
Transplant Genomics Enters into Clinical Trial Agreement with Astellas Pharma
Deal in Brief
Transplant Genomics Inc., a molecular diagnostics company, has entered into a laboratory services agreement with Astellas Pharma Global
Development, Inc., a pharmaceutical company and an affiliate of Astellas Pharma Inc.Under terms of the agreement, Astellas will provide
Transplant Genomics with funding and blood samples from renal transplant patients collected as part of a two year, prospective,
randomized, multi-center clinical trial examining surrogate markers for long-term kidney transplant outcomes while comparing two
immunosuppressive agents. The primary outcome measure in the study is a composite endpoint combining the incidence of de novo donor
specific antibodies (DSA) and molecular phenotyping using Transplant Genomics' TruGraf test. Transplant Genomics will provide real-time
molecular analysis of blood samples collected during the trial using TruGraf, which will measure molecular signatures of immune activation
in renal transplant patients.
Deal Information
Company Name Astellas Pharma Global Parent Astellas Pharma Inc
Development Inc
Source: GlobalData
Quark Pharma Enters into Agreement with Transplant Genomics

Quark Pharma Enters into Agreement with Transplant Genomics
Deal in Brief
Quark Pharmaceuticals, Inc., a pharmaceutical company, has entered into an agreement with Transplant Genomics Inc., a molecular
diagnostics company, to use Transplant Genomics' TruGraf blood test in a Phase III clinical trial involving patients being treated for delayed
graft function (DGF) with Quark Pharma’s proprietary drug candidate QPI-1002.Under the agreement, Transplant Genomics would be
Quark Pharma’s preferred provider of gene expression profiling services related to their clinical trial. Primarily, Quark Pharma and
Transplant Genomics will understand individual patient responses to QPI-1002 as a function of time and gene expression in pathways of
immune response injury post transplant. Results can be correlated with the extensive pre-clinical data created by Quark Pharma on the
therapy’s molecular mechanism. Later, Quark Pharma and Transplant Genomics will explore potential surrogate endpoints using the
possible predictive value of genomic profiling for longer term outcomes post transplant.This agreement enables Quark Pharma and
Transplant Genomics to evaluate patients in a Phase III trial of RNAi-based treatment for delayed graft function.
Deal Rationale
This agreement enables Quark Pharma and Transplant Genomics to evaluate patients in a Phase III trial of RNAi-based treatment for
delayed graft function.
Deal Information
Company Name Quark Pharmaceuticals Inc Parent SBI Biotech Co Ltd
Quark Pharmaceuticals Inc (Quark) is a clinical-stage pharmaceutical company that discovers and develops RNAi-based therapeutics. The
company’s pipeline product portfolio comprises QPI-1002, for acute kidney injury and delayed graft function; QPI-1007, for non arteritic
anterior ischemic optic neuropathy; and PF-655, for diabetic macular edema and age-related macular degeneration. It is also developing
clinical programs for the treatment of hearing and balance disorders, neurology, cancer, cardiac, lung, and skin diseases. The company
works in collaboration with pharmaceutical and biotechnology companies to research and develop its product portfolio. It has operations
in Israel and the US. Quark is headquartered in Newark, California, the US.
Source: GlobalData
Agilent Technologies Enters into Agreement with Eurofins Genomics

Agilent Technologies Enters into Agreement with Eurofins Genomics
Deal in Brief
Agilent Technologies, Inc., a provider of bio-analytical solutions and services, has entered into an agreement with Eurofins Genomics Inc., a
provider of DNA sequencing services and subsidiary of Eurofins Scientific Group, to provide custom components and an assembled plasmid
service for Agilent's SureVector next-generation cloning kits. The modular vector kit, SureVector enables biologists to construct customized
vectors-small DNA molecules within cells that can replicate independently-from standard components.Under the agreement, Eurofins will
offer Agilent's cloning kits as well as an assembled plasmid service using the kits. Agilent will also supply Eurofins with a set of catalog
components for its SureVector cloning kits.This agreement enables Agilent Technologies and Eurofins Genomics to expand access to
SureVector cloning kits.
Deal Rationale
This agreement enables Agilent Technologies and Eurofins Genomics to expand access to SureVector cloning kits.
Deal Information
Company Name Agilent Technologies Inc
Agilent Technologies Inc (Agilent) is a provider of instruments, reagents, software, services and consumables for comprehensive laboratory
workflow. Its product portfolio comprises liquid chromatography systems and components, gas chromatography systems and components,
microarray solutions, clinical and diagnostic testing, and automation systems, among others. The company serves biotechnology,
pharmaceutical, contract research organizations (CROs) and contract manufacturing organizations (CMOs), chemical and energy,
environmental and forensics, food and other industries. Agilent markets products through direct sales force, distributors, manufacturers’
representatives, resellers and e-commerce. It has research and development and manufacturing facilities in the US, the UK, Denmark,
Germany, Italy, Japan, Malaysia, China, Singapore and Australia. Agilent is headquartered in Santa Clara, California, the US.
Eurofins Genomics GmbH (Eurofins Genomics) provides genomic services. The company is a part of Eurofins Scientific Group.
It provides next generation sequencing services, genotyping and gene expression services, custom (deoxyribonucleic acid)
DNA sequencing services, oligonucleotides, siRNA (ribonucleic acid) and gene synthesis. It also offers genomics services for
plant breeding, seed production, crop protection, livestock breeding, industrial biotechnology and basic research. The
company operates in Germany, India, the US and Japan. Eurofins Genomics is headquartered in Ebersberg, Germany.
Source: GlobalData
IQuity Labs Enters into Agreement with Diatherix Labs

IQuity Labs Enters into Agreement with Diatherix Labs
Deal Type Partnership Deal Sub Type Co-Marketing
Deal in Brief
IQuity Labs, Inc., a medical diagnostic testing company, has entered into an agreement with Diatherix Laboratories, Inc., a molecular
diagnostic laboratory.Pursuant to the agreement, IQuity Labs will make available its autoimmune disease diagnostics through Diatherix
Lab's CLIA-certified clinical laboratory.This agreement enables IQuity Labs and Diatherix Labs to provide autoimmune disease diagnostics
services to the patients.
Deal Rationale
This agreement enables IQuity Labs and Diatherix Labs to provide autoimmune disease diagnostics services to the patients.
Deal Information
Company Name Iquity Labs Inc
Source: GlobalData
Biomnis Enters into Agreement with ODPM

Biomnis Enters into Agreement with ODPM
Deal in Brief
Biomnis SELAS, a medical testing company, has entered into agreement with ODPM, a biotechnology company, for the development of a
protocol of pharmacogenetic tests.ODPM developed a protocol to avoid severe toxic effects that may be caused during chemotherapy.
These pharmacogenetic tests are performed exclusively by the Biomnis laboratory in France.The new protocol initiated by Biomnis based
on two complementary approaches to avoid severe toxic effects that may be caused during treatment with 5-FU in chemotherapyThis
agreement enables both Biomnis and ODPM to offer innovative and reliable examinations for better therapeutic management of patients.
Deal Rationale
This agreement enables both Biomnis and ODPM to offer examinations for a better therapeutic management of patients.
Deal Information
Biomnis SELAS (Biomnis), a subsidiary of Eurofins Scientific SE, is a provider of medical laboratory testing services. The company offers
laboratory tests in the areas of generics, biochemistry, immunology, cytogenics, assisted reproductive technology-embrology-sperm
science, onco-haemotology, analytical chemistry, genetic fingerprinting, molecular biology, infectiology, and others. Biomnis also provides
pathological anatomy and cytology test for the treatment and management of cancers and others diseases. PAC laboratory serves its
services to various hospital, pharmaceutical companies, and medical biology laboratories. The company has its operations in France,
Ireland and the UK. Biomnis is headquartered in Lyon, France.
Company Name Onco Drug Personalized
Medicine
Source: GlobalData
Diatherix Labs Enters into Research Agreement with Vanderbilt University Medical Center
Diatherix Labs Enters into Research Agreement with Vanderbilt University Medical Center
Deal in Brief
Diatherix Laboratories, LLC, a provider of multiplex diagnostic services and solutions, has entered into a multi-year research agreement
with Vanderbilt University Medical Center and the Vanderbilt Vaccine Research Program.Under the agreement, Diatherix will provide
clinical laboratory services using its proprietary multiplex molecular diagnostic platform for the detection of infectious diseases. Diatherix
and the Vanderbilt Vaccine Research Program will collaborate on high-impact research programs that will enhance and expand both
organizations' capabilities related to the detection of bacterial and viral infections in both pediatric and adult patient populations. The
agreement enables the partners to advance scientific and medical knowledge, with a due regard for patient safety and improvement of
patient outcomes, particularly in children.
Deal Rationale
The agreement enables the partners to advance scientific and medical knowledge, with a due regard for patient safety and improvement of
patient outcomes, particularly in children.
Deal Information
Company Name Vanderbilt University Medical Parent Vanderbilt University
Center
Vanderbilt University Medical Center (VUMC), a subsidiary of Vanderbilt University is a healthcare service provider that offers
patient care, research and bio-medical education. The center’s services include adult emergency services, case management,
corporate health services, adult psychiatry, diabetes research, disease management, dialysis clinic, and home care services. It
provides patient care in the areas including heart and heart surgery, ear, nose and throat, endocrinology, gynaecology,
cancer, kidney disease, respiratory disorders, and urology. VUMC offers bio-medical research and post doctoral education
programs. The center provide distinctive personalized care. It also provides cancer wellness program to promote health and
well being for people affected by cancer. The center operates through its hospitals, health care centers, and rehabilitation
centers located in its campus. VUMC is headquartered in Nashville, Tennessee, the US.
Source: GlobalData
Rubicon Genomics Enters into Distribution Agreeement with Eurofins MWG Operon
Rubicon Genomics Enters into Distribution Agreeement with Eurofins MWG Operon
Deal in Brief
Rubicon Genomics, Inc., a biotechnology company, has entered into a distribution agreement with Eurofins MWG Operon LLC, a genomics
company, for the distribution of Rubicon Genomics' DNA library preparation products, including ThruPLEX DNA-seq kit and ThruPLEX
Plasma-seq kit in US. This agreement enables Rubicon Genomics to distribute its suite of DNA library preparation kits in US for the analysis
of cell-free circulating DNA in plasma for diagnostic and prognostic applications in cancer and other conditions.
Deal Rationale
This agreement enables Rubicon Genomics to distribute its suite of DNA library preparation kits in US for the analysis of cell-free circulating
DNA in plasma for diagnostic and prognostic applications in cancer and other conditions
Deal Information
Company Name Rubicon Genomics Inc Parent Takara Bio USA Holdings Inc
Rubicon Genomics Inc (Rubicon Genomics), a subsidiary of the Takara Bio Group, is a provider of pre-analytical amplification technologies.
The company offers various types of kits for whole genome sequencing, whole exome sequencing, targeted sequencing, copy number
variation analysis, aneuploidy, circulating tumor deoxyribose nucleic acid analysis and gene expression analysis. It employs high sensitivity
ligation based amplification and quasi-random primed linear amplification technologies in its sequencing kits. The companny sequencing
kits find applications in Formalin-fixed, paraffin-embedded DNA sequencing, DNA sequencing, ribose nucleic acid sequencing, pre-
implantation genetic screening and diagnosis and chromatin immunoprecipitation sequencing. Rubicon Genomics is headquartered in Ann
Arbor, Michigan, the US.
Company Name Eurofins MWG Operon LLC Parent Eurofins Scientific SE
Eurofins MWG Operon LLC (Eurofins) operates as a DNA sequencing service provider. The company offers DNA sequencing
services, DNA synthesis products, and bioinformatic services. Its product categories comprise DNA and RNA synthesis, DNA
sequencing, GENE synthesis and next gen seq. Eurofins provides next gen DNA technology express oligos, extremer oligos,
custom DNA oligos, custom RNA/chimeric oligos, NGS application oligos, QPCR / MGB probes, crisprs products, simax sirna,
purification and yields and modifications. The company also offers sequencing dashboard, overnight sequencing, simpleseq
kits, flexreads, tube sequencing, plate sequencing, fragment analysis, plasmid verification, clinical and GLP services and
standard primers. The company has its presence in the US, India, Europe and Japan. Eurofins is headquartered in Louisville,
Kentucky, the US.
Source: GlobalData
Qiagen Enters into Agreement with GATC Biotech

Qiagen Enters into Agreement with GATC Biotech
Deal in Brief
Qiagen N.V., a provider of sample and assay technologies, has entered into an agreement with GATC Biotech AG, a provider of DNA
sequencing and bio-informatics services, to provide GATC clients with full access to Qiagen's ingenuity variant analysis solution for analysis
and interpretation of genetic data. Under the agreement, the access will take the form of interpretation services and direct access to
ingenuity variant analysis as a feature of the GATC Biotech's services. Ingenuity Variant Analysis is a bioinformatics platform enabling
laboratories to efficiently evaluate data generated by high-throughput next-generation sequencing (NGS) technologies. The Qiagen
software quickly filters genetic variants in a secure, private cloud-based environment to identify variants most likely to cause disease,
drawing upon the industry-leading ingenuity knowledge base.This agreement enables Qiagen and GATC Biotech to provide ingenuity
variant analysis solution.Ingenuity Variant Analysis is a web-based software application quickly filtering genetic variants to identify those
most likely to cause disease and providing researchers a powerful platform for efficiently evaluating data generated by high-throughput
NGS technologies.
Deal Rationale
This agreement enables Qiagen and GATC Biotech to provide ingenuity variant analysis solution.
Deal Information
Company Name Qiagen NV
Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company’s sample technologies help isolate and process DNA, RNA
and proteins from samples such as blood, tissue and other materials; assay technologies to identify the genetic information of a pathogen
in a tumor; bioinformatics solutions to analyze and interpret genomic data; and solutions to automate the use of consumables into
efficient molecular testing workflows. It serves human healthcare, forensics, veterinary diagnostics, food safety testing, pharmaceutical
and biotechnology and life sciences research markets. The company offers products directly and also through a network of independent
distributors. It has operations in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Qiagen is headquartered in Venlo, the
Netherlands.
Source: GlobalData
Transplant Genomics Enters into Licensing Agreement with Scripps Research Institute and
Northwestern University
Transplant Genomics Enters into Licensing Agreement with Scripps Research Institute and Northwestern University
Deal Type Partnership Deal Sub Type Licensing Agreement
Deal in Brief
Transplant Genomics Inc., a molecular diagnostics company, has entered into an exclusive licensing agreement with The Scripps Research
Institute (TSRI), a non-profit research organization, and Northwestern University, a research university, for patent rights of well-validated
technology, that identifies biomarkers associated with organ rejection. As a part of the agreement, TGI intends to develop and
commercialize tests that use genomic markers of transplant graft status as part of a surveillance program to detect and respond to early
signs of graft injury. Under the agreement, Transplant Genomics received license to access to a broad portfolio of intellectual property
related to kidney and liver transplant diagnostics, including immune status monitoring and optimization. This agreement enables
Transplant Genomics, Scripps Research Institute and Northwestern University to provide tests to improve management of organ transplant
recipients with the potential to extend lives and reduce costs of associated healthcare.
Deal Rationale
This agreement enables Transplant Genomics, Scripps Research Institute and Northwestern University to provide tests to improve
management of organ transplant recipients with the potential to extend lives and reduce costs of associated healthcare.
Deal Information
Transplant Genomics Inc (TGI) is a part of Eurofins Scientific., is a biotech company. It carries out performing organ transplantation using
non-invasive serial monitoring under the guidance of genomics. It aims in detecting early signs of graft injury by conducting molecular
diagnostic tests, enabling in differentiating among various actionable causes and also enabling optimizing the therapy. Transplant
Genomics carries out the transplantation of organs such as the kidney, liver, lungs, pancreas, and intestines through genomics supervision.
The company has its operational presence in the US. TGI is headquartered in Mansfield, Massachusetts, the US.
Company Name The Scripps Research Institute
The Scripps Research Institute (TSRI) is a research and educational organization that conducts research in the areas of neurosciences,
cardiovascular diseases, immunology, autoimmune diseases, chemistry, molecular and cellular biology, virology and synthetic vaccine
development. The institute offers technology and scientific services such as antibody development and production, cell based screening,
high performance computing, normal blood donor service and murine behavioral assessment, among others. It also offers undergraduate,
graduate and postdoctoral programs. TSRI also organizes academic preparation and educational outreach programs. The institute operates
through its research centers and institutes including Integrative Molecular Biosciences, Center for Metabolomics, Dorris Neuroscience
Center, Molecular Screening Center, and others. TSRI is headquartered in La Jolla, California, the US.
Company Name Northwestern University
Northwestern University (NU) is an educational institution. The university provides undergraduate, graduate, research and
doctoral programs. It offers courses such as communication, education and social policy, applied sciences, journalism, media,
integrated marketing communications, law, management, medicine and music, languages and cultures, biological sciences,
biotechnology, engineering, communication studies, and economics. NU offers these courses through various departments
such as Weinberg College of Arts and Sciences, School of Communication, School of Education & Social Policy, and
McCormick School of Engineering & Applied Science. The university also offers pre-collegiate programs, research and
internship programs. Northwestern University is headquartered in Evanston, Illinois, the US.
Source: GlobalData
Eurofins Genomics Enters into Co-Marketing Agreement with AmpTec for IVT-RNAs
Eurofins Genomics Enters into Co-Marketing Agreement with AmpTec for IVT-RNAs
Deal in Brief
Eurofins Genomics Inc., a provider of DNA sequencing services and subsidiary of Eurofins Group, has entered into a co-marketing
agreement with AmpTec GmbH, a provider of RNA technology products, to distribute AmpTec's in vitro transcribed (IVT)-RNAs globally.
Under the agreement, Eurofins Genomics and AmpTec will deliver premium synthetic ssRNAs, dsRNAs and mRNAs that are widely used in a
variety of applications from in vitro diagnostics of pathogens and detection of rare gene mutants to the rapidly growing field of companion
diagnostics. Both partners will serve an international market with their combined custom services for synthetic genes and for very long
synthetic RNAs.This agreement enables Eurofins Genomics and AmpTec to provide IVT ssRNAs, dsRNAs and mRNAs includes RNAs up to
several thousand bases and a wide range of modifications. This transaction enables Eurofins Genomics to broaden its portfolio with
innovative nucleic acid products.
Deal Rationale
This agreement enables Eurofins Genomics and AmpTec to provide IVT ssRNAs, dsRNAs and mRNAs includes RNAs up to several thousand
bases and a wide range of modifications. This transaction enables Eurofins Genomics to broaden its portfolio with innovative nucleic acid
products.
Deal Information
Eurofins Genomics GmbH (Eurofins Genomics) provides genomic services. The company is a part of Eurofins Scientific Group. It provides
next generation sequencing services, genotyping and gene expression services, custom (deoxyribonucleic acid) DNA sequencing services,
oligonucleotides, siRNA (ribonucleic acid) and gene synthesis. It also offers genomics services for plant breeding, seed production, crop
protection, livestock breeding, industrial biotechnology and basic research. The company operates in Germany, India, the US and Japan.
Eurofins Genomics is headquartered in Ebersberg, Germany.
Company Name AmpTec GmbH
Source: GlobalData
Oxford Gene Enters Co-Development Agreement With Emory Genetics For New CGH Arrays
Oxford Gene Enters Co-Development Agreement With Emory Genetics For New CGH Arrays
Deal in Brief
Oxford Gene Technology (OGT), a provider of innovative clinical genetics and diagnostic solutions, entered into a co-development
agreement with Emory Genetics Laboratory (EGL), a provider of genetic services, to develop new molecular arrays. Under the agreement,
the partners will develop a menu of comparative genomic hybridization arrays focused on a variety of genetic disorders. Oxford Gene and
EGL designed more than 20 such chips, which enable the detection of copy number variants in genes associated with cardiovascular,
inherited eye, intellectual disability, and neuromuscular disorders, as well as a range of inherited cancers.OGT is also making these new
research tools available as catalog products under the name CytoSure Molecular Arrays. The company also welcomes custom projects
based on these existing array designs, calling them in a statement an "ideal complement to DNA sequencing”. Madhuri Hegde, EGL’s
executive director will be discussing her lab's partnership with OGT and the new chips during a workshop at the America College of Medical
Genetics and Genomics' annual meeting, which will be held in Nashville, Tennessee, later this month. CytoSure molecular arrays, to
investigate DNA copy number variation (CNV) underlying a variety of genetic disorders, including cardiovascular, inherited eye, intellectual
disability and neuromuscular disorders, as well as a range of inherited cancers the arrays are the ideal complement to DNA sequencing,
providing a particularly powerful tool for investigating the variety of aberrations underlying genetic disorders.This agreement enables
Oxford Gene to expand its range of research-validated CytoSure Molecular Arrays to investigate DNA copy number variation (CNV)
underlying a variety of genetic disorders.
Deal Rationale
This agreement enables Oxford Gene to expand its range of research-validated CytoSure Molecular Arrays to investigate DNA copy number
variation (CNV) underlying a variety of genetic disorders.
Deal Information

Company Name Oxford Gene Technology Inc Parent Oxford Gene Technology Ltd
Company Name Emory Genetics Laboratory Parent Eurofins Scientific SE
Source: GlobalData
Venture Financing
Transplant Genomics Raises USD1.5 Million in Venture Financing
Deal Type Venture Financing Deal Sub Type Growth Capital/Expansion
Deal in Brief
Transplant Genomics Inc., a biotechnology company, has raised additional USD1.5 million in a private stock offering round, bringing the
proceeds to USD3.2 million. The finance was provided by new and existing investors.Earlier, on November 24, 2014, Transplant Genomics
raised USD1.7 million in a venture financing round. To raise this finance, the company issued equity securities to the investors.The
company intends to use the proceeds to continue building its team to commercialize the TruGraf post-transplant diagnostic test and to
fund clinical trials to establish the test's clinical utility as the firm looks to increase market adoption and pursue reimbursement for the test.
Deal Rationale
The company intends to use the proceeds to continue building its team to commercialize the TruGraf post-transplant diagnostic test and to
fund clinical trials to establish the test's clinical utility as the firm looks to increase market adoption and pursue reimbursement for the test.
Deal Information
Deal Finance None
Deal Financials
Deal Value (US$ m) 1.50
Source: GlobalData

Deal Type Venture Financing Deal Sub Type Growth Capital/Expansion
Deal in Brief
Transplant Genomics Inc., a biotechnology company, has raised USD1.7 million in a venture financing round. To raise this finance, the
company issued equity securities to the investors.The company intends to use the proceeds for working capital purposes.Stanley D. Rose is
the chief Executive officer of Transplant Genomics.
Deal Rationale
The company intends to use the proceeds for working capital purposes.
Deal Information
Deal Finance None
Deal Financials
Source: GlobalData
Transplant Genomics Raises US$2.8 Million In Venture Financing

Transplant Genomics Raises US$2.8 Million In Venture Financing
Deal Type Venture Financing Deal Sub Type Start-up
Deal in Brief
Transplant Genomics Inc., a biotechnology company, raised US$2.8m of its planned US$3m venture financing round. To raise the finance,
the company issued debt securities, options, warrants or other right to acquire another security to 33 investors. The company intends to
use the proceeds for working capital purposes.
Deal Rationale
The company intends to use the proceeds for working capital purposes.
Deal Information
Deal Finance None
Deal Financials
Source: GlobalData
Section 5 – Company’s Recent Developments

Jul 14, 2020: Eurofins publishes robust method to analyse SARS-CoV-2 in wastewater
samples, providing early warning of potential COVID-19 outbreak at a given site
A study undertaken by Eurofins scientists has resulted in a robust method to analyse SARS- CoV-2 in wastewater samples, allowing for early
detection of virus presence at a given site, before the virus spreads too broadly or as a way to monitor the effectiveness of containment
measures put in place.
As part of the study, Eurofins team of scientists used wastewater samples which had been collected during the COVID-19 pandemic in
Denmark. They were able to detect the virus in a sample taken three days before patient 0 was identified in the country.
The findings of this study are particularly relevant for municipalities, production facilities, hospitals, nursing homes etc. At those sites,
wastewater testing, offered as part of the Eurofins COVID-19 Sentinel&tradeprogramme, can give an early indication of the presence of SARS-
CoV-2, therefore allowing for relevant containment measures in order to avoid an outbreak of the disease. With a growing understanding of
the very significant role pre-symptomatic and asymptomatic virus carriers play in the pandemic, early detection of virus presence on a site is a
vital first step to identifying the potential carrier(s) and putting increased measures in place to contain the disease. As the method developed
by Eurofins is semi-quantitative, it also offers a strong tool to monitor the development of an outbreak over time and the efficacy of the
containment measures put in place when an outbreak is detected.
This waste water testing method comes as yet another powerful tool in the Eurofins COVID-19 Sentinel&tradesuite of tests to help with the
identification and containment of the COVID-19 pandemic. In real life over the last few weeks without requiring human testing, the Eurofins
COVID-19 Sentinel&tradeprogramme has demonstrated its capacity to detect the presence of the SARS-CoV-2 virus on a site, before the
affected employee had symptoms and knew of his/her infection.
Jun 29, 2020: Eurofins DiscoverX further expands its bioassay certification program with
Catalent Biologics
Eurofins DiscoverX, the products company of Eurofins Discovery, announced the expansion of their CRO Certification Program for Bioassays
with Catalent Biologics as a North American provider certified in the program.
As a certified provider of PathHunter®assay services, Catalent Biologics' Morrisville/RTP facility in North Carolina has successfully
demonstrated their capability to expeditiously implement multiple client-sponsored GLP validation programs using the PathHunter assay
platform to perform highly reproducible potency lot release assays under GLP/GMP conditions.
Eurofins DiscoverX launched their CRO certification program to support the growing needs of biotech and pharma companies to partner with
CROs and CDMOs to run potency lot release programs for bioinnovator and biosimilar drugs. Since its launch, the program has attracted the
attention of multiple global partners interested in becoming certified. This certification provides biopharma developers a platform to access
experienced biologics analytical labs that can, in an expedited manner, provide potency and nAB study support.
This bioassay certification program plays a critical role in that biopharma product developers have to prove their drug products are safe and
effective (potent). While potency can be determined using a binding assay, regulators often require the use of a functional cell-based
mechanism of action (MOA)-reflective assay, like PathHunter bioassays, that mimics conditions in living cells when the molecule allows for it
for potency lot release studies. The simplicity of the PathHunter platform, coupled with its broad menu of assays, makes it an attractive
platform for pharma and biotech companies to drive their drug molecules for filings by using the assays.
Jun 03, 2020: TGI and Viracor announce Transplant Advisory Board
Transplant Genomics, Inc. ("TGI") and Viracor Eurofins ("Viracor"), announce the formation of the Eurofins Transplant Medical and Scientific
Advisory Board, employing diverse expertise and experience in transplantation technology development and clinical studies to enhance the
clinical value of diagnostics throughout the transplant community. The members will be tasked with providing independent advice on the
unmet clinical needs in transplantation to guide the evolution of TGI and Viracor's current and future products that expand the indications for
the TruGraf and TRAC product lines through Clinical Studies, and the R&D or acquisition of additional disruptive technologies into the Eurofins
Transplant portfolio. The Board will be convened by Dr. John Holman, VP Medical Affairs at Eurofins - TGI.
Covering the breadth of geographies within the US market, the Board welcomes Dr. Roz Mannon, University of NebraskaDr. Michael
Abecassis, University of ArizonaDr. Fuad Shihab, University of UtahDr. Win Williams, Massachusetts General HospitalDr. Anil Chandraker,
Brigham and Women's HospitalDr. Allan Kirk, Duke University (joining in August after completing his term as Editor-in-Chief of AJT)Dr.
Jonathan Bromberg, University of Maryland, Dr. Robert Fairchild, Cleveland Clinic, and Dr. Matt Cooper, Georgetown University.
Advisor Dr. Johnathan Bromberg, Professor of Surgery and Microbiology and Immunology at the University of Maryland says, "For too long
transplant patients have had limited or invasive diagnostic options, so it is tremendously exciting to join a Board with a mission in science and
medicine to improve current diagnostic options available to transplant patients, and subsequently offer physicians better tools to alter and
improve our approach to treatment."
Advisor Dr. Michael Abecassis, Dean of the University of Arizona, College of Medicine - Tucson, says, "The formation of this Board will help to
expand the product portfolio to create new opportunities for the powerful commercial teams assembled by TGI and Viracor." By combining
TruGraf and TRAC, Eurofins has assembled the largest transplant diagnostics sales force, and has the most comprehensive portfolio of non-
invasive kidney rejection tests available today, and is focused on aggressively growing beyond blood tests for kidney with more technologies
and more organs. Combining this group expertise and Eurofin's resources in research and development, this advisory board is uniquely
positioned to drive clinical value throughout the transplant community.
For information on ordering tests and arranging remote sample collection, physicians may contact TGI about TruGraf tests by calling 1-844-
TruGraf. Ordering and general information is also available on our websites at www.trugraf.com. For information on ordering or remote
collection for TRAC or other Viracor products.
Apr 28, 2020: Eurofins Scientific to enable over 20 million COVID-19 tests per month by end
May 2020 with multiple new solutions
Eurofins Scientific, a world leader in Testing for Life, employing 47,000 in 800 laboratories in 50 countries published its Q1 trading statement
and on this occasion announced a number of positive developments to support the worlds’ fight against COVID 19.
Eurofins has developed one of the most comprehensive testing and service offering to support healthcare practitioners and authorities
around the world as well as the biopharmaceutical industry respond to the COVID-19 crisis. This includes:
Several of its laboratories received approval for their laboratory-developed RT-PCR tests (LDTs) by the Food and Drug Administration (FDA) in
the U.S.A. and other national authorities. Combining its own LDTs with reagents provided by its suppliers, the Group's goal is to reach a global
capacity to carry out in excess of 2 million tests per month by mid-May 2020.
Eurofins started to offer ELISA and CLIA-based serology testing services to detect Antibodies expressed after COVID-19 infection and capacity
for these is also expected to exceed 2 million tests per month by mid-May 2020.
Eurofins also launched highly specific serology testing kits to be used by state or private laboratories on most open ELISA systems and expects
to reach a production capacity of over 10 million tests per month by end May 2020.
Eurofins has launched a number of additional tests for example to detect the presence of SARS-CoV-2 on environmental surfaces, eg. in work
or retail environment or to control Personal Protective Equipment (PPE) and medical equipment.
Eurofins Genomics' six sites around the world are increasing their capacity to provide primers and probes to be incorporated in millions of
SARS-CoV-2 testing kits produced by IVD companies and genome sequencing services to support research and epidemiology.
The Group has also launched a large number of products and services aimed at supporting research for the development of novel vaccines
and therapeutics.
Apr 16, 2020: Eurofins Genomics U.S. launches new SARS-CoV-2 plasmid DNA controls and
increases its capacity to produce probes and primers, all of which being key components of
SARS-CoV-2 RT-PCR testing
Eurofins Genomics U.S. announces that, together with its subsidiary BlueHeron Biotechnology, it has launched a series of SARS-CoV-2 plasmid
DNA controls that can be used to verify the presence of the SARS-CoV-2 virus. They are intended to be used for both research and
development and IVD diagnostic applications.
Eurofins Genomics U.S. offers three different COVID-19 controls, which target key segments of the 30,000 base SARS-CoV-2 genome. One of
the positive controls, CVGP, covers a wide swath of the sequence so that users can set up multiple reactions under a single control. Eurofins
Genomics U.S. is able to produce and ship the plasmid control within one day (12-18 hours from order receipt).
In addition to the SARS-CoV-2 controls, the company has ramped up production of reverse transcription quantitative polymerase chain
reaction (qPCR RT) dual-labeled probes and primers for commercial and molecular diagnostic companies producing their own test kits. With
six oligo production facilities globally, Eurofins Genomics has already fulfilled demand for millions of COVID-19 test kits worldwide. Despite
the surge in demand for such material, Eurofins Genomics U.S. has managed to meet demand and exceed delivery timelines thanks to its
logistical position in a major courier hub as well as proprietary synthesis technology. On average, Eurofins Genomics U.S. ships out qPCR assay
panels in three days.
All material for SARS-CoV-2, both the qPCR RT probes and plasmid controls, are produced under ISO 13485 and ISO 9001 for IVD products. The
company's experience partnering with IVD kit producers in the past has allowed them to respond rapidly to the spike in demand for test kits.
This further demonstrates the commitment of Eurofins Genomics, global leader in genomic products and services, to take the lead to develop
a full suite of products and services to support the COVID-19 crisis, including qPCR probes for targeting the virus, plasmid controls for
validation, and testing kits for verification.
Apr 13, 2020: Eurofins Discovery supports critical COVID-19 drug discovery research with
products and accelerated drug discovery services
Eurofins Discovery's mission is to support Pharmaceutical and Biotech companies in their efforts to accelerate drug discovery research and
development.
Eurofins Discovery's mission is to support Pharmaceutical and Biotech companies in their efforts to accelerate drug discovery research and
development.The COVID-19 crisis is putting the focus on the need for drugs and vaccines to treat patients and provide protection to the global
population.
Through its worldwide presence, depth of scientific experience, and breadth of assays and services, Eurofins Discovery is striving to provide
expert support in identifying and assessing potential drug targets.
Pharmaceutical, biotech, government, and non-profit organizations are working diligently to identify new or existing drug modalities that
potentially can be used to treat COVID-19 affected populations.
Some of these antiviral treatment strategies include targeting angiotensin-converting enzyme 2 (ACE2), transmembrane protease serine 2
(TMPRSS2), and SARS-CoV-2 Mpro, as well as large molecule therapies.
Eurofins Discovery provides the experience, reliability, global locations, and breadth of custom and off-the-shelf services and products to
support researchers in these endeavors.
The Eurofins Discovery solution portfolio that can support COVID-19 research include: Safety profiling Drug repositioning services Bioassays
and target specific assays Cytokine storm assessment.
As recommended by the FDA and EMA, early-stage evaluation of cellular activation, proliferation, and cytokine release, as offered by Eurofins
Discovery, may help reduce the risk of adverse reactions in later clinical development.
Eurofins Discovery provides a vast product and service portfolio for drug discovery and a global team of experts that are ready to work on this
global problem.
For more information on Eurofins Discovery's comprehensive services and products supporting COVID-19 research, please visit
eurofinsdiscoveryservices.com/covid-19-resources .
ENDS www.eurofins.com About Eurofins Discovery Eurofins Discovery, a business operating under the Eurofins BioPharma Services division,
has supported Drug Discovery research for over 40 years.
Eurofins is recognized as the industry leader for providing drug discovery researchers the largest and most diverse portfolio of standard and
custom in vitro safety & pharmacology assays and panels for drug screening and profiling.
In addition to in vitro safety pharmacology strengths, we also offer a broad portfolio of over 3500 drug discovery services and 1800 products.
These include in vitro assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design,
synthetic chemistry, and custom proteins and assay development capabilities.
We support a variety of drug discovery targets such as GPCRs, Kinases, Ion Channels, Nuclear Hormone Receptors and other proteins &
enzymes.
The Eurofins Discovery capabilities, expertise, knowledge and skill sets enable the company to provide clients the benefit of being able to
work with a single outsourcing provider (CRO) for all their drug discovery programs.
Eurofins a global leader in bio-analysis Eurofins Scientific, through its subsidiaries (hereinafter "Eurofins" or "the Group"), believes it is a global
leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services.
It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology,
forensics, CDMO, advanced material sciences and in the support of clinical studies.
In addition, Eurofins is one of the leading global emerging players in esoteric clinical diagnostic testing.
With over 47,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client
markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety,
identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical
diagnostic testing services.
The Group's objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert
advice by its highly-qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its
clients unique analytical solutions and a very large range of testing methods.
As one of the most innovative and quality-oriented international companies in its industry, Eurofins is ideally positioned to support its clients'
increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around
the world.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
For more information, please visit www.eurofins.com .
SOURCE Eurofins Discovery
Apr 07, 2020: The National Kidney Registry and Viracor Eurofins announce Coronavirus
Antibody Testing for Donors and Recipients
The National Kidney Registry (NKR) and Viracor Eurofins announced a partnership to deliver the newly released COVID-19 antibody testing for
NKR's vast network of Member Centers. NKR is the largest paired exchange program in the world and serves approximately 100 transplant
programs throughout the United States. NKR has relied on Eurofins' specialty transplantation laboratories, VRL Eurofins and Viracor Eurofins,
for over seven years to process mission critical tests to support NKR's paired exchange operation. The two Eurofins sister companies launched
COVID-19 PCR testing on March 13th and quickly followed with the launch of the COVID-19 antibody testing on April 8th.
"We are pleased to announce that COVID-19 antibody testing will be available to NKR Member Centers by Friday, April 10th. Some centers are
already planning to use the newly released antibody test for screening donors and recipients prior to surgery, in conjunction with the PCR
test, and for research related to waitlisted patients and transplant recipients," said Garet Hil, Founder and CEO, National Kidney Registry. "We
are grateful for the rapid response from Eurofins in developing this solution and we indebted to key members of our Medical Board for
guiding us through this process."
Viracor Eurofins is thrilled to be working with NKR and believes that by combining resources we can play a pivotal role in better understanding
the impact of COVID-19 on transplant donors and recipients while reducing infection risk. Given the concerns surrounding COVID-19,
particularly within immunosuppressed populations, like transplant recipients, we are pleased to support the transplant community as we
work through this current healthcare challenge.
Apr 06, 2020: Eurofins Scientific offers a full range of testing services for Personal
Protective Equipment (PPEs) and Medical Devices used in the fight against the COVID
pandemic
Eurofins, a global leader in testing and laboratory services, announces that its laboratories across the U.S.A., Europe and Asia are now
providing a global service offer for testing, inspection and regulatory services focused on medical face masks, gloves and gowns, respiratory
protective devices and equipment, its materials and components, as well as disinfectants and hand sanitizers, to serve the increasing demand
caused by the severe coronavirus pandemic.
With a service offering that covers a scope spanning from product concept and risk assessment, Notified Body services, through chemical,
biological, physical, mechanical or electrical testing, efficacy and performance evaluations and all the way down to product certification and
quality controls, Eurofins strives to be the one-stop solution provider for its clients supplying PPEs and Medical Devices to the healthcare
sector worldwide.
Mar 30, 2020: Viracor Eurofins launches Labs@HOME, a mobile phlebotomy service for
post-transplant patient testing
Viracor Eurofins announces the launch of Labs@HOME, a mobile phlebotomy service to aid in specimen collection for vital post-transplant
testing directly from patient's home. As the hospital system becomes increasingly stressed with Coronavirus Disease 2019 (COVID-19)
patients, bone marrow transplant (BMT) and solid organ transplant (SOT) patients may be unable to return to the hospital for routine and
specialized post-transplant testing and management. These immunosuppressed and immunocompromised patients are already at risk for
transplant rejection due to infection or graft failure, and subsequently fall into the high risk category for COVID-19.
Viracor's Labs@HOME service allows physicians to order and customize a limited menu of infectious disease and transplant-related testing.
The specimen collection is performed safely and securely by a qualified phlebotomist who will work with the patient to schedule an
appointment at the patient's residence. With testing tailored for BMT or SOT patients, options include key PCR tests (Adenovirus, BKV, CMV,
EBV, or HHV-6), therapeutic drug monitoring for immunosuppressive and antifungal medications, CMV T Cell Immunity Panel, Viracor's TRAC
(Transplant Rejection Allograft Check), as well as TruGraf Blood Gene Expression Test (powered by Transplant Genomics Eurofins). The results
of these tests can aid providers in making critical treatment decisions with the hope of more successful outcomes.
By providing this specialty service for the transplant community, Labs@HOME enables Viracor to help these critical patients in an integral
time post-transplant in the wake of a rapidly changing healthcare situation.
Mar 19, 2020: Eurofins Scientific supports healthcare authorities in Europe, the U.S.A. and
Brazil in their fight against the COVID-19 pandemic with additional testing options and fast
growing capacity
Eurofins, a global leader in testing and laboratory services, announces that, in addition to the U.S.A. and Germany, as previously
communicated, it is now offering testing for detection of SARS-CoV-2 in France, Spain and Brazil with the Netherlands expected to start
processing samples shortly. Global capacity created is currently around 10,000 tests per day split about equally between Europe and America.
Following requests from government health authorities, Eurofins teams are working round the clock to increase capacity. It is now expected
to increase to well over 15,000 tests per day by Monday 23 March 2020 and significantly more by 01 April 2020 as new sites and testing
methods are added. In each geography, Eurofins laboratories are working closely with public health authorities and following their priorities
to support hospitals and medical professionals fighting this unseen health crisis.
This week, five laboratories started testing for SARS-CoV-2 in France. In particular, Eurofins Biomnis' laboratories started testing for SARS-CoV-
2 using a test they developed and successfully validated and after receiving approval from the government health authorities. As part of this
effort to support Healthcare authorities, Eurofins Biomnis is enabling French hospitals to free up capacity to perform SARS-CoV-2 tests on site
at short turnaround times by also offering outsourcing for other infectious diseases testing. In Spain, Eurofins Megalab Madrid also started
testing for COVID-19 this week. On 11 March 2020, Eurofins Brazil started offering COVID-19 tests through its Clinical Laboratory Centro de
Genomas.
In the U.S.A., where Eurofins started testing last week, capacity is also ramping up fast to meet growing demand.
In Germany, Eurofins Medizinisches Labor Gelsenkirchen (Eurofins GeLaMed) started testing for COVID-19 on 03 March 2020 and while facing
fast growing testing volumes, is looking into options to increase capacity in the near future.
In addition, Eurofins Technologies, a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection
methods, is finalizing the development and preparing to start validating new SARS-CoV-2 clinical testing kits and testing kits for detection of
SARS-CoV2 in environmental swabs of surfaces and in food or feed samples.
"As a world leader and innovator in analytical testing, we are pleased to be able to contribute to the global response to the SARS-CoV-2 crisis
by giving healthcare providers around the world options in evaluating their patients during this terrible outbreak. A growing number of
healthcare authorities across the world are now adopting broader testing regimes to complement social isolation and other measures and
rapidly identify, care for and isolate SARS-CoV-2 positive persons either within front line healthcare workers or hospitalized patients only or
suspected cases and their contacts in the population at large depending on the country in order to, amongst other objectives, reduce
contagion risks. As a Group, Eurofins is committed to leveraging all of its technical capabilities, including in its genomics and forensics
laboratories, to support current and future SARS-CoV-2 testing needs as defined by government healthcare authorities and exploring
innovative solutions to further increase capacity and the range of testing options available to support the admirable work of medical teams
around the world, said Chief Executive Officer Dr. Gilles Martin.
Mar 18, 2020: Eurofins Transplant Genomics and Viracor will partner to offer Remote
Sample Collection Options to support care for Kidney Transplant Recipients during COVID-
19 Outbreak
Transplant Genomics, Inc., a molecular diagnostics company committed to improving organ transplant outcomes with non-invasive serial
monitoring guided by genomics, announced that it has partnered with sister Eurofins company Eurofins Viracor, and established relationships
with Quest and various mobile sample collection groups, to enable patients to have samples collected remotely for analysis with our unique
catalog of tests critical to monitoring health of kidney transplant recipients without requiring them to visit transplant centers.
Key testing services include:
- TruGraf®: the only blood test approved by CMS for surveillance to rule out silent rejection in stable kidney transplant recipients and provide
comfort that patients are likely to be immune quiescent (via Transplant Genomics)
- Viracor TRAC&trade: to analyze donor-derived cell-free-DNA levels in blood to rule out rejection in patients suspected of rejecting (via
Viracor)
In addition, Eurofins Viracor is now offering testing for SARS-CoV-2 in kidney transplant donors and recipients. Please contact us for details
concerning how we can help you provide your patients with access to this important test.
Eurofins is committed to supporting physicians in providing optimal care for their transplant patients. With the outbreak of COVID-19, we
understand that transplant programs are minimizing office visits, both to ensure patient health and safety, as well as reduce the burden on
staff so they may focus their care on patients who are most in need. By offering our unique catalog of tests, and making available remote
sample collection options, we are doing our part to support patient care during this difficult time.
Mar 16, 2020: The National Kidney Registry and Viracor Eurofins Announce Coronavirus
COVID-19 Rapid Turnaround Transplant Testing for Donors and Recipients
With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical
patients, Viracor Eurofins is committed to helping medical professionals, transplant teams, reference labs and biopharmaceutical companies
get results faster, when it matters most.
https://www.viracor-eurofins.com (PRNewsfoto/Viracor Eurofins) GREENWICH, N.Y. and LEE'S SUMMIT, Mo., March 16, 2020 /PRNewswire/ -
- The National Kidney Registry (NKR) and Viracor Eurofins announced a partnership today to deliver testing for Coronavirus SARS-CoV-2 (the
virus that causes COVID-19 disease) to NKR's vast network of Member Centers.
NKR is the largest paired exchange program in the world and serves approximately 100 transplant programs throughout the United States.
NKR has relied on Eurofins' specialty transplantation laboratories, VRL Eurofins and Viracor Eurofins, for over seven years to process mission
critical tests to support NKR's paired exchange operation.
Viracor announced availability of its COVID-19 assay on March 13th following validation in accordance with the FDA Emergency Use
Authorization Guidance.
"We are pleased to announce that thousands of COVID-19 test kits will arrive at NKR Member Centers by Thursday March 19th.
These test kits can be used to test living donors, recipients of living donor organs and recipients of deceased donor organs.
Our goal is to increase transplant safety for donors and recipients during this challenging time," said Garet Hil, Founder and CEO, National
Kidney Registry.
"We are grateful for the rapid response from Eurofins in developing this solution and we are indebted to key members of our Medical Board
for guiding us through this process.
We are especially grateful to Dr. Robert Redfield at UW Madison for quickly overcoming a serious regulatory obstacle that had the potential
to stop the roll-out of this solution."
Viracor Eurofins is thrilled to be working with NKR and believe that by combining resources we can play a pivotal role in helping transplant
programs reduce COVID-19 risk for their donors and patients.
Given the concerns surrounding COVID-19, particularly within immunosuppressed populations, like transplant recipients, we are pleased to
support the transplant community as we work through this current healthcare challenge.
Mar 14, 2020: Eurofins Scientific Supports SARS-CoV-2 analyses needs in the U.S.A. and in
Europe with multiple testing options
Eurofins announces that two of its clinical diagnostic testing laboratories in the United States now offer testing for evaluation of COVID-19. On
13 March 2020, Viracor Eurofins, one of the largest and most recognised infectious diseases testing laboratories in the U.S.A., is launching a
stand-alone real time reverse transcriptase PCR assay for the qualitative detection of SARS-CoV-2.
Additionally, next week, Diatherix Eurofins expects to begin testing for SARS-CoV-2 as part of its newly updated Target Enriched Multiplex PCR
(TEM-PCR) Respiratory Viral Panels. Both laboratories shall offer testing in accordance with the FDA Emergency Use Authorization Guidance.
These testing methods give healthcare providers options for either evaluating patients at risk for SARS-CoV-2 exposure with targeted testing
or screening patients with respiratory complications for the cause of their symptoms. Both laboratories plan to provide results back to
healthcare providers the same day the specimens are received for samples received early in the morning (12 to 18 hours after sample
receipt). These tests will be available directly from the testing laboratories or through the other Eurofins U.S. Clinical Diagnostic Laboratories:
Eurofins NTD, Boston Heart Diagnostics, Eurofins VRL and EGL Genetics. This extensive network of options will continue to aid in the response
to this novel virus.
In Germany, Eurofins GeLaMed started testing for COVID-19 last week and has already tested hundreds of samples. Eurofins' laboratories in
France, the Benelux and Spain are getting ready to start testing immediately with tests they developed and validated, after approval by public
health authorities which is expected shortly.
"As a world leader and innovator in analytical testing, we are pleased to support the global response to SARS-CoV-2 by giving healthcare
providers options in evaluating their patients during this terrible outbreak, said Chief Executive Officer Dr. Gilles Martin.
Mar 04, 2020: Eurofins delivers strong growth again in 2019

As a result of both the major impact of the criminal cyber-attack on Eurofins’ operations that hit many laboratories of the Group on 02 June
2019 and the first implementation of IFRS 16 on Eurofins’ accounts, FY 2019 reported results are not easily comparable with FY 2018 results.
Therefore, in addition to reported and adjusted results, this press release also provides estimates on a comparable adjusted basis. The
comparable adjusted basis corrects the adjusted results for the estimated impact of the cyber-attack (EUR 75m at the EBITDA level) and of the
implementation of IFRS 16 on Eurofins’ FY 2019 consolidated accounts. Were it not for these impacts on profits, investments and cash flows,
Eurofins believes it would have achieved all its objectives for FY 2019.
Total revenues grew 20.7% from EUR 3,781m to EUR 4,563m for the full financial year 2019 (FY 2019), not corrected for the lost revenues
following the 02 June 2019 criminal cyber-attack (estimated at EUR 69m). In spite of the cyber-attack, this is well above the Group's EUR
4,500m revenue objective for FY 2019. In Q4 2019, revenues increased 13.4% year-on-year to EUR 1,228m from EUR 1,083m in Q4
2018.Organic growth10 was strong at 5.4% in Q4 2019. Due to the lack of comparability with the revenues of the month of June 2018 as a
result of the 02 June 2019 cyber-attack on Eurofins servers, like for like organic growth for the full year 2019 unfortunately cannot be
determined. However, organic growth (adjusted for calendar working days' effect) showed increased momentum throughout the year (+4.9%
in Q1 2019, +5.1% in Q3 2019, and +5.6% in Q4 2019). Excluding Boston Heart Diagnostics ("BHD) which suffered very large reimbursement
reductions in 2019, organic growth (adjusted for calendar working days' effect) was +5.7% in Q1 2019, +6.0% in Q3 2019 and +6.5% in Q4
2019.Reported EBITDA3 increased 27.9% year-on-year in FY 2019, representing an 18.3% reported EBITDA margin, a 110bps improvement
year-on-year. At constant accounting rules15 (i.e. excluding the impact of IFRS 16 application of EUR +131m) and corrected for the estimated
impact of the cyber-attack (estimated at EUR -75m), reported EBITDA would have increased by 19.3% year-on-year to EUR 777m, resulting in
a 16.8% reported EBITDA margin, a moderate 40bps decrease year-on-year, mainly due to BHD losses and the dilutive margin of TestAmerica,
consolidated in full in FY 2019, more than offsetting underlying operational improvements.The impact of the loss of revenue and profit on FY
2019 results and the additional expenses incurred as a result of the criminal cyber-attack that hit Eurofins on 02 June 2019 is estimated at EUR
-69m on revenues and EUR -75m on EBITDA and EBITAS4 net of a ca. EUR 10m first insurance payment received in Q3 2019. Eurofins
insurance coverage exceeds these estimates, but efforts to determine and agree on exact damages reimbursements will be ongoing for a
while. The cyber-attack also had a residual impact on Eurofins' ability to collect receivables. Eurofins ended FY 2019 with a 5.3% net working
capital to sales ratio vs. its goal of 4.5% (-0.8%), which would have been a 30bps improvement vs. FY 2018.Separately Disclosed Items2 (SDI)
remain elevated at EUR 98m reflecting the ongoing efforts to achieve an optimal hub and spoke network of laboratories following the
significant acquisitions completed in 2017 and 2018 as well as BHD losses. SDI comprise EUR 48m of one-off costs from integrations,
reorganisations and discontinued operations, and other non-recurring income and costs (of which EUR 7m relates to BHD), and EUR 50m of
temporary losses and other costs related to network expansion, start-ups and new acquisitions in significant restructuring (of which EUR 12m
relates to BHD). Reorganisation costs relate for a significant part to the consolidation of the business in expanded campuses in Lancaster
(Pennsylvania), Hamburg (Germany), Montreal Longueuil (Canada), and Wiener Neudorf (Austria), as well as site consolidation costs between
historical Eurofins U.S.' Environment and Food testing laboratories and TestAmerica and Covance Food Solutions respectively and of Alpa sites
with historical Eurofins' activities in France.Comparable adjusted EBITDA (i.e. excluding the impact of IFRS 16 application of EUR +131m, and
corrected for the estimated EBITDA impact of the cyber-attack of EUR -75m) increased by 22.6% year-on-year to EUR 883m in FY 2019,
representing a 19.1% adj. EBITDA margin (+10bps year-on-year) exceeding the Group's EUR 850m adjusted EBITDA objective for FY 2019
(which was set prior to the implementation of IFRS 16 and the cyber-attack). 2018 acquisitions, especially TestAmerica, continued to have a
dilutive effect throughout FY 2019. However that company improved its EBITDA margin to a double-digit level.The Group's mature scope11,
representing 93% of the Group's revenues (EUR 4,250m), generated a comparable adjusted EBITDA margin (i.e. excluding the impact of IFRS
16 application, and corrected from the impact from the cyber-attack) of 20.5% in FY 2019, stable year-on-year. The Group saw a continued
improvement in the profitability of the mature business created or acquired before 2017, which posted a comparable adjusted EBITDA margin
of 21.6% in FY 2019 (+40bps vs. FY 2018). Acquisitions made in 2017 and 2018, though still dilutive as a whole, improved their comparable
adjusted EBITDA margin to 18.4% in FY 2019, +80bps year-on-year on a proforma basis, whilst 2019 acquisitions had an average of 14.3%
comparable adjusted EBITDA margin for the part included in the mature scope.Net Operating Cash Flow8 at constant accounting rules (i.e.
excluding the impact of IFRS 16 application of EUR +130m) stood at EUR 548m, stable year-on-year (+0.7%) despite the large and negative
impact of the cyber-attack and the high level of investments in SDIs. Similarly, the Group's net working capital was also impacted by slower
collections following the cyber-attack and stood at 5.3% of Group's revenues in 2019 (+50bps year-on-year).Net capex spend was EUR 321m
(7.0% of Group's revenues at constant accounting rules vs. 9.6% in FY 2018) including EUR 103m for buildings (EUR -29m vs. EUR 132m in FY
2018), representing a 11% decrease year-on-year (EUR 361m in FY 2018). At the end of 2019, Eurofins purchased two large buildings for a
total cost of EUR 29m, one near Los Angeles (California) and another one near Heathrow (UK) where it will install laboratories in 2020 and
2021. This was not planned in the 2019 budget and was brought forward due to competitive pressure in these local real estate markets. In
addition, before the implementation of IFRS 16, those buildings would have been leased by Eurofins instead of owned. This is why Net capex
was slightly above EUR 300m. As investment in M&A was well below the EUR 300m self-imposed maximum, Eurofins could afford those
investments while staying well below its EUR 600m total combined cap on M&A and capex.Free Cash Flow to the Firm9 reached EUR 258m
and EUR 379m after correcting for the cyber-attack impact on EBITDA (EUR 55m net of tax) and on net working capital (0.8% for EUR 37m)
and EUR 29m for buildings that would previously have been leased or purchased later. At constant accounting rules (i.e. excluding the impact
of IFRS 16 application of EUR +32m), Free Cash Flow to the Firm9 stood at EUR 226m, a significant increase of 24.0% year-on-year despite the
impact from the cyber-attack and those extra investments to own buildings that were purchased ahead of plan in 2019 and where
laboratories will start to be set up in 2020 for 2021 delivery only.Eurofins closed 26 acquisitions during the year 2019, representing annual
revenues of over EUR 130m in FY 2019 and a total investment of EUR 171m, a significant -86% year-on-year decrease as the Group took
advantage of exceptional M&A opportunities in 2017 and 2018 and has, at this point, to a large extent already managed to build its desired
laboratory platform and geographic footprint.Year-end net debt at constant accounting rules (i.e. excluding the impact of IFRS 16 application
of EUR +524m) remained stable year-on-year at EUR 2,721m (vs. EUR 2,737m at the end of June 2019 and EUR 2,651m at the end of
December 2018). As a result, Eurofins' leverage (net debt excluding IFRS 16 impact divided by comparable adjusted EBITDA) decreased to
3.08x at the end of December 2019, from 3.61x at the end of June 2019.Basic reported earnings per share (EPS) at constant accounting rules
(i.e. excluding the impact of IFRS 16 application of EUR -0.3) decreased -11.0% to EUR 11.26 in FY 2019, largely driven by the large cost of the
cyber-attack as well as a higher tax rate coupled with the Group not yet benefitting from the integration of recent acquisitions.As Eurofins'
management is confident in the positive cash flow outlook for the Company and in receiving further insurance reimbursements, it intends to
propose, at its upcoming general assembly, to distribute a dividend of EUR 3.45 per share, a 20% increase vs. 2018, corresponding to 42% of
FY 2019 basic reported EPS attributable to equity holders.In FY 2019, the Group continued to improve its Environmental, Social and
Governance (ESG) practices, including a revision of its Group Code of Ethics, the publication of eight Group compliance policies and the
introduction of a number of non-financial KPIs covering some significant social and environmental matters. Eurofins is also working on
expanding its Board of Directors and intends to propose the appointment of at least one new Independent Non-executive Director at its
upcoming AGM scheduled for 23 April 2020.Corona virus update: With only slightly over 3% of its revenues derived from China, South Korea
and Italy Eurofins revenues have so far not been meaningfully affected by the SARS 2-CoV crisis. Eurofins' Food testing laboratories in China
have already developed testing methods for SARS 2-CoV to help manufacturers resume their business activities. After a very slow February,
our Chinese Food testing laboratories are seeing a significant pick-up of activity this month. Most of Eurofins' laboratories operate in resilient
non-cyclical healthcare-related areas, which have historically been less affected by economic crises. Like any company, Eurofins' laboratories
are updating their business continuity plans to attempt to mitigate potential supply chain or other interferences to operations. Until last
weekend, in countries where Eurofins operates human clinical pathology laboratories, tests for SARS 2-CoV were generally only carried out by
public health laboratories. Testing is now increasingly being opened to highly qualified independent high complexity molecular testing
laboratories. Eurofins laboratories are finalising the development of their own tests and sourcing some commercially available ones to
support health authorities testing needs for the hopefully unlikely case the epidemy were to expand much more broadly. Eurofins Diatherix is
also working to integrate SARS 2-CoV in its broad respiratory syndromic panels detecting 32 viruses and bacteria to help healthcare
practitioners identify other pathogens causing similar symptoms. Eurofins Technologies is also working to add CoV to its range of virus testing
kits for both laboratories and for on-site use by the industry should this become a question in certain environmental or food samples.Outlook:
Following a strong set of 2019 results in spite of the cyber-attack and a positive outlook on its non-cyclical health focused markets, Eurofins is
setting new objectives for 2020 and 2021 as follows (all below objectives include IFRS 16 and are set at constant average 2019 FX rates):For
2020, Eurofins' objectives are to achieve EUR 5bn of revenues, including 5% from organic growth and EUR 100m from acquisitions (EUR200m
annual revenues consolidated at mid-year), EUR 1.1bn adjusted EBITDA and EUR 500m Free Cash Flow to the Firm.For 2021, Eurofins'
objectives are to achieve EUR 5.45bn revenues, including 5% from organic growth and EUR 100m from acquisitions (EUR200m annual
revenues consolidated at mid-year), EUR 1.25bn adjusted EBITDA and EUR 600m Free Cash Flow to the Firm.These objectives reflect the
continuation of a strong focus on margins and cash flow generation and are accompanied by significantly reduced investments with a self-
imposed limit of EUR 700m for Net capex and M&A spend combined in both 2020 and 2021 (i.e. ca. EUR 400m Net capex spend including EUR
100m related to IFRS 16 and ca. EUR 300m M&A spend as previously communicated). In 2020, Eurofins should complete its five year
infrastructure development programme and thus Net capex in laboratories and IT solutions, which remain relatively high in 2020, should
reduce thereafter towards historical levels as a percentage of revenues. The opening of new start-up laboratories should be limited with
majority of focus to be on Asia in 2020 and 2021. Most of Eurofins' capex spend is discretionary and could be delayed should the SARS 2-CoV
crises cause significant supply chain or market disruptions. The objective is for SDIs not to exceed EUR 60m at EBITDA level in 2020 and EUR
30m in 2021.
If Q4 2019 trends in Eurofins' markets continue in 2020, it could be that these revenue and profits objectives may also be achieved with
higher levels of organic growth than 5% and less acquisitions. The EUR 700m annual investments including IFRS 16 are a self-imposed cap. As
in 2019, Eurofins may not reach this total if it does not identify enough high quality acquisition targets at the right price. The Group's priority
remains investment discipline and deleveraging.
As a result, by the end of 2021, Eurofins' objective is to bring its leverage (net debt / adjusted EBITDA) back to ca.2.5x. Beyond 2021 and at
least in 2022, Eurofins plans to continue to focus on further deleveraging towards the mid-point of its historical 1.5-2.5x net debt to adjusted
EBITDA range.
Comments from the CEO, Dr. Gilles Martin:
"In 2019, following two years of intense M&A activity in 2017 and 2018, the Group moved into the final phase of its five year 2016-2020 plan
to build a unique global network of state-of-the-art laboratories, market leadership positions, scale and scientific excellence to offer even
better, faster, more cost effective and innovative services to its clients. From a financial perspective, this translated into lower investments, in
terms of both M&A and Net capex, as well as continued improvement in the profitability of the mature business created or acquired before
2017, leading to improved free cash flow generation.
Unfortunately, the Group suffered a criminal cyber-attack on 02 June 2019, which severely hit several Group laboratories and temporarily
stopped or reduced production. This has significantly impacted the financial performance of the Group in 2019. While operations recovered
for the most part within two weeks, many of Eurofins' businesses were still feeling the negative impact of those service interruptions and the
ensuing efforts to harden IT systems through H2 2019. Combined with the resulting defocus of management beyond the costs and revenue
losses incurred, this cyber-attack has probably delayed progress towards the Group's growth objectives by six months. Any lag should
however be neutralised within 2020 and the IT spend normalised. The good performance achieved in Q4 in spite of this incident is
encouraging and an indication of the dynamism and resilience of Eurofins' health focused markets as well as Eurofins' strong competitive
position in those.
The ongoing integration efforts following the exceptional M&A activity of 2017 and 2018 as well as investments into building an unmatched
state-of-the-art laboratory platform (laboratory buildings, start-ups and IT) with significant scale advantages and consolidating businesses
therein, continued to weigh on the overall margin and cash flow generation in 2019. In 2020, the Group's focus will continue to be to finalise
the internal investments required to complete this five year plan. In particular our focus will be on completing the planned site
reorganisations and IT solutions deployment, making progress towards operational excellence, and, as a result, further improving profitability
and cash flow generation, with a subsequent continued deleveraging of the balance sheet. Beyond 2020, once the 2016-2020 five year plan
shall be completed, the Group expects to benefit from significantly improved competitive advantage and to be ready to enter its next growth
cycle, which should be even more innovation led. After having achieved the expansion targets in North America announced in 2011, the
Group will be more focused on expansion in Asia and Latin America. We believe that the operational benefits of all investments carried out in
the 2016-2020 period should result in significantly improved profitability, cash flow generation and return on investment.
Business Review
02 June 2019 cyber-attack:
In H2 2019, Eurofins teams worked very hard to fully recover from the 02 June cyber-attack and to further harden IT systems.
The impact of the loss of revenue and profit and the additional expenses resulting from the 02 June 2019 cyber-attack, based on the most
current estimates, stands at ca. EUR 69m on revenues and ca. EUR 75m on EBITDA and EBITAS net of a ca. EUR 10m first insurance payment
received in Q3 2019. These higher estimates than those shared at the time of the Q3 2019 press release are mainly due to IT incident
response costs incurred both locally and centrally in the second half of 2019.
The net financial impact (after insurance compensation) is expected to be much lower, as Eurofins has business interruption insurance
coverage for an amount exceeding the above estimates and coverage for this criminal cyber-attack has been confirmed. The first payment
was received in Q3 2019. The Group expects efforts to determine and agree on exact damage reimbursement to be ongoing for a while. In line
with Eurofins' conservative accounting, no future reimbursement has been booked in 2019 accounts.
The following figures are extracts from the Consolidated Financial Statements and should be read in conjunction with the Consolidated
Financial Statements and Notes for the period ended 31 December 2019.
Revenues
Revenues increased 13.4% year-on-year to EUR 1,228m in Q4 2019 from EUR 1,083m in Q4 2018. For the full financial year 2019, total
revenues grew 20.7% from EUR 3,781m during the same period last year to EUR 4,563m. Revenues were reduced as a result of the cyber-
attack (estimated at EUR 69m in revenue lost). In spite of this severe criminal act, Eurofins exceeded its EUR 4,500m revenue objective for FY
2019. Organic growth was strong at 5.4% in Q4 2019 and 6.3% corrected for BHD. Due to the lack of comparability between the revenues of
June 2018 and June 2019 as a result of the 02 June 2019 cyber-attack on Eurofins' servers, like for like organic growth for the full year 2019
unfortunately cannot be determined. However, organic growth (adjusted for calendar working days effect) showed increased momentum
throughout the year (+4.9% in Q1 2019, +5.1% in Q3 2019, and +5.6% in Q4 2019). Excluding BHD which suffered very large reimbursement
reductions in 2019, organic growth (adjusted for calendar working days effect) was +5.7% in Q1 2019, +6.0% in Q3 2019 and +6.5% in Q4
2019.
In Europe, Eurofins' largest market which accounts for 55% of Group revenues, revenues increased 13.1% to EUR 2,501m in FY 2019. Q4 2019
organic growth was above Group average in Europe with double digit growth in BioPharma services, mid to high single digit organic growth in
both Clinical Diagnostics and Environment testing, whilst Food testing organic growth was slightly below Group average. The very strong
performance of BioPharma services in Europe in Q4 2019 was driven by a particularly buoyant demand for the Group's services from the
BioPharma industry both for R&D-related and quality control testing services. The recent completion of building extensions in Ireland,
Germany, Italy, Belgium and Sweden will enable the Group to continue to meet this demand and will provide an increased panel of services to
the BioPharma and Medical Device industries. The Clinical Diagnostics business in Europe delivered organic growth above Group average in
Q4 2019 thanks to very positive developments in its innovative test portfolio as well as an easy comparable basis and despite the strikes in
France which had an adverse effect on the routine laboratories, particularly in the Paris area. Eurofins saw particularly strong growth in non-
invasive prenatal testing ("NIPT) across Europe, cementing its leadership position in that segment. In France, the strong performance of NIPT
followed the decision made by the French National Healthcare system last year to reimburse such tests. The Environment testing business
saw strong momentum in most European countries driven by demand in its main segments, market share gains, as well as innovation,
particularly in the areas of PFAS, microplastics and pesticides testing, all delivering double digit organic growth. The Food and Feed testing
business experienced low to mid-single digits organic growth in Europe in Q4 2019. The growth remained very robust, above Group average,
in several countries including France, Southern Europe and the Nordics, where the Group continued to benefit from its leadership position
and very large network of local laboratories and competence centres offering clients an unrivalled portfolio of tests and a unique level of
services. The Forensics business also rebounded strongly following the cyber-attack, delivering double digit organic growth in Q4 2019.
In North America, Eurofins' second largest market which accounts for 37% of Group sales, revenues increased 33.5% to EUR 1,677m in FY
2019. The strong increase is partly attributable to the acquisitions of Covance Food Solutions and TestAmerica, which were both acquired in
the second half of 2018 and therefore consolidated for a full year in 2019. Organic growth in Q4 2019 was slightly below Group average
despite double-digit growth in BioPharma services and a solid performance, in-line with Group average, in Food testing, somewhat tempered
by a negative contribution from the Clinical Diagnostics business driven by continued significant reimbursement challenges at BHD. The
BioPharma business, which accounted for a third of North America revenues in Q4 2019, continued to benefit from strong R&D spend, high
levels of biotech funding and increased levels of strategic outsourcing. In particular, Eurofins' position as a leading player in the fast-growing
biologics and gene/cell therapy markets helped fuel growth. Thanks to the expansion of the Lancaster Laboratories campus, significant
additional capacity has become available allowing for further expansion of advanced capabilities in both traditional biologics and advanced
therapy medicinal products. The expansion of both drug substance and drug product capabilities into an integrated CDMO offering at the
Toronto biopharma campus has also enabled Eurofins to optimise its service portfolio in early phase drug development, allowing its clients to
accelerate time to clinic and ultimately time to market. The Food and Feed testing business also delivered solid organic growth in North
America in Q4 2019, in line with Group average. This business was supported by innovation, for example, through the development of a new
method for the detection of microplastic particles in food and water, which is expected to experience good adoption rates in light of increased
legislation in environmentally-conscious States in the U.S.. A laboratory in Canada was successfully audited by the European Medicinal Agency
for the testing of cannabinoids, a growing market as a result of legislative changes. The integration of Covance Food Solutions continues as
planned, with the relocation of the main hub in Madison to a new building scheduled for Q1 2021. In Environment testing, a positive
regulatory environment fuelled above target growth in Drinking Water, Specialty Services, and Built Environment (Asbestos, Mold, Legionella
and Industrial Hygiene). This growth occurred against a backdrop of laboratory rationalisations (Nashville and Richland) and relocations
(Massachusetts/Rhode Island, Specialty Metals and Montreal), setting the business up for a strong 2020. The integration of TestAmerica
progressed ahead of schedule and delivered cost savings in excess of USD 10m in FY 2019, leading to significantly improved margins. Eurofins
continues to roll out the TestAmerica Laboratory Information Management System ("LIMS) across its U.S. Environment testing sites in order to
operate across a unified market leading IT platform. In Quebec, the Environment testing business completed two site integrations in Montreal
and Quebec City, consolidated the LIMS on a single system and is well positioned to take market share in 2020. During Q4 2019, the North
America Clinical Diagnostics business saw negative organic growth, as continued strong performance in testing for organ transplants and
infectious diseases as well as new product launches could not fully offset the revenue losses at BHD. BHD was reorganised during 2019 and its
service portfolio refocused on preventive health offerings for patients looking to improve their health and companies willing to invest in the
long-term health of their employees. BHD represented less than 1% of Group revenues in 2019. In H1 2019, Eurofins bought Transplant
Genomics, a start-up offering TruGraf®a patented, highly-innovative molecular test which detects silent rejection after kidney transplantation.
In late November 2019, Eurofins successfully launched the TruGraf®test after receiving reimbursement approval for Medicare patients at a
level of $2,840.75 per test performed. TruGraf®is the first and only non-invasive test on the market that can rule out subacute rejection in
kidney transplant patients with stable renal function. TruGraf®will benefit from Eurofins' existing relationship with a large number of
transplant hospitals in the U.S. This test was launched in November 2019 and since December the number of samples tested is increasing over
30% from one month to the next. In addition, in December 2019, Eurofins successfully worked with AMA/CPT®to secure a Proprietary
Laboratory Analyses (PLA) code for TRAC&trade, a proprietary donor derived cell-free DNA assay for use in transplant rejection monitoring.
TRAC&tradehas been assigned to the gapfill process in 2020 to establish a payment rate for the test under the Medicare Clinical Laboratory
Fee Schedule. In April 2019, Eurofins received approval from the New York State Department of Health for MaternalFetalScreenSM, the only
test to combine first-trimester aneuploidy risk assessment with early onset preeclampsia (EOPE) in one report, providing patients with a
comprehensive, personalised risk assessment as early as 10 weeks gestation.
Eurofins generated EUR 385.0m of revenues in the Rest of the World in FY 2019, an increase of 22.4% versus FY 2018 and representing 8% of
Group revenues as Eurofins continues to invest in expanding its reach and service offering in Asia Pacific and emerging markets. The region
delivered high single digit organic growth during Q4 2019, with Food and Feed testing, Environment testing and BioPharma services all
recording double digit organic growth. The region remains a focus area for organic growth and should continue to benefit from a growing
customer demand for Food, Environment and Pharmaceuticals testing, increased regulation and maturing supply chains. In Asia Pacific, the
business saw particularly strong growth in Food testing services in China, India, Taiwan and Vietnam and in Environment testing services in
Japan, South Korea and Singapore. The year 2019 was marked by the acceleration of a start-up programme in Asia, with the completion of
new laboratories in Hanoi (Food, Vietnam), Can Tho (Food & Environment, Vietnam), Dalian (Food, China), Singapore (Food & Clinical
Diagnostics) and a major expansion in Hamamatsu, Japan (Asbestos). This programme will continue into 2020 with several other laboratories
currently under construction. In Latin America, the Brazilian Food testing business delivered solid growth, well in excess of targets,
underpinned by specialty services and key global and regional account activity whilst the Chilean business was resilient to the local civil unrest
that took place in the latter part of the year. The Australia and New Zealand Environment testing laboratories delivered double digit organic
growth. The business commissioned and relocated into a world-class Lean 5,200 m² full service state-of-the-art laboratory campus in
Melbourne, upgraded and expanded two full service laboratories in Sydney and Brisbane, and commissioned express turnaround time
laboratories in Perth and Auckland. The business continued to invest in advanced technologies and specialty services. Further major
laboratory expansions are expected in 2020. The Australian Biopharma Product testing business completed the acquisition of Melbourne-
based Chemical Analysis, further complementing the successfully-performing Sydney-based Eurofins AMS business. The Australia and New
Zealand BioPharma Product testing business now offers a full range of services across Microbiological and Chemistry testing.
Profitability
Comparable adjusted results
2019 reported and adjusted results are not easily comparable as a result of the major impact of the 02 June 2019 cyber-attack on Eurofins'
operations and of the implementation of IFRS 16 on Eurofins' accounts. The table below attempts to facilitate comparison. Due to the
difficulty of determining what results would have been achieved should Eurofins not have been hit by the cyber-attack, the numbers
presented are only estimates. In fact several of Eurofins' businesses continued to be impacted in H2 2019 by the reverberation of the attack
on quality of service. Neither this, nor the time lost by Eurofins' leadership on remedial actions as opposed to focusing on the growth of the
business can be evaluated.
Comparable adjusted EBITDA increased by 22.6% year-on-year to EUR 883m in FY 2019, representing a 19.1% adjusted EBITDA margin
(+10bps year-on-year). This is above the Group's EUR 850m adjusted EBITDA objective for FY 2019 (which was set prior to the implementation
of IFRS 16 and the cyber-attack).
Separately disclosed items (SDIs) as a proportion of adjusted EBITDA stood at 10.5% in FY 2019 vs. 9.5% in FY 2018 reflecting the effort to align
the Group's structure towards its optimal target hub and spoke model. Following the significant acquisitions completed in 2017 and 2018,
many sites are being consolidated into larger campuses, for example the chemistry laboratories acquired from Covance Food Solutions in
Battle Creek (Missouri) and Boulder (Colorado) were moved to the existing Madison (Wisconsin) campus in 2019 and several TestAmerica
sites were or are in the process of being consolidated in other existing sites of the Group or into a new site being built in California. BHD also
generated material losses in FY 2019. Indeed BHD remained very dilutive both in terms of revenue growth (90bps headwind to Group organic
growth in Q4 2019) and profits, but the settlement reached with the U.S. Department of Justice and previous owners in late 2019 will enable
BHD to now start growing a business focused on innovation and preventive cardiovascular tests.
Reported results
Reported EBITDA increased 27.9% year-on-year to EUR 833m in FY 2019, representing an 18.3% reported EBITDA margin, a 110bps
improvement year-on-year.
The reported EBITDA margin in FY19 was significantly impacted by the implementation of IFRS16 accounting standard on leases and the
cyber-attack, and therefore is not directly comparable to FY18 reported EBITDA margin. Nevertheless, Europe saw some good progress in its
reported EBITDA margin, thanks to a better pricing environment in Clinical diagnostics in France and Spain, as well as a good operating
environment in Biopharma services. With regards to North America, where overall EBITDA margin remained accretive for the Group, the full
year consolidation of Covance brought significant accretion which largely compensated for dilution resulting from BHD losses, while Test
America, though still dilutive, generated a double digit EBITDA margin. Finally, the profitability in the Rest of the world segment, significantly
improved, especially in Asia-Pacific, and in FY19 was almost on par with the Group average reported EBITDA margin.
Due to the strong impact of IFRS 16 and the cyber-attack on these reported results, the discussion below is focused on comparable adjusted
results.
The Group's mature scope11, representing 93% of the Group's revenues (EUR 4,250m), generated a comparable adjusted EBITDA margin at
constant accounting rules (i.e. excluding the impact of IFRS 16 application of EUR +118.4m) and correcting for the impact of the cyber-attack
(estimated at EUR -70.3m for this scope) of 20.5% in FY 2019, stable year-on-year. The Group saw a continued improvement in the
profitability of the mature business created or acquired before 2017, which posted a comparable adjusted EBITDA margin of 21.6% in FY 2019
(+40bps vs. FY 2018), whilst acquisitions made in 2017 and 2018, though still dilutive as a whole, improved their profitability to 18.4%
comparable adjusted EBITDA margin in FY 2019, or +80bps year-on-year on a proforma basis. 2019 acquisitions averaged a 14.3% comparable
adjusted EBITDA margin for the part included in the mature scope.
Depreciation and amortisation at constant accounting rules (i.e. excluding the impact of IFRS 16 application of EUR +110.8m) increased
slightly year-on-year to 6.2% of the Group's revenues in FY 2019 vs. 5.9% in FY 2018, reflecting the significant investments made in IT and the
Group's network of laboratories in recent years.
Finance costs at constant accounting rules as a percentage of the Group's revenues decreased year-on-year to 1.6% in FY 2019 vs. 1.8% in FY
2018.
Profit before tax at constant accounting rules (i.e. excluding the impact of IFRS 16 application of EUR -7.2m) decreased slightly from EUR 290m
in FY 2018 to EUR 279m in FY 2019, mostly driven by the impact of the cyber-attack.
Income tax rate increased to 28.1% in 2019 from 22.9% in 2018, mainly driven by a differing geographic mix in terms of profit distribution and
a higher contribution from the U.S. to the Group's taxable income as well as a conservative approach to deferred tax assets not recognised for
tax losses generated by a number of loss making start-ups and recently acquired companies.
Net profit to equity holders at constant accounting rules (i.e. excluding the impact of IFRS 16 application of EUR -5.2m) decreased to EUR
200.4m in FY 2019 vs. EUR 223.9m in FY 2018, resulting in basic reported earnings per share (EPS) at constant accounting rules (i.e. excluding
the impact of IFRS 16 application of EUR -0.3) to decrease -11.0% to EUR 11.26 in FY 2019, largely impacted by the cyber-attack.
Cash Flow & Financing
Net Operating Cash Flow at constant accounting rules (i.e. excluding the impact of IFRS 16 application of EUR +130m) stood at EUR 548m in FY
2019, stable year-on-year (+0.7%) despite the impact of the cyber-attack on EBITDA of EUR -75 m. Net working capital stood at 5.3% of
Group's revenues (+50bps year-on-year) impacted by difficulties in collections resulting from disruptions to the billing and dunning systems of
several Eurofins companies, as a result of the cyber-attack.
In the second half of 2019, Net Operating Cash Flow at constant accounting rules (i.e. excluding the impact of IFRS 16 application of EUR
+69m) increased by 15.7% vs. the same period of 2018. This was achieved despite continued adverse change in net working capital mainly due
to collateral cyber-attack effects and higher income tax paid.
In the second half of 2019, Free Cash Flow to the Firm at constant accounting rules (i.e. excluding the impact of IFRS 16 application of EUR
+6m) also increased by 30.4% vs. the same period of 2018 to EUR 177m in spite of the cyber-attack impact and still heavy SDI investments.
Net capex spend at constant accounting rules (i.e. excluding the impact of IFRS 16 application of EUR +98m) was EUR 321m (7.0% of Group's
revenues vs. 9.6% of Group's revenues in FY 2018), representing a -11.1% decrease year-on-year despite continued investments into large
building extensions and construction in 2019 including extensions to its Lancaster campus in the U.S. (adding over 15,000 m2) and its
Hamburg campus in Germany (adding over 14,800 m2), construction of new buildings like its Wiener Neudorf campus in Austria (3,500 m2),
new campuses in Hungary (over 2,000 m2) and Romania (ca. 4,000 m2) and a new Food testing laboratory in Heerenveen in the Netherlands
(adding 2,800 m2) as well as investments to harden Eurofins' IT systems. The Group is now nearing the end of its five year 2016-2020 plan to
build a unique global network of state-of-the-art laboratories and, as a result, management expects Eurofins' Net capex to sales ratio to trend
below 6% from 2021 onwards (at constant accounting rules).
Free Cash Flow to the Firm at constant accounting rules (i.e. excluding the impact of IFRS 16 application of EUR +32m for FY 2019) increased
significantly by 24.0% to EUR 226m for FY 2019 vs. FY 2018. Eurofins has managed to improve its cash flow generation in 2019, despite the
substantial headwinds from the cyber-attack on profits and net working capital, and expects ongoing further improvements over the coming
years.
M&A spend stood at EUR 171m in FY 2019, representing a significant -86.4% year-on-year decrease as the Group took advantage of
exceptional M&A opportunities in 2017 and 2018 and has, to a large extent, now managed to build its desired laboratory platform and
geographic footprint. Net capex and M&A spend in 2019 totalled EUR 492m at constant accounting rules (i.e. excluding the impact of IFRS 16
application of EUR +98m on Net capex spend) well below the Group's self-imposed limit of EUR 600m. This is in line with the deleveraging
priority Eurofins has set for 2019-2022.
Year-end net debt at constant accounting rules (i.e. excluding the impact of IFRS 16 application of EUR +524m) remained stable year-on-year
at EUR 2,721m (vs. EUR 2,737m at the end of June 2019 and EUR 2,651m at the end of December 2018). As a result, Eurofins' leverage (net
debt of EUR 2,721m excluding IFRS 16 impact divided by comparable adjusted EBITDA of EUR 883m) decreased to 3.08x at the end of
December 2019 from 3.61x at the end of June 2019. This is below the Group's self-imposed limit of 3.5x and on track to revert to the historical
range of 1.5-2.5x.
The implementation of IFRS 16 (EUR +524m net debt, EUR +118m adjusted EBITDA) only had a minor impact on leverage, bringing the ratio of
net debt to adjusted EBITDA, corrected for the estimated impact of the cyber-attack, to 3.24x at the end of December 2019.
During 2019, the Group continued to reduce its average cost of funding whilst extending the maturity of its debt instruments at low fixed
interest rates, limiting the potential negative impact of a potentially rising interest rate environment and giving the Group visibility on its
financing structure and costs. In September/October 2019, the Group successfully redeemed its 7% &euro300m hybrid bond and issued a new
2.875% &euro300m hybrid bond, bringing the average cost of dividend coupons on Hybrid capital from 4.86% to below 3.7%. This had a
negative impact of EUR 19.8m on the FY 2019 cash flow statement as the January 2020 coupon was included in the redemption costs of 2019.
The Group closed the year with a solid liquidity position, with EUR 297m of cash on its balance sheet, and over EUR 500m of undrawn and
available committed bank credit lines, with an average remaining life greater than three years, in addition to those used to back the
commercial paper issued by Eurofins.
Acquisitions
During 2019, the Group completed 26 acquisitions, representing annual revenues of over EUR 130m in FY 2019 for a total investment of EUR
171m.
In June 2019, Eurofins closed the acquisition of Transplant Genomics Inc. ("TGI), a molecular diagnostics company committed to improving
organ transplant outcomes with non-invasive serial monitoring guided by genomics. The initial acquisition price paid was USD 27.5m with a
preliminary deferred element (related to expected reimbursement price per test and future revenues during the period between 2020 and
2024) recorded for USD 44m. This "pre-revenuecompany generated USD 0.6m of revenues and a negative EBITDA of USD 3.7m with 11
employees in 2018.
Focus on Scientific Innovation
Eurofins is structured as a network of intrapreneur-led companies. This decentralised structure promotes closer relationships with and more
individualised services for clients and fosters business agility and scientific innovation. Here are a few highlights demonstrating innovation
achievements in 2019 alone:
Tackling Microplastics in Food and the Environment
The presence of microplastics (plastic fragments less than 5mm and greater than 1um), is a growing concern in both food and the
environment with legislation under way. Polluting the environment through multiple channels, microplastics contain or can carry hazardous
chemicals that may have a negative impact on nature and human health. Their ingestion through air, water, or food such as fish or shellfish, is
of particular concern. Eurofins has recently expanded its offering in microplastics testing:
Eurofins Australia is the first laboratory to offer a commercial service for Microplastic detection using the innovative Laser Direct Infra-Red
(LDIR) imaging system. This technique enables the sizing of Microplastic particles to 10 µm and also identifies polymer types against standard
published Infra-Red libraries. This technology has significantly reduced the time it takes to obtain results from days to several hours for
complex samplesEurofins' Norwegian teams, using Pyrolytic Gas Chromatography Mass Spectrometry (GC-MS) for detection, have developed
new methodologies with custom filtration in a polymer-dust-free laboratory environment, increasing processing speed by up to 60
timesEurofins SF Analytical Laboratories in the U.S. was the first laboratory to make dye imaging and NOAA methodology under Fourier-
Transform Infra-Red (FTIR) spectroscopy and microscopy technologies commercially available. The method may become an industry
benchmark for Microplastics testing in California where pending legislation is expected to mandate Microplastics testing by the end of
2021.Developing Per- and Polyfluorinated Alkyl Substances (PFAS) and Non-Target Detection Techniques in Environment Testing
Demand for PFAS analysis continues to grow globally. Whilst much of the focus has been on the regulated PFAS compounds, Perfluorooctane
Sulfonate (PFOS) and Perfluorooctannoic Acid (PFOA), there are an estimated 4,000 other PFAS compounds in the environment with minimal
toxicological data. Demand for identification of these unknowns is increasing and Eurofins has responded by developing methodologies using
state-of-the-art Liquid Chromatography Quadrupole Time-of-Flight instrumentation (LC-QToF) to concurrently enhance regulated compound
detection whilst also building a library of non-target compounds for future identification and quantificationLC-QToF adopted by Eurofins in
Europe, the U.S. and Australia has also provided Eurofins' scientists with new tools to detect "known unknowns(emerging target compounds)
and "unknown unknowns(non-target compounds) thereby facilitating the identification of previously unquantified emerging contaminants.
This powerful tool can elucidate the presence of compounds that may be of greater toxicological significance than regulated target
compounds.Tackling Silent Rejection in Kidney Transplants with Patented Test TruGraf®
In H1 2019, Eurofins acquired a start-up called Transplant Genomics, a company which offers TruGraf®, a patented test to determine silent
transplant rejection, to kidney transplant recipients. This test has received financial coverage from the U.S. Medicare healthcare
reimbursement body. The acquisition further strengthens Eurofins' position as a market leader in the pre- and post-transplant testing market
in the U.S.:
TruGraf®is the first and only blood test available that allows physicians to reassure kidney transplant patients with stable renal function that
their graft is not harbouring silent rejection (approximately 25% of transplant patients suffer from this[1]). The test provides an alternative to
performing an invasive, risky and costly surveillance biopsy. As the only non-invasive test reimbursed for use as a surveillance tool,
TruGraf®enables early intervention, before indicative signs of kidney damage can be detectedTruGraf®is one of Eurofins' first proprietary
clinical genetic assays to achieve reimbursement, with a significant market potentialSeparately, in 2020, Eurofins is launching a proprietary
cell-free DNA test called TRAC that can help guide physician treatment decisions when acute rejection is suspected.Innovating in the Area of
Non-Invasive Pre-Natal Testing (NIPT)
NTD Eurofins received approval from the New York State Department of Health (NYSDOH) for the addition of Y chromosome assessment to its
MaternalFetalScreenSM | T1 test. This is the only test to combine first-trimester aneuploidy risk assessment with early onset preeclampsia
(EOPE) testing in one report, providing patients with a comprehensive, personalised risk assessment, as early as at 10 weeks' gestation.
Through the measurement of five serum markers, MaternalFetalScreenSM | T1 casts a wide net from which it can identify maternal and fetal
issues, such as aneuploidy, preeclampsia, low birth weight, fetal loss and stillbirth. With this new test, NTD Eurofins has added the category of
Genetic Testing (Molecular) to its NYSDOH permit.
Eurofins has also developed a unique range of Next-Generation Sequencing (NGS) based NIPT tests and achieved significant sales growth in
this area in Europe in 2019.
Developing a Comprehensive and Customisable Cell and Gene Therapy Testing Offering to Support the Development of Advanced Therapy
Medicinal Products (ATMPs) both for Traditional Use as well as for Use in Personalised Medicine in BioPharma Product Testing
The development of ATMPs, such as gene and cell therapy products, has resulted in significant progress in the treatment of many diseases,
including cancer, genetic and autoimmune disorders. By their nature, these technologies are very complex and vastly different to traditional
biopharmaceutical products, especially in terms of their use in personalised medicine. These complexities span the development pipeline,
creating challenges in relation to manufacturing, testing requirements, regulatory approval, and commercialisation. The U.S. Food and Drug
Administration (FDA) expects more than 200 new investigational drug applications for cell and gene therapies by 2020[2], which has
prompted the agency to significantly strengthen its regulatory programmeEurofins provides Good Manufacturing Practice (GMP) compliant
Chemistry, Manufacturing and Controls (CMC) testing support to ensure the identity, potency, purity and safety of starting materials, cell and
virus banks, intermediate products, vectors and final drug products, as well as supporting manufacturing process development and validation.
The Group's broad testing portfolio coupled with its state-of-the-art IT solutions, which ensure standardised best practices across its global
network of laboratories, make Eurofins BioPharma Product Testing a supplier of choice for global biopharmaceutical companies requiring
support regarding the incredibly complex testing requirements for ATMPs.The "Focus on Scientific Innovationsection of the annual report
2019 (pages 9 to 12) contains more detailed information and additional examples.
Infrastructure Programme
As of the end of 2019, Eurofins occupied more than 1,400 sites throughout the world (laboratories, offices, phlebotomy sites,
storage/warehouses, etc.). The total net floor area of these sites amounted to about 1.35 million m2, of which more than 1.0 million m² is
laboratory space.
Between 2005 and 2019, Eurofins has added or brought to the most modern standards close to 815,000 m2 of laboratory and office surface
(including space used by companies acquired during this period). This is a clear demonstration of Eurofins' commitment to continue to invest
significantly in new buildings, extensions and renovations to build the largest and most efficient state-of-the-art laboratory network in its
industry. In 2020 and 2021, Eurofins has planned an additional ca. 100,000 m2 expansion and modernisation of its laboratory network. These
investments represent the final stage of Eurofins' exceptional 2016-2020 infrastructure and IT solutions investment programme.
In 2019, over 40 real estate projects were delivered to build, expand, renovate, relocate or acquire new state-of-the-art laboratories and
offices. At the same time, in an effort to rationalise and consolidate Eurofins' footprint, a significant number of buildings were vacated and
leases terminated in order to move into new or expanded existing sites. In total, ca. 65,000 m2 of new or renovated laboratory and office
space was added in 2019.
Following the acquisition of TestAmerica in the U.S. in 2018, site rationalisations and reorganisations are progressing according to plan.
TestAmerica sites in Richland (Washington) and Nashville (Tennessee) have been exited with workload redistributed throughout the network.
The Eurofins Frontier Specialty metals laboratory located in Bothell (Washington) has been relocated to the TestAmerica Seattle (Washington)
site and a number of Eurofins and TestAmerica service centres have been co-located. In Tustin (California), a new site has been purchased,
with the design phase in progress to facilitate the co-location of the TestAmerica Irvine and Eurofins (Garden Grove) Calscience sites. This
project is expected to be completed in 2021.
Following the acquisition of Covance Food Solutions in the U.S. in 2018, Eurofins has started to organise its U.S. Food testing laboratory
network around larger Centres of Excellence where customers can be better served with shorter testing times, personalised service and
innovative testing offerings. The chemistry laboratories from Battle Creek (Missouri) and Boulder (Colorado) were moved to the existing
Madison (Wisconsin) laboratory. In Madison, Eurofins purchased a new site and the construction of a new 10,000 m2 state-of-the art
laboratory is fully underway in order to move the existing operations to the new laboratory early 2021. This new site will become the Centre
of Excellence for much of the Group's U.S. specialty food chemistry departments serving the nutritional supplements market and other large
food industry clients.
In Q4 2019, Eurofins purchased a new building located close to Heathrow (U.K.) in order to consolidate Eurofins' major Forensic DNA, drugs,
toxicology, food and water testing laboratories away from rented premises into new 5,500 m2 owned facilities by 2021. Eurofins Environment
testing Canada also consolidated its footprint and moved its Pointe Claire (Quebec) operations to the expanded 3,600 m2 facilities in
Longueuil (Quebec), previously occupied by EnvironeX.
In October 2019, Eurofins Food Testing Singapore has expanded and moved its business location to a new 1,000 m2 laboratory in Singapore.
Earlier in 2019, several strategic new laboratories and extensions to existing campuses were delivered and are now operational. Among these
were a 15,000 m2 extension to the Lancaster (Pennsylvania) campus, a 15,000 m2 extension to the Hamburg (Germany) campus, and the
delivery of the new campus in Wiener Neudorf (Austria) (3,500 m2). Further building, expansion and renovation projects were successfully
completed in 2019, of which the most significant are the new 2,800 m2 building in Heerenveen (The Netherlands) for Food testing, the
renovation and expansion of 1,200 m² in Nazareth (Belgium) for Food testing, and the new Clinical Diagnostics presence at Médip&ocircle in
Lyon (France). In China, Eurofins EAG Laboratories have also moved into a newly renovated 3,400 m2 facility in Shanghai significantly
increasing capacity to serve its customers in the area.
Start-ups Programme
Start-ups or green-field laboratories are generally undertaken in new markets and in particular in emerging markets, where there are often
limited viable options in terms of acquisitions or in developed markets where Eurofins transfers technology developed by its R&D and
Competence Centres abroad or expands geographically.
In 2019, the Group opened 15 new start-up laboratories, bringing the total number of start-ups created since 2000 to 160. The 160 start-up
laboratories opened since the year 2000 had a 90bps contribution to Group organic growth for the period January–May 2019, 120bps in Q3
2019 and 90bps in Q4 2019.
Of these 160 start-ups, over 40% are located in Europe, ca. 20% in North America and close to 40% in the Rest of the World. By business line,
ca. 40% are in Food & Feed testing, ca. 20% are in Pharma/Biotech/Agroscience services, ca. 20% in Environment testing, and ca. 6% in Clinical
Diagnostics.
Of the 15 start-ups opened in 2019, a large majority (60%) are located in the Rest of the World, over 25% in North America and over 10% in
Europe, as the Group has, to a large extent, now built its desired laboratory platform and geographical footprint in its two home markets
(Europe and North America) and is on track to deliver the Group's plan to rebalance business towards Asia Pacific over the coming years. By
business line, close to 50% of start-ups are in Food & Feed testing, ca. 40% in Clinical Diagnostics and over 5% in Pharma/Biotech/Agroscience
services.
Post-Closing Events
Change of scope:
Since the beginning of 2020, Eurofins has completed the acquisition of three small companies / asset deals: one in Norway, one in the U.S.
and one in India. The total annual revenues of these acquisitions were ca. EUR 5m in 2019.
In February 2020, TestAmerica Air Emission Corporation divested its stack emission testing business Metco in the U.S. (annual revenues of ca.
EUR 5m in 2019).
Jan 10, 2020: Transplant Genomics appoints Dr. John Holman as VP Medical Affairs
Transplant Genomics, Inc. (“TGI”), a molecular diagnostics company committed to improving organ transplant outcomes with non-invasive
serial monitoring guided by genomics, announced that Dr. John Holman has joined the Company as VP Medical Affairs. Dr. Holman comes to
TGI having served for the past two years as VP, Immunology and Translational Medicine, at Quark Pharmaceuticals. John has over 30 years of
experience in delivery of clinical healthcare (general surgery and transplantation surgery) as well as pharmaceutical and molecular diagnostic
development. Previous appointments have included serving for three years as VP Clinical Research at Myriad Genetics, and eleven years at
Astellas, most recently as Executive Medical Director. Dr. Holman is a transplant surgeon by training who received his MD from the University
of Texas Southwestern Medical Center at Dallas.
"We are extremely grateful to have Dr. Holman join TGI at this critical time in our growth, concurrent with our TruGraf®blood test receiving
CMS coverage as the first non-invasive test developed, validated and reimbursed for use in ruling out silent subclinical rejection in kidney
transplant recipients with stable renal function. With a variety of new biomarkers coming to market recently it is important to have people in
leadership roles who are well known and trusted in the transplant community so they can help physicians understand the proper intended
use for these exciting tools.said Dr. Stan Rose, President of TGI.
Dr. Holman succeeds our good friend Dr. Roy First, another widely respected member of the transplant community, and past President of the
American Society of Transplantation. Dr. First will continue working with TGI as Senior Clinical Advisor, leading various collaborative studies
currently underway, assisting Dr. Holman in the design of new studies, and continuing to provide public presentations and write papers
related to the use of TGI's non-invasive tests aimed at improving care of organ transplant recipients.
Dec 11, 2019: Viracor Eurofins expands its clinical diagnostic footprint to oncology
Viracor Eurofins (Viracor), proudly announces the addition of Karina Eterovic, PhD, as the Director of Research & Development for Oncology
Diagnostics for Eurofins U.S. Clinical Diagnostics group. Dr. Eterovic will lead the development and growth of oncology clinical diagnostic
solutions to benefit our healthcare clients and their patients.
Dr. Eterovic joins us from MD Anderson Cancer Center, where she was Associate Professor and Director of the Cancer Genomics Laboratory,
as well as a driving force in the implementation of precision medicine at the prestigious instituteestablishing a genomics laboratory for their
NGS (Next Generation Sequencing) research projects, and enabling the discovery and identification of new biomarkers for personalized cancer
care. Dr. Eterovic has authored many publications in high impact oncology journals, and holds both her PhD in Biochemistry and Molecular
Biology, a Masters in Biochemistry from University of Sao Paulo, Medical School, in Brazil, and a postdoctoral training in Neuro-Oncology at
MD Anderson.
"Dr. Eterovic brings a wealth of knowledge from her extensive experience in academia, assay development and operational management in
both the U.S. and globally. She is uniquely suited to lead Eurofins U.S. Clinical Diagnostics' expansion into Oncology, and her keen insight and
background will allow her to identify key unmet needs and underserved markets," said David Morgan, Senior Vice President of Eurofins U.S.
Clinical Diagnostics. "We are excited to expand on our infectious disease, transplantation, allergy and immunology portfolios, by offering
cutting-edge test solutions in cancer diagnostics and drug development. Combining our efforts with other clinical laboratories of Eurofins and
partnering with leading Research & Development organizations dedicated to Oncology, we aim to accelerate our expansion in this dynamic
field and improve the standards of patient care.
Dec 09, 2019: Laboratory to pay $26.67 million to settle allegations of kickbacks to
physicians
Laboratory Boston Heart Diagnostics Corporation (Boston Heart), of Framingham, Massachusetts, has agreed to pay $26.67 million to resolve
False Claims Act allegations involving payments for patient referrals in violation of the Anti-Kickback Statute and the Stark Law and claims
otherwise improperly billed to federal health care programs for laboratory testing, U.S. Attorney McGregor W. Scott announced.
The Anti-Kickback Statute prohibits offering, paying, soliciting, or receiving remuneration to induce referrals of items or services covered by
Medicare, Medicaid, and other federally funded programs. The Stark Law forbids a laboratory from billing Medicare and Medicaid for certain
services referred by physicians that have a financial relationship with the laboratory. The Anti-Kickback Statute and the Stark Law are intended
to ensure that medical providers' judgments are not compromised by improper financial incentives and are instead based on the best
interests of their patients.
The settlement resolves allegations that Boston Heart provided physician practices with in-office dieticians in exchange for physician referrals
for laboratory testing. These allegations were originally made in a case filed in the Eastern District of California under the whistleblower, or
qui tam, provision of the False Claims Act. The Act permits private parties to sue for fraud on behalf of the United States and to share in any
recovery. The settlement also resolves allegations that Boston Heart directly or indirectly paid processing and handling fees and waived
patient copayments and deductibles. These allegations were originally made in the District of Columbia under the Act. Whistleblowers Chris
Riedel and Claudia Bradshaw will receive approximately $4.36 million of the settlement.
In addition, the settlement resolves allegations that Boston Heart conspired with others to pay doctors kickbacks disguised as investment
returns and conspired with certain Texas hospitals and others to submit claims for outpatient laboratory testing for patients who were not
hospital outpatients, in order to receive higher reimbursements from federal health care programs.
"This office will continue to take all appropriate action to prevent improper inducements that can corrupt the integrity of physician decision-
making,said U.S. Attorney Scott.
The civil settlement was the result of an investigation by the U.S. Attorney's Offices for the Eastern District of California, the Eastern District of
Texas, and the District of Columbia, along with the Commercial Litigation Branch of the Justice Department's Civil Division, OIG-HHS, and DCIS.
The two lawsuits are captioned United States ex rel. FBH1 LLC v. Boston Heart Diagnostics Corp., No. 17-cv-206 (E.D. Cal.) and United States ex
rel. Riedel v. Boston Heart Diagnostics Corp., No. 12-cv-1423 (D.D.C.). Assistant U.S. Attorney Catherine J. Swann handled the Eastern District
of California matter for the United States. The claims resolved by the settlement are allegations only and there has been no determination of
liability.
Oct 28, 2019: Eurofins reports strong organic growth (over 6%) in Q3 2019
Eurofins announced Q3 2019 report.
Q3 2019 revenues increased 22.3% year-on-year to EUR 1,167m vs. EUR 955m in Q3 2018. Over the first nine months of 2019, total revenues
grew 23.6% to EUR 3,335m vs. EUR 2,698m during the same period last year.Strong organic growth1 of 6.4% reported in Q3 2019. Excluding
Boston Heart Diagnostics ("BHD), organic growth was 7.3% in Q3 2019. Due to the lack of comparability of the revenues for the month of June
as a result of the June 2nd cyber-attack on Eurofins servers, like for like organic growth for the first nine months of 2019 unfortunately cannot
be determined.Eurofins teams have worked very hard in Q3 2019 to fully recover from the June 2nd cyber-attack and to further harden our IT
systems. Operations are now generally back to normal with occasional interferences of new security tools at some companies. Back office and
collection activities were last resume and are now essentially restored. Eurofins teams are still working hard to further optimize and
strengthen all IT operations and expect to have all things fully back to normal by year end. As can be judged today, the estimated impact of
the loss of revenue and profit and the additional expenses resulting from the June 2nd cyber-attack, as can be derived by different
interpolation estimates, is confirmed to be of the same magnitude as mentioned in our half-year report published on August 29th, i.e. ca. EUR
62m on revenues and ca. EUR 51.5m on EBITAS5 and EBITDA4. Those numbers are of course only estimates. The net financial impact (after
insurance compensation) is expected to be much lower, as business interruption insurance coverage for this criminal cyber-attack has been
confirmed and a first payment received. Eurofins insurance coverage exceeds the estimates mentioned above but efforts to determine and
agree on exact damages will be on going for a while.Comment from the CEO, Dr. Gilles Martin:
"Q3 2019 was a very positive quarter for Eurofins as the Group demonstrated prompt recovery following the June cyber-attack and delivered
strong organic growth. This is concrete evidence of our positioning in attractive end markets as well as our ability to leverage our scale as we
approach the end of our 2016-2020 strategic investment plan to build a one-of-a-kind global network of state-of-the-art laboratories and
bespoke IT solutions aimed at offering a unique outstanding level of service to our customers. We remain confident on our ability to achieve
our objectives for this and next year. By the end of 2020, this exceptional investment phase started in 2016 will largely be completed and
Eurofins clients should benefit from further improved levels of service from a more efficient network of Eurofins laboratories. This should
enable the group to start significantly improving cash flow generation and return on investment from 2021 onwards.
Western Europe remains the largest region for Eurofins, representing c.46% of total Group revenues in Q3 2019, with France generating
18.5% of total Group revenues, ahead of Germany which accounted for 10% of total Group revenues, whilst Benelux, the UK & Ireland, and
the Nordic countries each contributed ca.5-6% to Q3 2019 revenues. North America generated c.38% of total Group revenues and the Rest of
the World the remaining 16%.
By segment, the Group continued to deliver robust growth across all geographies except the UK, which continued to be negatively impacted
by the June cyber-attack in July as Eurofins Forensics UK had not received the green light from authorities for restarting.
In Western Europe, Eurofins' BioPharma Testing services continued to perform very well, with a double digit organic growth in Q3 2019
thanks to sustained, above market, growth overall. Food Testing services also continued to perform well with organic growth in line with
Group average. Environment testing activities posted a strong performance in Q3 2019 with an organic growth above Group average. The
Genomics business saw negative organic growth as it was one of the most heavily disrupted activity by the June cyber-attack, leading some
customers to switch suppliers. The business is working to regain these over the next few quarters with a range of superior new product
launches. In France, Clinical Diagnostics continued to perform in line with management's expectations with a positive organic growth even if
below Group average. In North America, Eurofins' BioPharma Testing services continued to perform very well, with a double digit organic
growth in Q3 2019 as strategic outsourcing remains strong in the biopharmaceutical industry. In particular, the group continues to see strong
and increasing demand in the biologics and gene/cell therapy markets, as it benefits from a strong and comprehensive service offering for
these therapies both in the U.S. and Europe. We are also seeing commercial leverage and benefit from the cross selling of services across the
business lines, for example between our GMP testing and product development services. The business is also benefiting from the increased
capacity that is now on line following several facility expansions that were completed in the last 12 months. Food Testing services were also
very strong in North America with a strong double digit organic growth and well above industry rates thanks to the successful greenfield start-
ups of our national food microbiology laboratory network. Large national clients are starting to find our network to be advantageous to their
supply chains and their production plants. Clinical Diagnostics organic growth was below Group average, as the division continued to be
negatively impacted by Boston Heart Diagnostics, which suffered from lower year-over-year testing volumes, along with lower reimbursement
for the volume received from patients' third party payers for advanced preventive cardiology testing.
Eurofins delivered double-digit organic growth in the Rest of the World, driven by strong performance in Food Testing services in China and
Vietnam, Environment Testing services in Japan and South Korea, and Food & Environment Testing services in Singapore and Taiwan. All these
markets continue to benefit from the recent investments made in expanding and upgrading laboratories, hiring and training talented staff and
improving turnaround times.
On Wednesday 16th October, a report containing many inaccurate, incomplete, irrelevant and misleading statements together with sarcastic
and defamatory comments was issued by a party that stands to gain if Eurofins' share price falls. Eurofins stands firmly behind the reliability of
its Group published financial statements in all material aspects. It does not appear worthy of the readers time to discuss all typos and
meaningless and insignificant matters that the reports' author seems to show great pride having spotted and voluntarily or involuntarily
misinterpreted while scrutinizing 14 years of filings by hundreds of Eurofins subsidiaries. We addresses below the main alleged concerns
raised in that biased publication. Eurofins shared this disparaging report with regulatory authorities and its auditors and is considering further
actions with its advisors.
Liquidity
Over the last two years Eurofins has significantly improved its financing strategy. As opposed to carrying a lot of cash received from bonds on
its balance sheet like the Group did until 2017, Eurofins is now using medium-term (typically five year term) committed bank lines of credit to
fund part of its funding needs. This is a much more cost effective approach, especially considering European banks now charge interest to
hold large Euro balances for their clients. As of 30th June 2019, on top of the amount of credit lines used to back up the outstanding
commercial paper (EUR 320.5m) and the amount used via short-term drawings on its bank credit lines (EUR 410m), Eurofins had access to
more than EUR 500m of undrawn and available bank credit lines, with an average remaining life greater than three years. The latter remains
the case today. Eurofins liquidity is thus largely sufficient to execute on the Group's growth plans for 2019 and 2020 and should significantly
improve from 2021 onwards after the end of Eurofins 2015-2020 investment programme to build a leading laboratories network in its
markets.
Group Legal Structure
Eurofins structure fosters entrepreneurship through the use of small, agile companies. One managing director/president is in charge of each
entity. Operating companies are generally focused on one single market and activity while support functions (accounting, treasury, finance
reporting and financial controlling) are handled by teams in the National Service Centres (NSCs) which are independent of the leaders of
operating companies, and are reporting to the Group CFO. It is Eurofins belief that the benefits of empowering business leaders and their
teams to act as real entrepreneurs which speeds up decision making and responsiveness to clients' needs far outweigh the cost of managing a
larger number of legal entities and that strict independent financial supervision by the NSCs balances potential risks of this operational
freedom.
Inorganic growth is part of Eurofins' strategy to build scale, acquire new customers and/or technology, and expand its footprint. Companies
acquired are often too diversified and are therefore often split post-acquisition, or some of their activities transferred to other Eurofins legal
entities to achieve the desired Eurofins structure, aligned with Eurofins' hub and spoke model. This process can last several years as
sometimes new sites must be built or existing sites expanded to fit the most efficient structure or activities must grow to a sufficient size to
justify a separate legal entity.
Intercompany Transactions and Reorganisations
As explained above, when a company is acquired, it comes with its existing sites and legal structure which generally doesn't fit Eurofins'
streamlined hub and spoke model. Oftentimes, the acquisition includes multiple activities and some of them need to be transferred into the
right business lines and entities within the Eurofins Group post acquisition. In some cases, this can only be achieved over time. As long as
Eurofins is too small in one country/market, some companies carry out multiple activities until each activity is large enough to cover the cost
of operating a legal entity.
If the transfer of a part of a business from a company takes place more than a year after the acquisition, Eurofins typically must conduct a
revaluation to comply with local fiscal rules (the selling company must sell assets at fair value - which may come with a profit or a loss for the
seller compared to the original book value of assets to be transferred). For this, valuation formulas are applied, generally based mainly on
EBITDA which are reviewed by local auditors. Those transactions are part of an internal reorganisation and given that the buying and selling
companies are both fully consolidated in the Group accounts, any resulting profit or loss generated locally is eliminated at Group level and
doesn't have any impact on Eurofins Group's consolidated financial statements. Any profit or loss made by the seller is not reflected either at
the seller's parent level since the parent isn't a party to the transaction.
Local vs. Group Impairments and other accounting observations
Impairments at a local company's level when they are required are not automatically reflected in the Group's consolidated accounts for a
number of reasons, the main ones being discussed below.
Local statutory accounts are prepared according to local GAAP (applicable legislation) whereas Group consolidated accounts are prepared in
accordance with IFRS standards (applicable legislation) and these accounting rules may differ.
Impairment tests for the purpose of preparing the local statutory accounts are done for each local company according to the relevant local
materiality threshold. Impairment tests for the purpose of preparing the Group consolidated accounts are done at a higher level, so called
cash generating units (defined in accordance with IFRS and reviewed by auditors). Therefore the applicable legislation, materiality thresholds
and scopes (within which activities may have been transferred as part of reorganisations to align with Eurofins standard structure), may differ
and lead to different results between local statutory accounts and consolidated financial accounts.
Some sites are sometimes closed after reorganizations and the company who owned them liquidated. Others are sometimes renamed and
reused for other purposes to save the cost and time required for creating new companies. Companies tender their statutory audit work from
time to time and local auditors may change as a result. Dividends up streaming up the corporate structure including with the use of
intercompany loans are standard practice in any group, etc. It is of course difficult to understand every transaction within a large group or its
purpose from an outside review of filings of individual subsidiaries only. This is why group consolidated accounts and their auditors exist. It is
hard to comprehend why all these matters are worthy of being mentioned in a report over multiple pages, unless it is the intention of the
author to give normal transactions a negative appearance by lacing their description with disparaging comments.
Related Party Transactions
Eurofins already mentioned in its 2018 Annual Report that related party transactions are conducted at arm's length and described the work of
the independent Corporate Governance Committee of its board that oversees them. The allegation that the rent paid by the company
Bioservice Scientific Laboratories ("BSL) in Germany to a related party real estate company would imply ‘avaricious (sic)' rental yields and
return on equity for the landlord is entirely false as it is based on wrong assumptions. The rent amount paid by BSL to a related party real
estate company mentioned and used to calculate these erroneous figures in this defamatory report includes rent paid to other non-related
parties for two other buildings. The annual rent paid by BSL (including indexation since 2012) for the building rented from a related party in
2014 was EUR 494,000 corresponding to 11.9 EUR/m2/ month for a 3,467 m2 mixed office and laboratories building in Planegg near Munich.
Cash flow
Eurofins communicated consistently that its 2016-2020 plan to build a world class global infrastructure in its attractive markets enjoying
secular high growth profiles implies significant Capex and costs for reorganization of acquired companies as well as funding of operational
losses of more than 100 startup laboratories until they reach a critical size. Developing bespoke IT solutions to make Eurofins fully digital and
able its customers to benefit from the resulting efficiencies and from the large amount of data it generates is also very costly. Taking this into
account it should be no surprise to anyone who followed the company's publications for a while or visited the group's new campuses that free
cash flow reflects these investments. Eurofins is now nearing the end of this investment phase and is starting to see its benefits on speed,
quality, efficiency and reliability of service in the countries and laboratories where this has been completed already for over a year and initial
inefficiencies are ironed out. Eurofins is confident that as investments reduce and bear their fruits more broadly from 2021 cash flow should
increase significantly. Due to seasonality, profits and cash flow are always lower in H1 than in H2. In addition, H1 2019 was also significantly
affected by the criminal cyber-attack that hit many Eurofins laboratories on June 2nd 2019 and led to much reduced revenues and profits in
June and H1 than would be normally the case.
Other allegations in the report appear to be mainly spinning erroneous, out-dated or immaterial facts or inconsequential typos, to create a
negative impression around Eurofins which the publishing third party expects to profit of at the expense of Eurofins shareholders. It is
Eurofins belief that all transactions mentioned in the report are properly accounted for in Eurofins Group consolidated accounts and were
done with the best interest of the company and all its shareholders in mind.
Organic growth for a given period (Q1, Q2, Q3, Half Year, Nine Months or Full Year) - non-IFRS measure calculating the growth in revenues
during that period between 2 successive years for the same scope of businesses using the same exchange rates (of year Y) but excluding
discontinued operations8.
For the purpose of organic growth calculation for year Y, the relevant scope used is the scope of businesses that have been consolidated in
the Group's income statement of the previous financial year (Y-1). Revenue contribution from companies acquired in the course of Y-1 but not
consolidated for the full year are adjusted as if they had been consolidated as from 1st January Y-1. All revenues from businesses acquired
since 1st January Y are excluded from the calculation.
Adjusted - reflect the ongoing performance of the mature7 and recurring activities excluding "separately disclosed items3.
Separately disclosed items - includes one-off costs from integration, reorganisation, discontinued operations and other non-recurring income
and costs, temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant
restructuring, share-based payment charge6, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill, loss/gain
on disposal and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for
business acquisitions, net finance costs related to borrowing and investing excess cash and one-off financial effects (net of finance income)
and the related tax effects.
4EBITDA – Earnings before interest, taxes, depreciation and amortisation, share-based payment charge, impairment of goodwill, amortisation
of acquired intangible assets, negative goodwill, loss/gain on disposal and transaction costs related to acquisitions as well as income from
reversal of such costs and from unused amounts due for business acquisitions.
5EBITAS – EBITDA less depreciation and amortisation.
Share-based payment charge and acquisition-related expenses, net – Share-based payment charge, impairment of goodwill, amortisation of
acquired intangible assets, loss/gain on disposal, negative goodwill and transaction costs related to acquisitions as well as income from
Mature scope: excludes start-ups and acquisitions in significant restructuring. A business will generally be considered mature when: i) The
Group's systems, structure and processes have been deployedii) It has been audited, accredited and qualified and used by the relevant
regulatory bodies and the targeted client baseiii) It no longer requires above-average annual capital expenditures, exceptional restructuring or
abnormally large costs with respect to their current revenues for deploying new Group IT systems. The list of entities classified as mature is
reviewed at the beginning of each year and is relevant for the whole year. In FY 2018, 93% of total Group revenues were included in the
mature scope up from 91% in FY 2017.
Discontinued activities / disposals: discontinued operations are a component of the Group's core business or product lines that has been
disposed of, or liquidatedor a specific business unit or a branch of a business unit that has been shut down or terminated, and is reported
separately from continued operations. Disposals correspond to the sale by Eurofins of business assets to a third party. For more information,
please refer to Note 3.19 of the Consolidated Financial Statements for the year ended 31 December 2018.
Sep 26, 2019: CareDx files patent infringement lawsuit against Eurofins Viracor
CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated,
high-value healthcare solutions for transplant patients and caregivers, announced that it has filed a patent infringement suit against Eurofins
Viracor, Inc., in the United States District Court for Delaware.
CareDx is asserting U.S. Patent No. 8,703,652, which is exclusively licensed to CareDx from Stanford University. This patent covers non-
invasive monitoring of organ transplant rejection through cell-free DNA analysis. CareDx is seeking all available remedies, including damages
and injunctive relief. The suit asserts that Eurofins Viracor infringes CareDx's patent by marketing and performance of a test that performs an
analysis of cell-free DNA from a transplant patient to inform on rejection.
CareDx has been dedicated to continued research and development in transplantation for 20 years, and secured an exclusive license to the
technology when it acquired ImmunMetrix in 2014.
"The intellectual property behind AlloSure was developed both with and for the transplant community,said Peter Maag, CEO of CareDx. "We
are prepared to vigorously defend our intellectual property where appropriate to support continued innovation in transplantation and to
protect the substantial investments we have made, as well as the leadership position we have developed over many years of effort.
Aug 29, 2019: Eurofins reports robust financial performance in H1 2019 despite disruptions
from the June cyber-attack
Eurofins Scientific SE, announced its financial report for H1 2019.
Revenues increased 24.3% year-on-year to EUR 2,168m in H1 2019 vs. EUR 1,743m in H1 2018.Due to the lack of comparability of the
revenues for the month of June as a result of the June 2nd cyber-attack, like for like organic growth10 for Q2 and H1 2019 unfortunately
cannot be determined. Organic growth in the period January to May 2019 was over 4.5% (5.5% excluding Boston Heart Diagnostics, "BHD), in
line with the Group's annual objective. In July 2019, organic growth was above those year-to-date May 2019 values, confirming the good
recovery of the business after the cyber-attack.The exact revenues and profits that were lost during the month of June will unfortunately
never be known exactly. As can be judged today, estimates based on extrapolation of year-to-date May 2019 growth figures, or taking into
account July growth, lead to a range of values with an average impact of EUR 62m on revenues and EUR 51.5m on EBITAS4 and EBITDA3.
Those numbers are of course only estimates. The net financial impact (after insurance compensation) is expected to be much lower, as
business interruption insurance coverage for this criminal cyber-attack has been confirmed. Eurofins insurance coverage exceeds the
estimates mentioned above but efforts to determine and agree on exact damages will be on-going for a while.Reported EBITDA increased
28.9% year-on-year to EUR 371m, resulting in a 17.1% reported EBITDA margin, a 60bps improvement year-on-year. Excluding a rounded
estimated impact from the cyber-attack of EUR -50m and the impact of IFRS 16 application (EUR +62m), reported EBITDA would have
increased by 24.6% year-on-year to EUR 359m with previous accounting rules, resulting in a 16.1% reported EBITDA margin, a moderate
40bps decrease year-on-year, mainly due to BHD losses and the consolidation of lower margins of TestAmerica offsetting operational
improvements.Adjusted1 EBITDA increased 29.5% year-on-year to EUR 415m, resulting in a 19.1% adjusted EBITDA margin, a 70bps increase
year-on-year.Reduced spend in H1 2019 on capex (EUR 157m, EUR 121m excluding IFRS 16) and M&A (EUR 115m), in line with the Group's
objectives, had a positive impact on cash generation, with free cash flow to the firm9 of EUR 75m (+60.1% year-on-year, EUR 49m excluding
IFRS 16) in spite of the impact of the cyber-attack.Adjusted basic earnings per share (EPS)7 was stable at EUR 8.83 whilst reported basic EPS
fell by 35.7% in H1 2019 to EUR 3.31 mostly due to the impact of the cyber-attack.Net debt at the end of June 2019 increased to EUR 3,241m
from EUR 2,651m at the end of December 2018 mainly as a result of IFRS 16 implementation (IFRS 16 increased net debt by EUR 505m and
EBITDA by EUR 62m for six months). Leverage at the end of June 2019 (net debt to adjusted L12M EBITDA) stood at 3.52x on a pro-forma basis
and at constant accounting rules (excluding IFRS 16), in line with the Group's self-imposed limit of 3.5x in spite of the fact that Eurofins has
not yet received insurance payments to cover for the cyber-attack losses and L12M EBITDA was not corrected for the one-off missing gross
margin resulting from revenue losses which followed the cyber-attack.On April 26th, 2019, the Annual General Meeting of Eurofins'
shareholders approved the change of Group auditors to Deloitte Audit.Outlook: Whilst Eurofins believes the bulk of the gross financial impact
from the cyber-attack was recorded in June 2019, it is too early to assess the total net financial impact on the Group's full-year 2019 results.
As is customary in such matters, Eurofins is still in discussions with its insurers regarding the reimbursement amount that they will provide. As
evidenced in July, the Group has returned to good performance, in line with its objectives and has a positive outlook on the rest of the
year.Comments from the CEO, Dr. Gilles Martin:
"In H1 2019, Eurofins continued to make significant progress towards the objectives of its five year 2015-2020 plan to build a unique global
network of state-of-the-art laboratories, market leadership positions, scale and scientific excellence to offer even better, faster, more cost
effective and more differentiated services to its clients and as a result significantly improve its competitive advantage, profitability and cash
flow generation to benefit its long-term oriented shareholders for years to come. As the Group moves closer to the end of its five-year
infrastructure development plan, the focus has shifted from new investments, including start-ups and M&A, to finalising the internal
investments already initiated, integrating the recently acquired businesses and making progress towards operational excellence, and thus
laying the groundwork for improved profitability, cash flow and return on investment. Unfortunately several Group laboratories were hit by a
severe criminal cyber-attack on Sunday June 2nd 2019, which significantly affected some of Eurofins businesses in June and temporarily
hampered their financial performance. Due to the strong commitment and hard work of our teams, normal operations have now fully
recovered and the outlook is good for the remainder of 2019 and 2020. The Group will now continue to focus on further improving its
margins, cash flow generation, return on investment and on deleveraging.
Business Review
June 2nd cyber-attack:
As communicated in an ad-hoc press release on Monday June 24th, since Monday June 17th, the vast majority of affected laboratories'
operations had been restored. The production and reporting IT systems of essentially all those that still were not live then became operational
again during the following week. Restoration operations continued for a few more weeks for some less important back office and software
development systems. Most affected companies worked diligently to catch up on their cyber-attack related backlog in the last two weeks of
June.
Eurofins companies alerted and are cooperating with law enforcement agencies and renowned IT forensics and security companies in the
investigation of this matter. Forensics investigations have been completed and historic or related dormant threat agents identified were
eliminated. Additional security and monitoring tools were deployed since then and world class cyber security experts were engaged. All this
will be providing additional protection and monitoring. We are continuing to work intensively with leading cybersecurity experts to further
secure our current systems and infrastructure and to add enhanced security features and measures to protect our systems and data. The
investigations conducted so far by our internal and external IT forensics experts have concluded that there now should be no significant
residual risk from the ransomware attack and have not found evidence of any unauthorised theft or transfer of confidential client data. The
security of our client data and of all our IT systems is of the utmost importance to Eurofins. Eurofins companies remain committed to making
significant investments in the continuous improvement of the security of their IT systems.
Eurofins being fortunately well insured, it could well be that the full missing margin caused by this criminal act will be compensated by its
insurers. Coverage has been confirmed and discussions about exact determination of damages will be on-going for some months. We hope to
have brought this close to resolution and to have received at least partial payments by year end. However, unfortunately the significant
impact of lost revenues in June due to IT systems disconnection or unavailability, forensics and remediation costs, renders the comparability
of H1 2019 financial statements to those of H1 2018 substantially meaningless. We have attempted to provide indications regarding revenues
evolution trends based on year-to-date May 2019 results. As no exact determination of lost revenues and margins for June is possible,
correcting results for such estimated effects in our H1 financial statements would be hazardous. Missing revenues in July originated
essentially only from Eurofins Forensics UK awaiting government clearance to restart operations which was given at the end of July. As July's
revenues growth confirms, the operations of other affected Eurofins companies appear to have fully restarted.
The following figures are extracts from and should be read in conjunction with the Unaudited Condensed Interim Consolidated Financial
Statements and Notes for the period ended 30 June 2019.
Western Europe generated total revenues of EUR 1,034.3m in H1 2019, representing 47.7% of total Group revenues, and an increase of 13.4%
vs. H1 2018. In H1 2019, Western Europe organic growth was above that of the Group year-to-date to May 2019, with a solid performance
across Food, Environment and BioPharma testing.
By country, France generated revenues of EUR 426.8m in H1 2019, a 15.3% increase vs. H1 2018, and representing 19.7% of total Group
revenues. Year-to-date to May 2019 organic growth in France was above Group average with double digit organic growth in Food,
Environment and BioPharma testing services. In Food testing, chemistry analyses grew particularly fast thanks to significant market share
gains whilst the integration of Alpa's activities also helped consolidate Eurofins' leadership in the hygiene audit and consulting business. The
growth in Environment testing activities was mainly supported by Eurofins' water testing and polluted sites analytical services, which saw
strong sales activities towards key accounts. Clinical Diagnostics was stable with encouraging growth in the second quarter both for the
routine and specialty testing activities and despite the reimbursement cuts applied from April 1st 2019.
Germany generated revenues of EUR 220.7m in H1 2019, a 10.6% increase vs. H1 2018, and representing 10.2% of total Group revenues. Year-
to-date to May 2019 organic growth in Germany was overall slightly below Group average despite double digit organic growth in Environment
testing services and above Group average in Food testing services.
The Group's businesses in the Benelux generated revenues of EUR 134.5m in H1 2019, representing a 12.3% increase vs. H1 2018, and 6.2% of
total Group revenues. Year-to-date to May 2019 organic growth in Benelux was slightly below Group average despite double digit organic
growth in Environment testing services and organic growth above Group average in BioPharma testing services as the Group continues to
successfully take market share.
In the UK and Ireland, Eurofins generated revenues of EUR 133.2m in H1 2019, representing an 18.8% increase vs. H1 2018, and 6.1% of total
Group revenues. Year-to-date to May 2019 the UK and Ireland saw double digit organic growth, as the significant site reorganisation efforts
made during the last two years start to yield results as demonstrated by the double digit organic growth performance in BioPharma services.
Eurofins' Environment testing services also saw double digit organic growth.
Eurofins' businesses in the Nordic Countries generated revenues of EUR 119.0m in H1 2019, representing a 7.6% increase vs. H1 2018, and
5.5% of total Group revenues. Year-to-date to May 2019 organic growth in the Nordic Countries was slightly below Group average despite
gaining market share on the back of strong service levels, in particular much improved turnaround times and high quality IT solutions for
customers.
Eurofins' business in North America generated total revenues of EUR 798.1m in H1 2019, representing 36.8% of total Group revenues, and an
increase of 44.4% vs. H1 2018. Year-to-date to May 2019 organic growth was below Group average, largely driven by the negative impact of
BHD, which represented a -90bps drag to Group organic growth and despite a very strong performance elsewhere, particularly in the Food
and Environment testing businesses, both generating organic growth above the Group average. The integrations of TestAmerica in the U.S.
and EnvironeX in Canada are progressing ahead of schedule, including site reorganisations and Laboratory Information Management System
(LIMS) consolidation. The integration of Covance Food Solutions (renamed Eurofins Food Integrity and Innovation, "EFII) also continues to be
significantly ahead of schedule. IT infrastructure is now integrated and commercial activities of the legacy food testing business and EFII have
been coordinated across market verticals and areas of expertise producing significant organic growth opportunities. The BioPharma division
saw positive organic growth despite continued disruption from the rollout of the new LIMS system, which is progressing to plan and should be
substantially completed at the largest sites by year end. Demand for services continues to be strong, particularly for new drug modalities, and
accordingly the Group is increasing capacity in a number of key areas. In Clinical Diagnostics, the performance continues to be negatively
impacted by BHD. However, the other businesses saw solid developments and their pipeline is promising. For instance, Eurofins NTD launched
a new test (Presence of Y) that improves the clinical utility of its first trimester testing and offers a valuable lower cost alternative to Next
Generation Sequencing (NGS) based non-invasive prenatal testing ("NIPT) and Viracor and TGI have a number of high potential tests to be
launched soon.
Eurofins' business in the Rest of the World generated revenues of EUR 335.3m in H1 2019, a 20.4% increase vs. H1 2018, representing 15.5%
of total Group revenues. Year-to-date to May 2019 organic growth in the Rest of the World was close to double digit. In Latin America, activity
in the Food sector has maintained a very positive trajectory in both Brazil and Chile resulting in three separate laboratory capacity expansion
projects. In Asia, strong organic growth was experienced in both Food and Environment testing on the back of capacity and service
investments made in the last couple of years. In Australia and New Zealand, strong organic growth in Food and Environment testing was
supported by the Group's expansion into testing of emerging environmental contaminants as well as food nutrition and food contaminants,
and the addition of laboratory capacity.
Profitability
Adjusted EBITDA increased 29.5% year-on-year to EUR 415m, resulting in a 19.1% adjusted EBITDA margin, a 70bps increase year-on-year.
Separately disclosed items2 (SDI) as a proportion of adjusted EBITDA stood at 10.6% vs. 10.2% in H1 2018. They include significant costs for
the consolidation into modern campuses of acquired businesses in Canada, Austria and California, as well as extra remediation and forensics
expenses incurred following the cyber-attack. Beyond the reorganisation and cyber-attack remediation costs, ramp up of start-up losses and
BHD losses contributed to higher SDI in H1 2019. Estimated operating losses generated by missing revenues due to the business interruption
following the cyber-attack in affected laboratories are not included in SDI. This missing margin is due to the revenue losses in June 2019 in
those affected laboratories and the resulting loss of profit given that fixed costs (mainly personnel expenses and facilities costs) could not be
eliminated or reduced during the period as personnel was doing more manual work to fulfil the most urgent orders while systems were being
screened and restored.
Reported EBITDA grew by 28.9% in H1 2019 to EUR 370.9m, largely impacted by the implementation of IFRS 16 (which increased reported
EBITDA by EUR 62m) and the cyber-attack impact, resulting in a 17.1% margin (+60bps vs. last year).
Depreciation and amortisation increased to 8.4% of revenues in H1 2019 vs. 6.0% in H1 2018, due to IFRS 16 (6.1% excluding IFRS 16).
Finance costs amounted to EUR 49m, representing 2.2% of revenues vs. 1.8% in H1 2018 (1.7% excluding IFRS 16 impact).
The income tax expense was relatively stable in absolute terms at EUR 30.0m vs. EUR 31.7m in H1 2018, despite a lower profit before tax,
mostly due to a one-time unfavourable comparable in the U.S. in 2018.
Net profit decreased to EUR 58m in H1 2019 vs. EUR 91m in H1 2018, mainly as a result of the cyber-attack disruptions, leading basic EPS to
decrease from EUR 5.15 in H1 2018 to EUR 3.31 in H1 2019.
Net working capital stood at 6.4% of revenues impacted by higher days of sales outstanding (DSO) at recently acquired companies (as it
usually takes some time to align them to Group standards) and difficulties in collections during the cyber-attack. Free cash flow to the firm
remained stable excluding IFRS 16, despite the impact from the cyber-attack. Net cash provided by financing activities decreased by EUR 99m
to –EUR 200m excluding the impact from IFRS 16 as the Group repaid some of its commercial paper and credit facilities, in an effort to
manage its cash on hand and borrowings more optimally at quarter end. As previously reported, the Group believes that it has already
secured ample and sufficient liquidity to carry on with the execution of its 2015-2020 mid-term plan.
Net debt increased to EUR 3,241m as of June 2019 vs. 2,651m as of December 2018, with the majority of the increase coming from the
implementation of IFRS 16 (EUR +505m net debt, EUR +62m EBITDA). The Group's leverage at the end of June 2019 (net debt to adjusted
L12M EBITDA) stood at 3.52x vs. 3.38x at December end on a pro-forma basis and at constant accounting rules (excluding the impact of IFRS
16), in line with the Group's self-imposed limit of 3.5x in spite of the negative impact of the cyber-attack on EBITDA. The implementation of
IFRS 16 only had a minor impact on leverage, bringing net debt to adjusted L12M EBITDA on a pro-forma basis to 3.62x in June 2019.
Acquisitions
During the first six months of 2019, the Group performed sixteen acquisitions which generated total revenues in excess of EUR 95m in 2018
with approximately 1,200 employees.
In particular, in June 2019, Eurofins announced the acquisition of Transplant Genomics Inc. ("TGI), a molecular diagnostics company
committed to improving organ transplant outcomes with non-invasive serial monitoring guided by genomics. Eurofins' Clinical Diagnostics
capabilities and market footprint serving transplant patients, which includes VRL, Inc. (the largest pre-transplant laboratory network in the
U.S.) and Viracor, Inc. (the largest specialty post-transplant clinical laboratory in the U.S. currently serving approximately 70% of all transplant
programs in the U.S., focusing on post-transplant infectious disease and immune status monitoring services) provide an ideal platform in
which to launch TGI's highly anticipated TruGraf blood gene expression test. TruGraf is the first blood test that allows physicians to reassure
patients with stable renal function following kidney transplants that their graft is not harbouring silent rejection without the need for an
invasive and costly surveillance biopsy. TGI has recently received a draft Local Coverage Determination (LCD) decision from Centers for
Medicare & Medicaid Services (CMS) via Palmetto GBA's Molecular Diagnostic Services (MolDX) Program, supporting the upcoming launch of
TruGraf and is awaiting final reimbursement decisions.
Infrastructure Programme
In the first six months of 2019, according to its plans, Eurofins has added significant state-of-the-art laboratory space through delivery of new
building projects, new acquisitions, but also through expansion of its world class campuses.
Eurofins' new five-story 15,000m2 addition in Lancaster, Pennsylvania U.S., will be delivered in Q3 2019. It is designed with lean and
sustainability motives in mind. This thirteenth expansion in Eurofins Lancaster's nearly 60-year history adds 50% more capacity to its existing
30,000m2 facility, now totalling more than 45,000m2.
The Hamburg campus in Germany has added a new 15,000m2 building at the end of May and is now transferring Food testing, Agroscience
and BioPharma services activities from other locations in the area, thus allowing consolidation of activities on the Eurofins Hamburg campus.
This new laboratory has been designed for high flexibility, leaner processes and higher efficiency and will allow stronger interdisciplinary
cooperation.
In Austria, the new campus in Wiener Neudorf near Vienna has been delivered in March, consolidating the Food and Environment activities in
the area into a new 3,500m2 facility, while also renovating part of the pre-existing 1,300m2 building. This new campus is able to serve
customers from a common platform, the largest private service laboratory in Austria offering an unmatched range of testing services. It has
also been designed to allow for further extensions and consolidations.
Further new building and renovation projects have been successfully completed in H1 2019, of which the most significant are: in the
Netherlands a new 2,800m2 building in Heerenveen for Food testing, in Belgium the renovation of 1,200m2 in Nazareth for the Environment
testing business, and the new Clinical Diagnostics laboratory at Médip&ocircle in Lyon, France. Eurofins EAG Laboratories have also moved
into a new fully renovated 3,400m2 facility in Shanghai, significantly increasing its capacity to serve its customers in China.
Eurofins is well on track to deliver its 2019 plan for construction and renovation of 60,000m2 laboratory surfaces in addition to new space
from acquisitions.
Start-ups Programme
Start-ups or green-field laboratories are generally undertaken in new markets, and in particular in emerging markets, where there are often
limited viable options for acquisitions or in developed markets when Eurofins transfers technology developed by its R&D and Competence
Centres abroad or expands geographically.
In H1 2019, the Group opened 10 new start-ups, bringing the total number of start-ups created since 2000 to 155. The 155 start-up
laboratories opened since the year 2000 had a 90bps contribution to Group organic growth for the period January–May 2019.
Of these 155 start-ups, over 40% are in Europe, close to 30% in APAC, over 20% in North America and close to 10% in Latin America. By
business line, ca. 40% are in Food & Feed testing, 20% are in Pharma/Biotech/Agroscience services, over 20% in Environment testing, and over
6% are in Clinical Diagnostics.
Post-Closing Events
Change of scope:
Since July 1st, 2019, Eurofins has completed the acquisition of five companies: one in Environment testing in Spain, one in Food testing in
France, one in Environment testing in Poland and two in Clinical Diagnostics in France and in Brazil. The total annual revenue of these
acquisitions was in excess of EUR 32m in 2018.
1Adjusted - reflect the ongoing performance of the mature11 and recurring activities excluding "separately disclosed items2.
2Separately disclosed items - includes one-off costs from integration, reorganisation, discontinued operations12 and other non-recurring
income and costs, temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant
restructuring, share-based payment charge5, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill, loss/gain
on disposal and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for
business acquisitions, net finance costs related to borrowing and investing excess cash and one-off financial effects (net of finance income)
and the related tax effects.
3EBITDA – Earnings before interest, taxes, depreciation and amortisation, share-based payment charge, impairment of goodwill, amortisation
of acquired intangible assets, negative goodwill, loss/gain on disposal and transaction costs related to acquisitions as well as income from
4EBITAS – EBITDA less depreciation and amortisation.
5Share-based payment charge and acquisition-related expenses, net – Share-based payment charge, impairment of goodwill, amortisation of
acquired intangible assets, loss/gain on disposal, negative goodwill and transaction costs related to acquisitions as well as income from
6Net Profit - Net profit for equity holders after non-controlling interests but before payment to Hybrid capital holders.
7Basic EPS – earnings per share (basic) total (to equity holders before payment of dividends to Hybrid capital holders).
8Net Operating Cash Flow – Net cash provided by operating activities (after tax).
9Free Cash Flow to the Firm - Operating Cash Flow, less Net capex.
10Organic growth for a given period (Q1, Q2, Q3, Half Year, Nine Months or Full Year) - non-IFRS measure calculating the growth in revenues
during that period between 2 successive years for the same scope of businesses using the same exchange rates (of year Y) but excluding
discontinued operations.
For the purpose of organic growth calculation for year Y, the relevant scope used is the scope of businesses that have been consolidated in
the Group's income statement of the previous financial year (Y-1). Revenue contribution from companies acquired in the course of Y-1 but not
consolidated for the full year are adjusted as if they had been consolidated as from 1st January Y-1. All revenues from businesses acquired
since 1st January Y are excluded from the calculation.
11Mature scope: excludes start-ups and acquisitions in significant restructuring. A business will generally be considered mature when: i) The
Group's systems, structure and processes have been deployedii) It has been audited, accredited and qualified and used by the relevant
regulatory bodies and the targeted client baseiii) It no longer requires above-average annual capital expenditures, exceptional restructuring or
abnormally large costs with respect to their current revenues for deploying new Group IT systems. The list of entities classified as mature is
reviewed at the beginning of each year and is relevant for the whole year. In FY 2018, 93% of total Group revenues were included in the
mature scope up from 91% in FY 2017.
12Discontinued activities / disposals: discontinued operations are a component of the Group's core business or product lines that has been
disposed of, or liquidatedor a specific business unit or a branch of a business unit that has been shut down or terminated, and is reported
separately from continued operations. Disposals correspond to the sale by Eurofins of business assets to a third party. For more information,
please refer to Note 3.19 of the Consolidated Financial Statements for the year ended 31 December 2018.
Section 6 – Appendix
The data and analysis within this report is driven by GlobalData.
GlobalData gives you key information to drive sales, investment and deal making activity in your business.
Our coverage includes 200,000 + reports on 185,000+ companies (including 150,000+ private) across 200+ countries and 29 industries. The
key industries include Alternative Energy, Oil & Gas, Clean Technology, Technology and Telecommunication, Pharmaceutical and Healthcare,
Power, Financial Services, Chemical and Metal & Mining.
Methodology
GlobalData company reports are based on a core set of research techniques which ensure the best possible level of quality and accuracy of
data. The key sources used include:
• Company Websites
• Company Annual Reports
• SEC Filings
• Press Releases
• Proprietary Databases
Currency Codes
Currency Code Currency
EUR Euro
GlobalData
Ratio Definitions
Capital Market Ratios
Capital Market Ratios measure investor response to owning a company's stock and also the cost of issuing stock.
Price/Earnings (P/E) ratio is a measure of the price paid for a share relative to the annual income earned
per share. It is a financial ratio used for valuation: a higher P/E ratio means that investors are paying more
Price/Earnings Ratio
for each unit of income, so the stock is more expensive compared to one with lower P/E ratio. A high P/E
(P/E)
suggests that investors are expecting higher earnings growth in the future compared to companies with a
lower P/E. Price per share is as of previous business close, and EPS is from latest annual report.
Calculation: Market Cap / Net Income
Enterprise Enterprise Value/EBITDA (EV/EBITDA) is a valuation multiple that is often used in parallel with, or as an
Value/Earnings before alternative to, the P/E ratio. The main advantage of EV/EBITDA over the PE ratio is that it is unaffected by a
Interest, Tax, company's capital structure. It compares the value of a business, free of debt, to earnings before interest.
Depreciation & Price per share is as of previous business close, and shares outstanding last reported. Other items are from
Amortization latest annual report.
(EV/EBITDA) Calculation: {(Market Cap + Debt + Minority Interest + Preferred Stock (Redeemable + Non-
Redeemable) - Cash & Cash Equivalents)} / (Operating Income + Depreciation + Amortization)
Enterprise Value/Sales (EV/Sales) is a ratio that provides an idea of how much it costs to buy the company's
sales. EV/Sales is seen as more accurate than Price/Sales because market capitalization does not take into
account the amount of debt a company has, which needs to be paid back at some point. Price per share is
Enterprise Value/Sales
as of previous business close, and shares outstanding last reported. Other items are from latest annual
report.
Calculation: {(Market Cap + Debt + Minority Interest + Preferred Stock (Redeemable + Non-
Redeemable) - Cash & Cash Equivalents)} / Revenue
Enterprise Value/Operating Profit measures the company's enterprise value to the operating profit. Price
Enterprise per share is as of previous business close, and shares outstanding last reported. Other items are from latest
Value/Operating Profit annual report.
Redeemable) - Cash & Cash Equivalents)} / Operating Income
Enterprise Value/Total Assets measures the company's enterprise value to the total assets. Price per share
Enterprise Value/Total is as of previous business close, and shares outstanding last reported. Other items are from latest annual
Assets report.
Redeemable) - Cash & Cash Equivalents)} / Total Assets
Dividend Yield Dividend Yield shows how much a company pays out in dividends each year relative to its share price. In
the absence of any capital gains, the dividend yield is the return on investment for a stock.
Calculation: Annual Dividend per Share / Price per Share
GlobalData
Equity Ratios
These ratios are based on per share value.

Earnings per share (EPS) is the portion of a company's profit allocated to each outstanding share of
Earnings per Share (EPS)
common stock. EPS serves as an indicator of a company's profitability.
Calculation: Net Income / Weighted Average Shares
Dividend per Share Dividend is the distribution of a portion of a company's earnings, decided by the board of
directors, to a class of its shareholders.
Dividend Cover Dividend cover is the ratio of company's earnings (net income) over the dividend paid to shareholders.
Calculation: Earnings per share / Dividend per share
Book Value per Share measure used by owners of common shares in a firm to determine the level of safety
Book Value per Share associated with each individual share after all debts are paid accordingly.
Calculation: {Shareholders Equity - Preferred Stock (Redeemable + Non-Redeemable)} / Outstanding
Shares
Cash Value per Share is a measure of a company's cash (cash & equivalents on the balance sheet) that is
Cash Value per Share
determined by dividing cash & equivalents by the total shares outstanding.
Calculation: Cash & equivalents / Outstanding Shares
GlobalData
Profitability Ratios
Profitability Ratios are used to assess a company's ability to generate earnings, based on revenues generated or resources used. For
most of these ratios, having a higher value relative to a competitor's ratio or the same ratio from a previous period is indicative that
the company is doing well.
Gross margin is the amount of contribution to the business enterprise, after paying for direct-fixed and
Gross Margin
direct-variable unit costs.
Calculation: (Gross Profit / Revenue}*100
Operating Margin Operating Margin is a ratio used to measure a company's pricing strategy and operating efficiency.
Calculation: (Operating Income / Revenue) *100
Net Profit Margin is the ratio of net profits to revenues for a company or business segment - that shows
Net Profit Margin
how much of each dollar earned by the company is translated into profits.
Calculation: (Net Profit / Revenue) *100
Profit Markup Profit Markup measures the company's gross profitability, as compared to the cost of revenue.
Calculation: Gross Income / Cost of Revenue
PBIT Margin (Profit Profit Before Interest & Tax Margin shows the profitability of the company before interest expense &
Before Interest & Tax) taxation.
Calculation: {(Net Profit+Interest+Tax) / Revenue} *100
PBT Margin (Profit Profit Before Tax Margin measures the pre-tax income over revenues.
Before Tax)
Calculation: {Net Income Before Tax / Revenue} *100
Return on Equity measures the rate of return on the ownership interest (shareholders' equity) of the
Return on Equity common stock owners.
Calculation: (Net Income / Shareholders Equity)*100
Return on Capital Employed is a ratio that indicates the efficiency and profitability of a company's capital
Return on Capital investments. ROCE should always be higher than the rate at which the company borrows; otherwise any
Employed
increase in borrowing will reduce shareholders' earnings.
Calculation: Operating Income / (Total Assets – Current Liabilities) * 100
Return on Assets is an indicator of how profitable a company is relative to its total assets, the ratio
Return on Assets
measures how efficient management is at using its assets to generate earnings.
Calculation: (Net Income / [Current Year Total Assets + Last Year Total Assets)/2])*100
Return on Fixed Assets measures the company's profitability to its fixed assets (property, plant &
Return on Fixed Assets
equipment).
Calculation: (Net Income / [Current Year Fixed Assets + Last Year Fixed Assets)/2]) * 100
Return on Working Return on Working Capital measures the company's profitability to its working capital.
Capital
Calculation: {Operating Income / (Current Assets-Current Liabilities)} * 100
GlobalData
Cost Ratios
Cost ratios help to understand the costs the company is incurring as a percentage of sales.
Operating costs (% of Operating costs as percentage of total revenues measures the operating costs that a company incurs
Sales) compared to the revenues.
Calculation: (Operating Expenses / Revenue) *100
Administration costs (% Administration costs as percentage of total revenue measures the selling, general and administrative
of Sales) expenses that a company incurs compared to the revenues.
Calculation: (Administrative Expenses / Revenue) *100
Interest costs (% of Interest costs as percentage of total revenues measures the interest expense that a company incurs
Sales) compared to the revenues.
Calculation: (Interest Expenses / Revenue) *100
GlobalData
Liquidity Ratios
Liquidity ratios are used to determine a company's ability to pay off its short-terms debts obligations. Generally, the higher the value
of the ratio, the larger the margin of safety that the company possesses to cover short-term debts. A company's ability to turn short-
term assets into cash to cover debts is of the utmost importance when creditors are seeking payment. Bankruptcy analysts and
mortgage originators frequently use the liquidity ratios to determine whether a company will be able to continue as a going concern.
Current Ratio measures a company's ability to pay its short-term obligations. The ratio gives an idea of the
company's ability to pay back its short-term liabilities (debt and payables) with its short-term assets (cash,
Current Ratio inventory, receivables). The higher the current ratio, the more capable the company is of paying its
obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they
came due at that point.
Calculation: Current Assets / Current Liabilities
Quick Ratio Quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets.
Calculation: (Current Assets - Inventories) / Current Liabilities
Cash ratio is the most stringent and conservative of the three short-term liquidity ratio. It only looks at the
most liquid short-term assets of the company, which are those that can be most easily used to pay off
Cash Ratio
current obligations. It also ignores inventory and receivables, as there are no assurances that these two
accounts can be converted to cash in a timely matter to meet current liabilities.
Calculation: {(Cash & Bank Balance + Marketable Securities) / Current Liabilities)}
GlobalData
Leverage Ratios
Leverage ratios are used to calculate the financial leverage of a company to get an idea of the company's methods of financing or to
measure its ability to meet financial obligations. There are several different ratios, but the main factors looked at include debt, equity,
assets and interest expenses.
Debt to Equity Ratio is a measure of a company's financial leverage. The debt/equity ratio also depends on
Debt to Equity Ratio the industry in which the company operates. For example, capital-intensive industries tend to have a higher
debt-equity ratio.
Calculation: Total Debt / Shareholders Equity
Debt to capital ratio gives an idea of a company's financial structure, or how it is financing its operations,
along with some insight into its financial strength. The higher the debt-to-capital ratio, the more debt the
company has compared to its equity. This indicates to investors whether a company is more prone to using
Debt to Capital Ratio
debt financing or equity financing. A company with high debt-to-capital ratios, compared to a general or
industry average, may show weak financial strength because the cost of these debts may weigh on the
company and increase its default risk.
Calculation: {Total Debt / (Total Debt + Shareholders Equity)}
Interest Coverage Ratio is used to determine how easily a company can pay interest on outstanding debt,
Interest Coverage Ratio
calculated as earnings before interest & tax by interest expense.
Calculation: Operating Income / Interest Expenses
GlobalData
Efficiency Ratios
Efficiency ratios measure a company's effectiveness in various areas of its operations, essentially looking at maximizing its use of
resources.
Fixed Asset Turnover ratio indicates how well the business is using its fixed assets to generate sales. A
higher ratio indicates the business has less money tied up in fixed assets for each currency unit of sales
Fixed Asset Turnover
revenue. A declining ratio may indicate that the business is over-invested in plant, equipment, or other
fixed assets.
Calculation: Revenue / [Current Year Fixed Assets + Last Year Fixed Assets)/2]
Asset turnover ratio measures the efficiency of a company's use of its assets in generating sales revenue to
Asset Turnover the company. A higher asset turnover ratio shows that the company has been more effective in using its
assets to generate revenues.
Calculation: Revenue / [Current Year Total Assets + Last Year Total Assets)/2]
Current Asset Turnover Current Asset Turnover indicates how efficiently the business uses its current assets to generate sales.
Calculation: Revenue / [Current Year Current Assets + Last Year Current Assets)/2]
Inventory Turnover ratio shows how many times a company's inventory is sold and replaced over a period.
Inventory Turnover A low turnover implies poor sales and, therefore, excess inventory. A high ratio implies either strong sales
or ineffective buying.
Calculation: Cost of Goods Sold /[Current Year Inventory + Last Year Inventory)/2]
Working Capital Turnover is a measurement to compare the depletion of working capital to the generation
Working Capital of sales. This provides some useful information as to how effectively a company is using its working capital
Turnover to generate sales.
Calculation: Revenue / (Current Assets – Current Liabilities)
Capital Employed Capital employed turnover ratio measures the efficiency of a company's use of its equity in generating sales
Turnover revenue to the company.
Calculation: Revenue / (Total Assets – Current Liabilities)
Capex to Sales ratio measures the company's expenditure (investments) on fixed and related assets'
Capex to sales
effectiveness when compared to the sales generated.
Calculation: (Capital Expenditure / Sales) *100
Net income per Net income per Employee looks at a company's net income in relation to the number of employees they
Employee have. Ideally, a company wants a higher profit per employee possible, as it denotes higher productivity.
Calculation: Net Income / No. of Employees
Revenue per Employee measures the average revenue generated per employee of a company. This ratio is
Revenue per Employee most useful when compared against other companies in the same industry. Generally, a company seeks the
highest revenue per employee.
Calculation: Revenue / No. of Employees
Efficiency Ratio is used to calculate a bank's efficiency. An increase means the company is losing a larger
Efficiency Ratio percentage of its income to expenses. If the efficiency ratio is getting lower, it is good for the bank and its
shareholders.
Calculation: [Non-interest expense / (Net Interest Income + Non-Interest Income)] * 100
GlobalData
Notes
• Financial information of the company is taken from the most recently published annual reports or SEC filings
• The financial and operational data reported for the company is as per the industry defined standards
• Revenue converted to USD at average annual conversion rate as of fiscal year end
About GlobalData
GlobalData is one of the world’s leading providers of company operational data and strategic analysis, providing detailed information on tens
of thousands of companies globally. Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources
and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to
sustain a competitive edge. Data is continuously updated and revised by large teams of research experts, so that it always reflects the latest
events and information. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research
techniques in developing unique data sets and research material for this series and its other reports. GlobalData offers comprehensive
geographic coverage across world’s most important sectors, focusing particularly on energy and healthcare.
Contact Us
If you have any queries about this report or would like further information, please contact info@globaldata.com
Disclaimer
All Rights Reserved
No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical,
photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData.
The data and analysis within this report is driven by GlobalData from its own primary and secondary research of public and proprietary
sources and does not necessarily represent the views of the company profiled.
The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings,
conclusions and recommendations that GlobalData delivers will be based on information gathered in good faith from both primary and
secondary sources, whose accuracy we are not always in a position to guarantee. As such GlobalData can accept no liability whatever for
actions taken based on any information that may subsequently prove to be incorrect.

Single 3436993005f205eca6caf3 PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Single 3436993005f205eca6caf3 PDF

Uploaded by

Copyright:

Available Formats

Eurofins Scientific SE (ERF)

Financial and Strategic SWOT Analysis Review

Report Code: GDPH34964FSA

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 2

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 3

Financial Performance ..................................................................................................................................................................... 46

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 4

Asset Transactions ......................................................................................................................................................................... 108

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 5

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 6

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 7

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 8

Section 1 - About the Company

Telephone +356 26 185320 No. of Employees 47,000

Fax +356 26 185331 Fiscal Year End December

URL www.eurofins.com Revenue (in USD Million) 5,108.2

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 9

Eurofins Scientific SE - Key Employees

Name Job Title Board Level Since Age

Gilles G. Martin Chairman, Chief Executive Officer Executive Board 57

Valerie Hanote Director Non Executive Board 54

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 10

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 11

Eurofins Scientific SE - Key Employee Biographies

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 12

Eurofins Scientific SE - Major Products and Services

Eurofins Scientific SE, Major Products and Services

Food and Feed Testing

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 13

Eurofins Scientific SE - History

2018 Acquisitions/Mergers/Takeovers In August, Eurofins agreed to acquire Nanolab Technologies, a provider of

2018 Acquisitions/Mergers/Takeovers In July, Eurofins acquired Laboratoire de Bromatologie de l’Ouest (LBO), a

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 14

2017 Acquisitions/Mergers/Takeovers In December, Eurofins announced the acquisition of Pasteur Group.

2016 Acquisitions/Mergers/Takeovers In January, Eurofins Scientific acquired Sinensis Life Sciences.

2016 Acquisitions/Mergers/Takeovers In March, the company agreed to acquire Advantar Laboratories.

2016 Acquisitions/Mergers/Takeovers In September, the company acquired Megalab SA for a value at

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 15

partnership with Onco Drug Personalized Medicine.

2016 Contracts/Agreements In December, Eurofins Scientific entered into an agreement to acquire

2015 Acquisitions/Mergers/Takeovers In May, the company acquired Experchem Laboratories.

2015 Contracts/Agreements In February, Eurofins Scientific acquired BioDiagnostics Inc.

2015 Contracts/Agreements In June, Eurofins Scientific signed an agreement, to acquire a controlling

2015 Contracts/Agreements In June, the company signed an agreement, to develop Bio-Access/Labazur

2015 Financing Agreements In December, Eurofins Scientific SE announced a private placement of

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 16

2014 Acquisitions/Mergers/Takeovers In May, Eurofins signed an agreement to acquire Calscience Environmental

2014 Plans/Strategy In November, the company planned to acquire SF Analytical Laboratories to

2013 Acquisitions/Mergers/Takeovers In January, the company acquired Laboratorium Zeeuws-Vlaanderen (LZV).

2012 Acquisitions/Mergers/Takeovers In April, the company completed the acquisition of ALAC.

2012 Acquisitions/Mergers/Takeovers In December, the company completed the acquisition of Cerep.

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 17

Labs pharmacology unit.

2012 Contracts/Agreements In November, Eurofins Eaton Analytical was selected by the US

2005 Acquisitions/Mergers/Takeovers In November, the company completed the acquisition of AvTech

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 18

1987 Incorporation/Establishment The company was founded in 1987.

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 19

Eurofins Scientific SE - Company Statement

© GlobalData 2020. This product is licensed and is not to be photocopied. Page 20

Eurofins Scientific SE - Locations And Subsidiaries

Other Locations & Subsidiaries

Eurofins Scientific SE, Subsidiaries